{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 515225, "items": [{"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T10:19:45Z", "timestamp": 1574158785652}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "7", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2003, 4, 1]], "date-time": "2003-04-01T00:00:00Z", "timestamp": 1049155200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drug Discovery Today"], "published-print": {"date-parts": [[2003, 4, 1]]}, "DOI": "10.1016/s1359-6446(03)02647-3", "type": "journal-article", "created": {"date-parts": [[2003, 3, 25]], "date-time": "2003-03-25T22:25:53Z", "timestamp": 1048631153000}, "page": "307-315", "source": "Crossref", "is-referenced-by-count": 161, "title": ["Potential for proteasome inhibition in the treatment of cancer"], "prefix": "10.1016", "volume": "8", "author": [{"given": "J", "family": "Adams", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Drug Discovery Today"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359-6446(03)02647-3?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359-6446(03)02647-3?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 24]], "date-time": "2019-03-24T12:59:24Z", "timestamp": 1553432364000}, "score": 42.722927, "issued": {"date-parts": [[2003, 4, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2003, 4, 1]]}, "issue": "7"}, "alternative-id": ["S1359-6446(03)02647-3"], "URL": "http://dx.doi.org/10.1016/s1359-6446(03)02647-3", "ISSN": ["1359-6446"], "issn-type": [{"value": "1359-6446", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T11:25:41Z", "timestamp": 1574162741136}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2003, 5, 1]], "date-time": "2003-05-01T00:00:00Z", "timestamp": 1051747200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Treatment Reviews"], "published-print": {"date-parts": [[2003, 5]]}, "DOI": "10.1016/s0305-7372(03)00081-1", "type": "journal-article", "created": {"date-parts": [[2003, 5, 12]], "date-time": "2003-05-12T22:41:46Z", "timestamp": 1052779306000}, "page": "3-9", "source": "Crossref", "is-referenced-by-count": 276, "title": ["The proteasome: structure, function, and role in the cell"], "prefix": "10.1016", "volume": "29", "author": [{"given": "J", "family": "ADAMS", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Cancer Treatment Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0305-7372(03)00081-1?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0305-7372(03)00081-1?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 21]], "date-time": "2019-03-21T20:25:10Z", "timestamp": 1553199910000}, "score": 33.86451, "issued": {"date-parts": [[2003, 5]]}, "references-count": 0, "alternative-id": ["S0305-7372(03)00081-1"], "URL": "http://dx.doi.org/10.1016/s0305-7372(03)00081-1", "ISSN": ["0305-7372"], "issn-type": [{"value": "0305-7372", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T07:21:44Z", "timestamp": 1575184904375}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2001, 12, 1]], "date-time": "2001-12-01T00:00:00Z", "timestamp": 1007164800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Seminars in Oncology"], "published-print": {"date-parts": [[2001, 12]]}, "DOI": "10.1016/s0093-7754(01)90034-x", "type": "journal-article", "created": {"date-parts": [[2005, 11, 3]], "date-time": "2005-11-03T12:48:34Z", "timestamp": 1131022114000}, "page": "613-619", "source": "Crossref", "is-referenced-by-count": 128, "title": ["Proteasome inhibition in cancer: Development of PS-341"], "prefix": "10.1016", "volume": "28", "author": [{"given": "J", "family": "ADAMS", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Seminars in Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S009377540190034X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S009377540190034X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 21]], "date-time": "2019-01-21T10:54:45Z", "timestamp": 1548068085000}, "score": 32.590313, "issued": {"date-parts": [[2001, 12]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2001, 12]]}, "issue": "6"}, "alternative-id": ["S009377540190034X"], "URL": "http://dx.doi.org/10.1016/s0093-7754(01)90034-x", "ISSN": ["0093-7754"], "issn-type": [{"value": "0093-7754", "type": "print"}], "subject": ["Oncology", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T22:11:17Z", "timestamp": 1574115077204}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2001, 12, 1]], "date-time": "2001-12-01T00:00:00Z", "timestamp": 1007164800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2001, 12]]}, "DOI": "10.1053/sonc.2001.28609", "type": "journal-article", "created": {"date-parts": [[2002, 8, 25]], "date-time": "2002-08-25T03:46:10Z", "timestamp": 1030247170000}, "page": "613-619", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Proteasome inhibition in cancer: Development of PS-341"], "prefix": "10.1053", "volume": "28", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Seminars in Oncology"], "deposited": {"date-parts": [[2019, 4, 12]], "date-time": "2019-04-12T00:50:18Z", "timestamp": 1555030218000}, "score": 29.52063, "issued": {"date-parts": [[2001, 12]]}, "references-count": 0, "journal-issue": {"issue": "6"}, "alternative-id": ["10.1053/sonc.2001.28609"], "URL": "http://dx.doi.org/10.1053/sonc.2001.28609", "ISSN": ["0093-7754"], "issn-type": [{"value": "0093-7754", "type": "print"}], "article-number": "asonc0280613"}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T13:43:32Z", "timestamp": 1576849412836}, "reference-count": 34, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2002, 4, 1]], "date-time": "2002-04-01T00:00:00Z", "timestamp": 1017619200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Trends in Molecular Medicine"], "published-print": {"date-parts": [[2002, 4]]}, "DOI": "10.1016/s1471-4914(02)02315-8", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T11:46:33Z", "timestamp": 1027597593000}, "page": "S49-S54", "source": "Crossref", "is-referenced-by-count": 111, "title": ["Proteasome inhibition: a novel approach to cancer therapy"], "prefix": "10.1016", "volume": "8", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Trends in Molecular Medicine"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1471491402023158?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1471491402023158?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 1]], "date-time": "2019-05-01T11:58:16Z", "timestamp": 1556711896000}, "score": 29.52063, "issued": {"date-parts": [[2002, 4]]}, "references-count": 34, "journal-issue": {"published-print": {"date-parts": [[2002, 4]]}, "issue": "4"}, "alternative-id": ["S1471491402023158"], "URL": "http://dx.doi.org/10.1016/s1471-4914(02)02315-8", "ISSN": ["1471-4914"], "issn-type": [{"value": "1471-4914", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T15:57:50Z", "timestamp": 1574524670280}, "publisher-location": "Totowa, NJ", "reference-count": 45, "publisher": "Humana Press", "isbn-type": [{"value": "9781617374524", "type": "print"}, {"value": "9781592597949", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2004]]}, "DOI": "10.1007/978-1-59259-794-9_6", "type": "book-chapter", "created": {"date-parts": [[2012, 12, 28]], "date-time": "2012-12-28T15:58:01Z", "timestamp": 1356710281000}, "page": "77-84", "source": "Crossref", "is-referenced-by-count": 1, "title": ["The Proteasome in Cell-Cycle Regulation"], "prefix": "10.1007", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "6_CR1", "doi-asserted-by": "publisher", "first-page": "295", "DOI": "10.1146/annurev.pharmtox.39.1.295", "volume": "39", "author": "DG Johnson", "year": "1999", "unstructured": "Johnson DG, et al. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 1999;39:295\u2013312.", "journal-title": "Annu Rev Pharmacol Toxicol"}, {"key": "6_CR2", "doi-asserted-by": "publisher", "first-page": "1652", "DOI": "10.1126/science.274.5293.1652", "volume": "274", "author": "RW King", "year": "1996", "unstructured": "King RW, et al. How proteolysis drives the cell cycle. Science 1996;274:1652\u20131659.", "journal-title": "Science"}, {"key": "6_CR3", "doi-asserted-by": "publisher", "first-page": "1501", "DOI": "10.1098/rstb.1999.0494", "volume": "354", "author": "P Zwickl", "year": "1999", "unstructured": "Zwickl P, et al. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 1999;354:1501\u20131511.", "journal-title": "Philos Trans R Soc Lond B Biol Sci"}, {"key": "6_CR4", "doi-asserted-by": "crossref", "first-page": "373", "DOI": "10.1152/physrev.00027.2001", "volume": "82", "author": "MH Glickman", "year": "2002", "unstructured": "Glickman MH, et al. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373\u2013428.", "journal-title": "Physiol Rev"}, {"key": "6_CR5", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1016/S0143-4160(98)90110-5", "volume": "23", "author": "L Santella", "year": "1998", "unstructured": "Santella L, et al. Calcium, protease action, and the regulation of the cell cycle. Cell Calcium 1998;23:123\u2013130.", "journal-title": "Cell Calcium"}, {"key": "6_CR6", "doi-asserted-by": "publisher", "first-page": "35140", "DOI": "10.1074/jbc.M205503200", "volume": "277", "author": "TK Fung", "year": "2002", "unstructured": "Fung TK, et al. Cyclin F is degraded during G2-M by mechanisms fundamentally different from other cyclins. J Biol Chem 2002;277:35140\u201335149.", "journal-title": "J Biol Chem"}, {"key": "6_CR7", "doi-asserted-by": "publisher", "first-page": "3158", "DOI": "10.1074/jbc.275.5.3158", "volume": "275", "author": "CH Yam", "year": "2000", "unstructured": "Yam CH, et al. Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclindependent kinase 2. J Biol Chem 2000;275:3158\u20133167.", "journal-title": "J Biol Chem"}, {"key": "6_CR8", "doi-asserted-by": "publisher", "first-page": "2344", "DOI": "10.1101/gad.823200", "volume": "14", "author": "A Nishiyama", "year": "2000", "unstructured": "Nishiyama A, et al. A nonproteolytic function of the proteasome is required for the dissociation of Cdc2 and cyclin B at the end of M phase. Genes Dey 2000;14:2344\u20132357.", "journal-title": "Genes Dey"}, {"key": "6_CR9", "doi-asserted-by": "publisher", "first-page": "431", "DOI": "10.1016/S0092-8674(00)80753-9", "volume": "97", "author": "DM Koepp", "year": "1999", "unstructured": "Koepp DM, et al. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999;97:431\u2013434.", "journal-title": "Cell"}, {"key": "6_CR10", "doi-asserted-by": "publisher", "first-page": "315", "DOI": "10.1016/S1357-2725(01)00137-6", "volume": "34", "author": "M Payton", "year": "2002", "unstructured": "Payton M, et al. Cyclin E2, the cycle continues. Int J Biochem Cell Biol 2002;34:315\u2013320.", "journal-title": "Int J Biochem Cell Biol"}, {"key": "6_CR11", "doi-asserted-by": "publisher", "first-page": "1979", "DOI": "10.1101/gad.10.16.1979", "volume": "10", "author": "BE Clurman", "year": "1996", "unstructured": "Clurman BE, et al. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dey 1996;10:1979\u20131990.", "journal-title": "Genes Dey"}, {"key": "6_CR12", "doi-asserted-by": "publisher", "first-page": "853", "DOI": "10.1006/bbrc.2001.4627", "volume": "282", "author": "KI Nakayama", "year": "2001", "unstructured": "Nakayama KI, et al. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 2001;282:853\u2013860.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "6_CR13", "doi-asserted-by": "publisher", "first-page": "676", "DOI": "10.1016/S0955-0674(00)00151-4", "volume": "12", "author": "SV Ekholm", "year": "2000", "unstructured": "Ekholm SV, et al. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000;12:676\u2013684.", "journal-title": "Curr Opin Cell Biol"}, {"key": "6_CR14", "doi-asserted-by": "publisher", "first-page": "2511", "DOI": "10.1021/cr0001030", "volume": "101", "author": "JW Harper", "year": "2001", "unstructured": "Harper JW, et al. Cyclin-dependent kinases. Chem Rev 2001;101:2511\u20132526.", "journal-title": "Chem Rev"}, {"key": "6_CR15", "doi-asserted-by": "publisher", "first-page": "1501", "DOI": "10.1101/gad.13.12.1501", "volume": "13", "author": "CJ Sherr", "year": "1999", "unstructured": "Sherr CJ, et al. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dey 1999;13:1501\u20131512.", "journal-title": "Genes Dey"}, {"key": "6_CR16", "doi-asserted-by": "publisher", "first-page": "701", "DOI": "10.1038/366701a0", "volume": "366", "author": "Y Xiong", "year": "1993", "unstructured": "Xiong Y, et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701\u2013704.", "journal-title": "Nature"}, {"key": "6_CR17", "doi-asserted-by": "publisher", "first-page": "707", "DOI": "10.1038/366707a0", "volume": "366", "author": "Y Gu", "year": "1993", "unstructured": "Gu Y, et al. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993;366:707\u2013710.", "journal-title": "Nature"}, {"key": "6_CR18", "doi-asserted-by": "publisher", "first-page": "534", "DOI": "10.1038/371534a0", "volume": "371", "author": "R Li", "year": "1994", "unstructured": "Li R, et al. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534\u2013537.", "journal-title": "Nature"}, {"key": "6_CR19", "doi-asserted-by": "publisher", "first-page": "3882", "DOI": "10.1101/gad.12.24.3882", "volume": "12", "author": "L Hengst", "year": "1998", "unstructured": "Hengst L, et al. Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1). Genes Dey 1998;12:3882\u20133888.", "journal-title": "Genes Dey"}, {"key": "6_CR20", "doi-asserted-by": "publisher", "first-page": "691", "DOI": "10.1097/00005072-199907000-00002", "volume": "58", "author": "R Piva", "year": "1999", "unstructured": "Piva R, et al. Proteasome-dependent degradation of p27/kip 1 in gliomas. J Neuropathol Exp Neurol 1999;58:691\u2013696.", "journal-title": "J Neuropathol Exp Neurol"}, {"key": "6_CR21", "doi-asserted-by": "publisher", "first-page": "682", "DOI": "10.1126/science.7624798", "volume": "269", "author": "M Pagano", "year": "1995", "unstructured": "Pagano M, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclindependent kinase inhibitor p27. Science 1995;269:682\u2013685.", "journal-title": "Science"}, {"key": "6_CR22", "doi-asserted-by": "publisher", "first-page": "1464", "DOI": "10.1101/gad.11.11.1464", "volume": "11", "author": "RJ Sheaff", "year": "1997", "unstructured": "Sheaff RJ, et al. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dey 1997;11:1464\u20131478.", "journal-title": "Genes Dey"}, {"key": "6_CR23", "doi-asserted-by": "publisher", "first-page": "12197", "DOI": "10.1074/jbc.274.18.12197", "volume": "274", "author": "T Urano", "year": "1999", "unstructured": "Urano T, et al. p57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor beta 1. J Biol Chem 1999;274:12197\u201312200.", "journal-title": "J Biol Chem"}, {"key": "6_CR24", "doi-asserted-by": "publisher", "first-page": "2870", "DOI": "10.1038/sj.onc.1203579", "volume": "19", "author": "M Thullberg", "year": "2000", "unstructured": "Thullberg M, et al. Ubiquitin/proteasome-mediated degradation of p19INK4d determines its periodic expression during the cell cycle. Oncogene 2000;19:2870\u20132876.", "journal-title": "Oncogene"}, {"key": "6_CR25", "doi-asserted-by": "publisher", "first-page": "1219", "DOI": "10.1126/science.279.5354.1219", "volume": "279", "author": "H Yu", "year": "1998", "unstructured": "Yu H, et al. Identification of a cullin homology region in a subunit of the anaphase-promoting complex. Science 1998;279:1219\u20131222.", "journal-title": "Science"}, {"key": "6_CR26", "doi-asserted-by": "publisher", "first-page": "169", "DOI": "10.1038/35056563", "volume": "2", "author": "AM Weissman", "year": "2001", "unstructured": "Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001;2:169\u2013178.", "journal-title": "Nat Rev Mol Cell Biol"}, {"key": "6_CR27", "doi-asserted-by": "publisher", "first-page": "263", "DOI": "10.1016/S0092-8674(00)80098-7", "volume": "86", "author": "C Bai", "year": "1996", "unstructured": "Bai C, et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996;86:263\u2013274.", "journal-title": "Cell"}, {"key": "6_CR28", "doi-asserted-by": "publisher", "first-page": "173", "DOI": "10.1126/science.1065203", "volume": "294", "author": "DM Koepp", "year": "2001", "unstructured": "Koepp DM, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001;294:173\u2013177.", "journal-title": "Science"}, {"key": "6_CR29", "doi-asserted-by": "publisher", "first-page": "602", "DOI": "10.1038/77929", "volume": "7", "author": "MA Verdecia", "year": "2000", "unstructured": "Verdecia MA, et al. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000;7:602\u2013608.", "journal-title": "Nat Struct Biol"}, {"key": "6_CR30", "first-page": "4363", "volume": "23", "author": "J Zhao", "year": "2000", "unstructured": "Zhao J, et al. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000;113 Pt 23:4363\u20134371.", "journal-title": "J Cell Sci"}, {"key": "6_CR31", "doi-asserted-by": "publisher", "first-page": "874", "DOI": "10.1126/science.288.5467.874", "volume": "288", "author": "Y Yang", "year": "2000", "unstructured": "Yang Y, et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000;288:874\u2013877.", "journal-title": "Science"}, {"key": "6_CR32", "first-page": "26661", "volume": "275", "author": "H Huang", "year": "2000", "unstructured": "Huang H, et al. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem 2000;275:26661\u201326664.", "journal-title": "J Biol Chem"}, {"key": "6_CR33", "doi-asserted-by": "publisher", "first-page": "8662", "DOI": "10.1073/pnas.161506698", "volume": "98", "author": "Y Suzuki", "year": "2001", "unstructured": "Suzuki Y, et al. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 2001;98:8662\u20138667.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "6_CR34", "first-page": "2649", "volume": "56", "author": "CG Maki", "year": "1996", "unstructured": "Maki CG, et al. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996;56:2649\u20132654.", "journal-title": "Cancer Res"}, {"key": "6_CR35", "first-page": "239", "volume": "11", "author": "F Chen", "year": "2000", "unstructured": "Chen F, et al. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 2000;11:239\u2013246.", "journal-title": "Cell Growth Differ"}, {"key": "6_CR36", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.1002/jcb.1150", "volume": "82", "author": "SA Shah", "year": "2001", "unstructured": "Shah SA, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110\u2013122.", "journal-title": "J Cell Biochem"}, {"key": "6_CR37", "doi-asserted-by": "publisher", "first-page": "243", "DOI": "10.1002/(SICI)1097-0320(19970701)28:3<243::AID-CYTO9>3.0.CO;2-E", "volume": "28", "author": "BM Machiels", "year": "1997", "unstructured": "Machiels BM, et al. Detailed analysis of cell cycle kinetics upon proteasome inhibition. Cytometry 1997;28:243\u2013252.", "journal-title": "Cytometry"}, {"key": "6_CR38", "first-page": "239", "volume": "11", "author": "F Chen", "year": "2000", "unstructured": "Chen F, et al. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 2000;11:239\u2013246.", "journal-title": "Cell Growth Differ"}, {"key": "6_CR39", "first-page": "3466", "volume": "58", "author": "DG Tang", "year": "1998", "unstructured": "Tang DG, et al. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 1998;58:3466\u20133479.", "journal-title": "Cancer Res"}, {"key": "6_CR40", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615\u20132622.", "journal-title": "Cancer Res"}, {"key": "6_CR41", "doi-asserted-by": "publisher", "first-page": "210", "DOI": "10.1038/sj.cdd.4400801", "volume": "8", "author": "AP MacLaren", "year": "2001", "unstructured": "MacLaren AP, et al. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001;8:210\u2013218.", "journal-title": "Cell Death Differ"}, {"key": "6_CR42", "doi-asserted-by": "publisher", "first-page": "12893", "DOI": "10.1074/jbc.272.20.12893", "volume": "272", "author": "UG Lopes", "year": "1997", "unstructured": "Lopes UG, et al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997;272:12893\u201312896.", "journal-title": "J Biol Chem"}, {"key": "6_CR43", "unstructured": "Neumeier H, et al. Hypoxia increases potency of the proteasome inhibitor VELCADE\u2122 (bortezomib) for injection: potential for a hypoxic cell cytotoxin in solid tumors. 2002;38(suppl 7):166.", "DOI": "10.1016/S0959-8049(02)81213-8", "doi-asserted-by": "crossref"}, {"key": "6_CR44", "first-page": "3719", "volume": "6", "author": "A Frankel", "year": "2000", "unstructured": "Frankel A, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719\u20133728.", "journal-title": "Clin Cancer Res"}, {"key": "6_CR45", "doi-asserted-by": "publisher", "first-page": "271", "DOI": "10.1006/excr.2000.5053", "volume": "261", "author": "R Yamaguchi", "year": "2000", "unstructured": "Yamaguchi R, et al. Proteasome inhibitors alter the orderly progression of DNA synthesis during S-phase in HeLa cells and lead to rereplication of DNA. Exp Cell Res 2000;261:271\u2013283.", "journal-title": "Exp Cell Res"}], "container-title": ["Proteasome Inhibitors in Cancer Therapy"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-59259-794-9_6", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 7, 7]], "date-time": "2019-07-07T17:30:58Z", "timestamp": 1562520658000}, "score": 27.910149, "issued": {"date-parts": [[2004]]}, "ISBN": ["9781617374524", "9781592597949"], "references-count": 45, "URL": "http://dx.doi.org/10.1007/978-1-59259-794-9_6", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T11:30:02Z", "timestamp": 1575199802312}, "publisher-location": "Totowa, NJ", "reference-count": 50, "publisher": "Humana Press", "isbn-type": [{"value": "9781617373428", "type": "print"}, {"value": "9781592597673", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2004]]}, "DOI": "10.1007/978-1-59259-767-3_41", "type": "book-chapter", "created": {"date-parts": [[2013, 3, 18]], "date-time": "2013-03-18T19:23:04Z", "timestamp": 1363634584000}, "page": "635-642", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Proteasome Inhibitors in Cancer Therapy"], "prefix": "10.1007", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "41_CR1", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615\u20132622.", "journal-title": "Cancer Res"}, {"key": "41_CR2", "doi-asserted-by": "crossref", "first-page": "1933", "DOI": "10.1093/jn/129.11.1933", "volume": "129", "author": "KD Wilkinson", "year": "1999", "unstructured": "Wilkinson KD. Ubiquitin-dependent signaling: the role of ubiquitination in the response of cells to their environment. J Nutr 1999;129:1933\u20131936.", "journal-title": "J Nutr"}, {"key": "41_CR3", "doi-asserted-by": "publisher", "first-page": "503", "DOI": "10.1146/annurev.biochem.70.1.503", "volume": "70", "author": "CM Pickart", "year": "2001", "unstructured": "Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001;70:503\u2013533.", "journal-title": "Annu Rev Biochem"}, {"key": "41_CR4", "doi-asserted-by": "publisher", "first-page": "141", "DOI": "10.1006/scdb.2000.0164", "volume": "11", "author": "KD Wilkinson", "year": "2000", "unstructured": "Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000;11:141\u2013148.", "journal-title": "Semin Cell Dev Biol"}, {"key": "41_CR5", "doi-asserted-by": "publisher", "first-page": "6735", "DOI": "10.1021/bi960099f", "volume": "35", "author": "CN Larsen", "year": "1996", "unstructured": "Larsen CN, Price JS, Wilkinson KD. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 1996;35:6735\u20136744.", "journal-title": "Biochemistry"}, {"key": "41_CR6", "doi-asserted-by": "crossref", "first-page": "252", "DOI": "10.1159/000468684", "volume": "47", "author": "A Lupas", "year": "1993", "unstructured": "Lupas A, Koster AJ, Baumeister W. Structural features of 26S and 20S proteasomes. Enzyme Protein 1993;47:252\u2013273.", "journal-title": "Enzyme Protein"}, {"key": "41_CR7", "doi-asserted-by": "publisher", "first-page": "739", "DOI": "10.1016/S1074-5521(01)00056-4", "volume": "8", "author": "AF Kisselev", "year": "2001", "unstructured": "Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001 8:739\u2013758.", "journal-title": "Chem Biol"}, {"key": "41_CR8", "first-page": "21", "volume": "11", "author": "PG Richardson", "year": "2002", "unstructured": "Richardson PG, Barlogie B, Berenson J, et al. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients (pts) with relapsed/refractory disease: results from cohort 1 analysis. Proc Annu Meet Am Soc Clin Oncol 2002;21:11a.", "journal-title": "Proc Annu Meet Am Soc Clin Oncol"}, {"key": "41_CR9", "first-page": "2649", "volume": "56", "author": "CG Maki", "year": "1996", "unstructured": "Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996;56:2649\u20132654.", "journal-title": "Cancer Res"}, {"key": "41_CR10", "doi-asserted-by": "publisher", "first-page": "1979", "DOI": "10.1101/gad.10.16.1979", "volume": "10", "author": "BE Clurman", "year": "1996", "unstructured": "Clurman BE, Sheaff RJ, Thress K, et al. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996;10:1979\u20131990.", "journal-title": "Genes Dev"}, {"key": "41_CR11", "doi-asserted-by": "publisher", "first-page": "3004", "DOI": "10.1038/sj.onc.1202746", "volume": "18", "author": "CE Nesbit", "year": "1999", "unstructured": "Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999;18:3004\u20133016.", "journal-title": "Oncogene"}, {"key": "41_CR12", "doi-asserted-by": "publisher", "first-page": "773", "DOI": "10.1016/S0092-8674(94)90482-0", "volume": "78", "author": "VJ Palombella", "year": "1994", "unstructured": "Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773\u2013785.", "journal-title": "Cell"}, {"key": "41_CR13", "doi-asserted-by": "crossref", "first-page": "2257", "DOI": "10.1096/fasebj.13.15.2257", "volume": "13", "author": "MA Bounpheng", "year": "1999", "unstructured": "Bounpheng MA, Dimas JJ, Dodds SG, Christy BA. Degradation of Id proteins by the ubiquitin-proteasome pathway. FASEB J 1999;13:2257\u20132264.", "journal-title": "FASEB J"}, {"key": "41_CR14", "doi-asserted-by": "publisher", "first-page": "3850", "DOI": "10.1073/pnas.070047997", "volume": "97", "author": "B Li", "year": "2000", "unstructured": "Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000;97:3850\u20133855.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "41_CR15", "doi-asserted-by": "publisher", "first-page": "7273", "DOI": "10.1074/jbc.271.13.7273", "volume": "271", "author": "LR Dick", "year": "1996", "unstructured": "Dick LR, Cruikshank AA, Grenier L, et al. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J Biol Chem 1996;271:7273\u20137276.", "journal-title": "J Biol Chem"}, {"key": "41_CR16", "doi-asserted-by": "publisher", "first-page": "294", "DOI": "10.1016/S0091-6749(99)70369-6", "volume": "104", "author": "PJ Elliott", "year": "1999", "unstructured": "Elliott PJ, Pien CS, McCormack TA, et al. Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 1999;104:294\u2013300.", "journal-title": "J Allergy Clin Immunol"}, {"key": "41_CR17", "doi-asserted-by": "publisher", "first-page": "467", "DOI": "10.1006/jmcc.1998.0880", "volume": "31", "author": "B Campbell", "year": "1999", "unstructured": "Campbell B, Adams J, Shin YK, Lefer AM. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 1999;31:467\u2013476.", "journal-title": "J Mol Cell Cardiol"}, {"key": "41_CR18", "doi-asserted-by": "publisher", "first-page": "10", "DOI": "10.1073/pnas.96.18.10403", "volume": "96", "author": "L Meng", "year": "1999", "unstructured": "Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999;96:10,403\u201310,408.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "41_CR19", "first-page": "2798", "volume": "59", "author": "L Meng", "year": "1999", "unstructured": "Meng L, Kwok BH, Sin N, Crews CM. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999;59:2798\u20132801.", "journal-title": "Cancer Res"}, {"key": "41_CR20", "doi-asserted-by": "publisher", "first-page": "245", "DOI": "10.1002/med.1009", "volume": "21", "author": "J Myung", "year": "2001", "unstructured": "Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001;21:245\u2013273.", "journal-title": "Med Res Rev"}, {"key": "41_CR21", "doi-asserted-by": "publisher", "first-page": "333", "DOI": "10.1016/S0960-894X(98)00029-8", "volume": "8", "author": "J Adams", "year": "1998", "unstructured": "Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333\u2013338.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "41_CR22", "first-page": "4342", "volume": "58", "author": "RZ Orlowski", "year": "1998", "unstructured": "Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor. Cancer Res 1998;58:4342\u20134348.", "journal-title": "Cancer Res"}, {"key": "41_CR23", "first-page": "3071", "volume": "61", "author": "T Hideshima", "year": "2001", "unstructured": "Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071\u20133076.", "journal-title": "Cancer Res"}, {"key": "41_CR24", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1006/jsre.2001.6194", "volume": "100", "author": "RJ Bold", "year": "2001", "unstructured": "Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11\u201317.", "journal-title": "J Surg Res"}, {"key": "41_CR25", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.1002/jcb.1150", "volume": "82", "author": "SA Shah", "year": "2001", "unstructured": "Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110\u2013122.", "journal-title": "J Cell Biochem"}, {"key": "41_CR26", "first-page": "3719", "volume": "6", "author": "A Frankel", "year": "2000", "unstructured": "Frankel A, Man S, Elliott P, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719\u20133728.", "journal-title": "Clin Cancer Res"}, {"key": "41_CR27", "first-page": "1419", "volume": "7", "author": "JB Sunwoo", "year": "2001", "unstructured": "Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappaB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419\u20131428.", "journal-title": "Clin Cancer Res"}, {"key": "41_CR28", "doi-asserted-by": "publisher", "first-page": "327", "DOI": "10.1002/ijc.1040", "volume": "96", "author": "JF Kurland", "year": "2001", "unstructured": "Kurland JF, Meyn RE. Protease inhibitors restore radiationinduced apoptosis to Bcl-2-expressing lymphoma cells. Int J Cancer 2001;96:327\u2013333.", "journal-title": "Int J Cancer"}, {"key": "41_CR29", "doi-asserted-by": "publisher", "first-page": "481", "DOI": "10.1002/ijc.1373", "volume": "93", "author": "XM Fan", "year": "2001", "unstructured": "Fan XM, Wong BC, Wang WP, et al. Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer 2001;93:481\u2013488.", "journal-title": "Int J Cancer"}, {"key": "41_CR30", "first-page": "3535", "volume": "61", "author": "JC Cusack Jr", "year": "2001", "unstructured": "Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-KB inhibition. Cancer Res 2001;61:3535\u20133540.", "journal-title": "Cancer Res"}, {"key": "41_CR31", "first-page": "4996", "volume": "62", "author": "R LeBlanc", "year": "2002", "unstructured": "LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996\u20135000.", "journal-title": "Cancer Res"}, {"key": "41_CR32", "first-page": "98", "volume": "310", "author": "P Steiner", "year": "2001", "unstructured": "Steiner P, Neumeier H, Lightcap ES, et al. Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. Blood 2001;98:310a.", "journal-title": "Blood"}, {"key": "41_CR33", "doi-asserted-by": "publisher", "first-page": "607", "DOI": "10.1016/S0093-7754(01)90033-8", "volume": "28", "author": "T Hideshima", "year": "2001", "unstructured": "Hideshima T, Chauhan D, Podar K, et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607\u2013612.", "journal-title": "Semin Oncol"}, {"key": "41_CR34", "first-page": "98", "volume": "368", "author": "R Feinman", "year": "2001", "unstructured": "Feinman R, Aris VM, Vergano S, et al. Transcriptional gene expression profiles in drug-sensitive and Bcl-2-resistant myeloma cells in response to dexamethasone, arsenic trioxide, and PS-341. Blood 2001;98:368a.", "journal-title": "Blood"}, {"key": "41_CR35", "doi-asserted-by": "publisher", "first-page": "126", "DOI": "10.1046/j.1365-2141.2001.02683.x", "volume": "113", "author": "D Soligo", "year": "2001", "unstructured": "Soligo D, Servida F, Delia D, et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001;113:126\u2013135.", "journal-title": "Br J Haematol"}, {"key": "41_CR36", "doi-asserted-by": "publisher", "first-page": "499", "DOI": "10.3109/10428190009059268", "volume": "38", "author": "P Masdehors", "year": "2000", "unstructured": "Masdehors P, Merle-Beral H, Magdelenat H, Delic J. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk Lymphoma 2000;38:499\u2013504.", "journal-title": "Leuk Lymphoma"}, {"key": "41_CR37", "doi-asserted-by": "publisher", "first-page": "1103", "DOI": "10.1038/bjc.1998.183", "volume": "77", "author": "J Delic", "year": "1998", "unstructured": "Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998;77: 1103\u20131107.", "journal-title": "Br J Cancer"}, {"key": "41_CR38", "first-page": "916", "volume": "6", "author": "Y Kudo", "year": "2000", "unstructured": "Kudo Y, Takata T, Ogawa I, et al. p27Kip 1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000;6:916\u2013923.", "journal-title": "Clin Cancer Res"}, {"key": "41_CR39", "doi-asserted-by": "publisher", "first-page": "7071", "DOI": "10.1073/pnas.87.18.7071", "volume": "87", "author": "A Kumatori", "year": "1990", "unstructured": "Kumatori A, Tanaka K, Inamura N, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990;87:7071\u20137075.", "journal-title": "Proc Natl Acad Sci USA"}, {"issue": "4420", "key": "41_CR40", "first-page": "4127", "volume": "20", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20: 4420 4127.", "journal-title": "J Clin Oncol"}, {"key": "41_CR41", "first-page": "2505", "volume": "8", "author": "C Aghajanian", "year": "2002", "unstructured": "Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505\u20132511.", "journal-title": "Clin Cancer Res"}, {"key": "41_CR42", "doi-asserted-by": "crossref", "first-page": "40", "DOI": "10.1074/jbc.M004392200", "volume": "276", "author": "Y Mao", "year": "2001", "unstructured": "Mao Y, Desai SD, Ting CY, et al. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J Biol Chem 2001;276:40,652\u201340,658.", "journal-title": "J Biol Chem"}, {"key": "41_CR43", "doi-asserted-by": "publisher", "first-page": "24", "DOI": "10.1074/jbc.272.1.24", "volume": "272", "author": "SD Desai", "year": "1997", "unstructured": "Desai SD, Liu LF, Vazquez-Abad D, D\u2019Arpa P. Ubiquitindependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997;272:24,159\u201324,164.", "journal-title": "J Biol Chem"}, {"key": "41_CR44", "doi-asserted-by": "publisher", "first-page": "874", "DOI": "10.1126/science.288.5467.874", "volume": "288", "author": "Y Yang", "year": "2000", "unstructured": "Yang Y, Fang S, Jensen JP, et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000;288:874\u2013877.", "journal-title": "Science"}, {"key": "41_CR45", "doi-asserted-by": "publisher", "first-page": "823", "DOI": "10.1006/bbrc.1999.1291", "volume": "262", "author": "P Chadebech", "year": "1999", "unstructured": "Chadebech P, Brichese L, Baldin V, et al. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitoticarrested cells after microtubule damage. Biochem Biophys Res Commun 1999;262:823\u2013827.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "41_CR46", "doi-asserted-by": "publisher", "first-page": "1329", "DOI": "10.1016/S0960-9822(00)00773-9", "volume": "10", "author": "H Tatebe", "year": "2000", "unstructured": "Tatebe H, Yanagida M. Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2. Curr Biol 2000;10:1329\u20131338.", "journal-title": "Curr Biol"}, {"key": "41_CR47", "doi-asserted-by": "publisher", "first-page": "682", "DOI": "10.1126/science.7624798", "volume": "269", "author": "M Pagano", "year": "1995", "unstructured": "Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682\u2013685.", "journal-title": "Science"}, {"key": "41_CR48", "doi-asserted-by": "publisher", "first-page": "2437", "DOI": "10.1038/sj.onc.1202189", "volume": "17", "author": "C Cayrol", "year": "1998", "unstructured": "Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 1998;17:2437\u20132444.", "journal-title": "Oncogene"}, {"key": "41_CR49", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1074/jbc.272.30.18694", "volume": "272", "author": "B Segnitz", "year": "1997", "unstructured": "Segnitz B, Gehring U. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J Biol Chem 1997;272:18,694\u201318,701.", "journal-title": "J Biol Chem"}, {"key": "41_CR50", "first-page": "4620", "volume": "56", "author": "SN Boyer", "year": "1996", "unstructured": "Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996;56:4620\u20134624.", "journal-title": "Cancer Res"}], "container-title": ["Cancer Chemoprevention"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-1-59259-767-3_41", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 11]], "date-time": "2019-05-11T21:02:18Z", "timestamp": 1557608538000}, "score": 27.29646, "issued": {"date-parts": [[2004]]}, "ISBN": ["9781617373428", "9781592597673"], "references-count": 50, "URL": "http://dx.doi.org/10.1007/978-1-59259-767-3_41", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T15:57:50Z", "timestamp": 1574524670871}, "publisher-location": "Totowa, NJ", "reference-count": 121, "publisher": "Humana Press", "isbn-type": [{"value": "9781617374524", "type": "print"}, {"value": "9781592597949", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2004]]}, "DOI": "10.1007/978-1-59259-794-9_7", "type": "book-chapter", "created": {"date-parts": [[2012, 12, 28]], "date-time": "2012-12-28T15:58:01Z", "timestamp": 1356710281000}, "page": "85-98", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Proteasome Inhibition and Apoptosis"], "prefix": "10.1007", "author": [{"given": "Simon A.", "family": "Williams", "sequence": "first", "affiliation": []}, {"given": "David J.", "family": "McConkey", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "7_CR1", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1038/bjc.1972.33", "volume": "26", "author": "JF Kerr", "year": "1972", "unstructured": "Kerr JF, et al. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239\u2013257.", "journal-title": "Br J Cancer"}, {"key": "7_CR2", "doi-asserted-by": "publisher", "first-page": "681", "DOI": "10.1007/BF01002719", "volume": "13", "author": "AH Wyllie", "year": "1981", "unstructured": "Wyllie AH, et al. Chromatin changes in apoptosis. Histochem J 1981;13:681\u2013692.", "journal-title": "Histochem J"}, {"key": "7_CR3", "doi-asserted-by": "publisher", "first-page": "817", "DOI": "10.1016/0092-8674(86)90004-8", "volume": "44", "author": "HM Ellis", "year": "1986", "unstructured": "Ellis HM, et al. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986;44:817\u2013829.", "journal-title": "Cell"}, {"key": "7_CR4", "doi-asserted-by": "publisher", "first-page": "519", "DOI": "10.1016/S0092-8674(00)81182-4", "volume": "93", "author": "B Conradt", "year": "1998", "unstructured": "Conradt B, et al. The C. elegans protein EGL-1 is required for programmed cell death and interacts with the bcl-2-like protein CED-9. Cell 1998;93:519\u2013529.", "journal-title": "Cell"}, {"key": "7_CR5", "doi-asserted-by": "publisher", "first-page": "494", "DOI": "10.1038/356494a0", "volume": "356", "author": "MO Hengartner", "year": "1992", "unstructured": "Hengartner MO, et al. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 1992;356:494\u2013499.", "journal-title": "Nature"}, {"key": "7_CR6", "doi-asserted-by": "publisher", "first-page": "1073", "DOI": "10.1101/gad.10.9.1073", "volume": "10", "author": "D Xue", "year": "1996", "unstructured": "Xue D, et al. The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev 1996;10:1073\u20131083.", "journal-title": "Genes Dev"}, {"key": "7_CR7", "doi-asserted-by": "publisher", "first-page": "305", "DOI": "10.1038/36889", "volume": "390", "author": "D Xue", "year": "1997", "unstructured": "Xue D, et al. Caenorhabditis elegans CED-9 protein is a bifunctional cell-death inhibitor. Nature 1997;390:305\u2013308.", "journal-title": "Nature"}, {"key": "7_CR8", "doi-asserted-by": "publisher", "first-page": "259", "DOI": "10.1038/336259a0", "volume": "336", "author": "JC Reed", "year": "1988", "unstructured": "Reed JC, et al. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 1988;336:259\u2013261.", "journal-title": "Nature"}, {"key": "7_CR9", "doi-asserted-by": "publisher", "first-page": "79", "DOI": "10.1016/0092-8674(89)90174-8", "volume": "57", "author": "TJ McDonnell", "year": "1989", "unstructured": "McDonnell TJ, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79\u201388.", "journal-title": "Cell"}, {"key": "7_CR10", "doi-asserted-by": "publisher", "first-page": "334", "DOI": "10.1038/348334a0", "volume": "348", "author": "D Hockenbery", "year": "1990", "unstructured": "Hockenbery D, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334\u2013336.", "journal-title": "Nature"}, {"key": "7_CR11", "doi-asserted-by": "publisher", "first-page": "399", "DOI": "10.1159/000019916", "volume": "35", "author": "JW Moul", "year": "1999", "unstructured": "Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999;35:399\u2013407.", "journal-title": "Eur Urol"}, {"key": "7_CR12", "doi-asserted-by": "publisher", "first-page": "301", "DOI": "10.1038/nrc780", "volume": "2", "author": "M Karin", "year": "2002", "unstructured": "Karin M. et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301\u2013310.", "journal-title": "Nat Rev Cancer"}, {"key": "7_CR13", "doi-asserted-by": "publisher", "first-page": "626", "DOI": "10.1016/S0093-7754(01)90036-3", "volume": "28", "author": "JR Berenson", "year": "2001", "unstructured": "Berenson JR, et al. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 2001;28:626\u2013633.", "journal-title": "Semin Oncol"}, {"key": "7_CR14", "doi-asserted-by": "publisher", "first-page": "967", "DOI": "10.1126/science.275.5302.967", "volume": "275", "author": "N Rampino", "year": "1997", "unstructured": "Rampino N, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967\u2013969.", "journal-title": "Science"}, {"key": "7_CR15", "doi-asserted-by": "publisher", "first-page": "1312", "DOI": "10.1002/neu.480230918", "volume": "23", "author": "LM Schwartz", "year": "1992", "unstructured": "Schwartz LM. Insect muscle as a model for programmed cell death. J Neurobiol 1992;23:1312\u20131326.", "journal-title": "J Neurobiol"}, {"key": "7_CR16", "doi-asserted-by": "publisher", "first-page": "436", "DOI": "10.1006/dbio.1995.1159", "volume": "169", "author": "ME Jones", "year": "1995", "unstructured": "Jones ME, et al. Changes in the structure and function of the multicatalytic proteinase (proteasome) during programmed cell death in the intersegmental muscles of the hawkmoth, Manduca sexta. Dev Biol 1995;169:436\u2013447.", "journal-title": "Dev Biol"}, {"key": "7_CR17", "doi-asserted-by": "crossref", "first-page": "3835", "DOI": "10.1002/j.1460-2075.1996.tb00757.x", "volume": "15", "author": "LM Grimm", "year": "1996", "unstructured": "Grimm LM, et al. Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996;15:3835\u20133844.", "journal-title": "EMBO J"}, {"key": "7_CR18", "doi-asserted-by": "publisher", "first-page": "293", "DOI": "10.1006/bbrc.1998.9291", "volume": "250", "author": "E Grassilli", "year": "1998", "unstructured": "Grassilli E, et al. Inhibition of proteasome function prevents thymocyte apoptosis: involvement of ornithine decarboxylase. Biochem Biophys Res Commun 1998;250:293\u2013297.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "7_CR19", "doi-asserted-by": "crossref", "first-page": "661", "DOI": "10.1042/bj3320661", "volume": "332", "author": "C Stefanelli", "year": "1998", "unstructured": "Stefanelli C, et al. Inhibition of etoposide-induced apoptosis with peptide aldehyde inhibitors of proteasome. Biochem J 1998;332:661\u2013665.", "journal-title": "Biochem J"}, {"key": "7_CR20", "first-page": "35", "volume": "161", "author": "T Hirsch", "year": "1998", "unstructured": "Hirsch T, et al. Proteasome activation occurs at an early, premitochondrial step of thymocyte apoptosis. J Immunol 1998;161:35\u201340.", "journal-title": "J Immunol"}, {"key": "7_CR21", "doi-asserted-by": "publisher", "first-page": "368", "DOI": "10.1038/sj.cdd.4400661", "volume": "7", "author": "B Dallaporta", "year": "2000", "unstructured": "Dallaporta B, et al. Proteasome activation as a critical event of thymocyte apoptosis. Cell Death Differ 2000;7:368\u2013373.", "journal-title": "Cell Death Differ"}, {"key": "7_CR22", "doi-asserted-by": "crossref", "first-page": "3845", "DOI": "10.1002/j.1460-2075.1996.tb00758.x", "volume": "15", "author": "R Sadoul", "year": "1996", "unstructured": "Sadoul R, et al. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J 1996;15:3845\u20133852.", "journal-title": "EMBO J"}, {"key": "7_CR23", "doi-asserted-by": "crossref", "first-page": "3845", "DOI": "10.1002/j.1460-2075.1996.tb00758.x", "volume": "15", "author": "R Sadoul", "year": "1996", "unstructured": "Sadoul R, et al. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J 1996;15:3845\u20133852.", "journal-title": "EMBO J"}, {"key": "7_CR24", "doi-asserted-by": "publisher", "first-page": "1070", "DOI": "10.1006/bbrc.1995.2878", "volume": "217", "author": "S Imajoh-Ohmi", "year": "1995", "unstructured": "Imajoh-Ohmi S, et al. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995;217:1070\u20131077.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "7_CR25", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1042/bj3170385", "volume": "317", "author": "K Shinohara", "year": "1996", "unstructured": "Shinohara K, et al. Apoptosis induction resulting from proteasome inhibition. Biochem J 1996;317:385\u2013388.", "journal-title": "Biochem J"}, {"key": "7_CR26", "doi-asserted-by": "publisher", "first-page": "542", "DOI": "10.1093/oxfordjournals.jbchem.a021620", "volume": "121", "author": "Y Tanimoto", "year": "1997", "unstructured": "Tanimoto Y, et al. Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells. J Biochem (Tokyo) 1997;121:542\u2013549.", "journal-title": "J Biochem (Tokyo)"}, {"key": "7_CR27", "doi-asserted-by": "publisher", "first-page": "855", "DOI": "10.1073/pnas.94.3.855", "volume": "94", "author": "HC Drexler", "year": "1997", "unstructured": "Drexler HC, Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997;94:855\u2013860.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "7_CR28", "doi-asserted-by": "publisher", "first-page": "7515", "DOI": "10.1073/pnas.94.14.7515", "volume": "94", "author": "H Cui", "year": "1997", "unstructured": "Cui H, et al. Proteasome regulation of activation-induced T cell death. Proc Natl Acad Sci USA 1997;94:7515\u20137520.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "7_CR29", "doi-asserted-by": "publisher", "first-page": "2931", "DOI": "10.1074/jbc.273.5.2931", "volume": "273", "author": "F Bertrand", "year": "1998", "unstructured": "Bertrand F, et al. A role for nuclear factor kappaB in the antiapoptotic function of insulin. J Biol Chem 1998;273:2931\u20132938.", "journal-title": "J Biol Chem"}, {"key": "7_CR30", "first-page": "79", "volume": "9", "author": "YC Chang", "year": "1998", "unstructured": "Chang YC, et al. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 1998;9:79\u201384.", "journal-title": "Cell Growth Differ"}, {"key": "7_CR31", "doi-asserted-by": "crossref", "first-page": "3130", "DOI": "10.4049/jimmunol.166.5.3130", "volume": "166", "author": "V Marshansky", "year": "2001", "unstructured": "Marshansky V, et al. Proteasomes modulate balance among proapoptotic and antiapoptotic bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 2001;166:3130\u20133142.", "journal-title": "J Immunol"}, {"key": "7_CR32", "first-page": "625", "volume": "15", "author": "SA You", "year": "1999", "unstructured": "You SA, et al. Potent antitumor agent proteasome inhibitors: a novel trigger for Bc12 phosphorylation to induce apoptosis. Int J Oncol 1999;15:625\u2013628.", "journal-title": "Int J Oncol"}, {"key": "7_CR33", "first-page": "4342", "volume": "58", "author": "RZ Orlowski", "year": "1998", "unstructured": "Orlowski RZ, et al. Tumor growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor. Cancer Res 1998;58:4342\u20134348.", "journal-title": "Cancer Res"}, {"key": "7_CR34", "first-page": "3881", "volume": "57", "author": "VA Soldatenkov", "year": "1997", "unstructured": "Soldatenkov VA, et al. Apoptosis of Ewing\u2019 s sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Cancer Res 1997;57:3881\u20133885.", "journal-title": "Cancer Res"}, {"key": "7_CR35", "doi-asserted-by": "publisher", "first-page": "1103", "DOI": "10.1038/bjc.1998.183", "volume": "77", "author": "J Delic", "year": "1998", "unstructured": "Delic J, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998;77:1103\u20131107.", "journal-title": "Br J Cancer"}, {"key": "7_CR36", "doi-asserted-by": "publisher", "first-page": "752", "DOI": "10.1046/j.1365-2141.1999.01388.x", "volume": "105", "author": "P Masdehors", "year": "1999", "unstructured": "Masdehors P, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999;105:752\u2013757.", "journal-title": "Br J Haematol"}, {"key": "7_CR37", "doi-asserted-by": "publisher", "first-page": "1388", "DOI": "10.1038/sj.leu.2402201", "volume": "15", "author": "JB Almond", "year": "2001", "unstructured": "Almond JB, et al. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia 2001;15:1388\u20131397.", "journal-title": "Leukemia"}, {"key": "7_CR38", "first-page": "4220", "volume": "92", "author": "J Chandra", "year": "1998", "unstructured": "Chandra J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998;92:4220\u20134229.", "journal-title": "Blood"}, {"key": "7_CR39", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615\u20132622.", "journal-title": "Cancer Res"}, {"key": "7_CR40", "first-page": "2638", "volume": "5", "author": "BA Teicher", "year": "1999", "unstructured": "Teicher BA, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638\u20132645.", "journal-title": "Clin Cancer Res"}, {"key": "7_CR41", "doi-asserted-by": "publisher", "first-page": "1276", "DOI": "10.1038/sj.leu.2401812", "volume": "14", "author": "WG An", "year": "2000", "unstructured": "An WG, et al. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000 14:1276\u20131283.", "journal-title": "Leukemia"}, {"key": "7_CR42", "first-page": "3071", "volume": "61", "author": "T Hideshima", "year": "2001", "unstructured": "Hideshima T, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001:61:3071\u20133076.", "journal-title": "Cancer Res"}, {"key": "7_CR43", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.1016/S1367-5931(02)00343-5", "volume": "6", "author": "J Adams", "year": "2002", "unstructured": "Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002;6:493\u2013500.", "journal-title": "Curr Opin Chem Biol"}, {"key": "7_CR44", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1016/S0360-3016(01)01446-8", "volume": "50", "author": "SM Russo", "year": "2001", "unstructured": "Russo SM, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001;50:183\u2013193.", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"key": "7_CR45", "first-page": "3535", "volume": "61", "author": "JC Cusack Jr", "year": "2001", "unstructured": "Cusack JC, Jr., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535\u20133540.", "journal-title": "Cancer Res"}, {"key": "7_CR46", "first-page": "1419", "volume": "7", "author": "JB Sunwoo", "year": "2001", "unstructured": "Sunwoo JB, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419\u20131428.", "journal-title": "Clin Cancer Res"}, {"key": "7_CR47", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1006/jsre.2001.6194", "volume": "100", "author": "RJ Bold", "year": "2001", "unstructured": "Bold RJ, et al. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11\u201317.", "journal-title": "J Surg Res"}, {"key": "7_CR48", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615\u20132622.", "journal-title": "Cancer Res"}, {"key": "7_CR49", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.1002/jcb.1150", "volume": "82", "author": "SA Shah", "year": "2001", "unstructured": "Shah SA, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110\u2013122.", "journal-title": "J Cell Biochem"}, {"key": "7_CR50", "doi-asserted-by": "publisher", "first-page": "12893", "DOI": "10.1074/jbc.272.20.12893", "volume": "272", "author": "UG Lopes", "year": "1997", "unstructured": "Lopes UG, et al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997;272:12893\u201312896.", "journal-title": "J Biol Chem"}, {"key": "7_CR51", "doi-asserted-by": "publisher", "first-page": "874", "DOI": "10.1126/science.288.5467.874", "volume": "288", "author": "Y Yang", "year": "2000", "unstructured": "Yang Y, et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000;288:874\u2013877.", "journal-title": "Science"}, {"key": "7_CR52", "doi-asserted-by": "publisher", "first-page": "8662", "DOI": "10.1073/pnas.161506698", "volume": "98", "author": "Y Suzuki", "year": "2001", "unstructured": "Suzuki Y, et al. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 2001;98:8662\u20138667.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "7_CR53", "doi-asserted-by": "publisher", "first-page": "55", "DOI": "10.1136/mp.51.2.55", "volume": "51", "author": "JA Royds", "year": "1998", "unstructured": "Royds JA, et al. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 1998;51:55\u201361.", "journal-title": "Mol Pathol"}, {"key": "7_CR54", "doi-asserted-by": "publisher", "first-page": "773", "DOI": "10.1016/S0092-8674(94)90482-0", "volume": "78", "author": "VJ Palombella", "year": "1994", "unstructured": "Palombella VJ, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773\u2013785.", "journal-title": "Cell"}, {"key": "7_CR55", "doi-asserted-by": "crossref", "first-page": "79", "DOI": "10.1242/jcs.1995.Supplement_19.11", "volume": "19", "author": "EB Traenckner", "year": "1995", "unstructured": "Traenckner EB, et al. Appearance of apparently ubiquitin-conjugated I kappa B-alpha during its phosphorylation-induced degradation in intact cells. J Cell Sci Suppl 1995;19:79\u201384.", "journal-title": "J Cell Sci Suppl"}, {"key": "7_CR56", "doi-asserted-by": "crossref", "first-page": "5433", "DOI": "10.1002/j.1460-2075.1994.tb06878.x", "volume": "13", "author": "EB Traenckner", "year": "1994", "unstructured": "Traenckner EB, et al. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994;13:5433\u20135441.", "journal-title": "EMBO J"}, {"key": "7_CR57", "first-page": "4624", "volume": "91", "author": "I Jeremias", "year": "1998", "unstructured": "Jeremias I, et al. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998;91:4624\u20134631.", "journal-title": "Blood"}, {"key": "7_CR58", "first-page": "891", "volume": "151", "author": "RE Bellas", "year": "1997", "unstructured": "Bellas RE, et al. Inhibition of NF-kappa B activity induces apoptosis in murine hepatocytes. Am J Pathol 1997;151:891\u2013896.", "journal-title": "Am J Pathol"}, {"key": "7_CR59", "doi-asserted-by": "publisher", "first-page": "538", "DOI": "10.1002/ijc.10398", "volume": "99", "author": "CC Bancroft", "year": "2002", "unstructured": "Bancroft CC, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99:538\u2013548.", "journal-title": "Int J Cancer"}, {"key": "7_CR60", "first-page": "5334", "volume": "60", "author": "S Huang", "year": "2000", "unstructured": "Huang S, et al. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000;60:5334\u20135339.", "journal-title": "Cancer Res"}, {"key": "7_CR61", "doi-asserted-by": "publisher", "first-page": "4188", "DOI": "10.1038/sj.onc.1204535", "volume": "20", "author": "S Huang", "year": "2001", "unstructured": "Huang S, et al. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188\u20134197.", "journal-title": "Oncogene"}, {"key": "7_CR62", "doi-asserted-by": "crossref", "first-page": "4015", "DOI": "10.1128/MCB.17.7.4015", "volume": "17", "author": "S Yoshida", "year": "1997", "unstructured": "Yoshida S, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997;17:4015\u20134023.", "journal-title": "Mol Cell Biol"}, {"key": "7_CR63", "doi-asserted-by": "publisher", "first-page": "243", "DOI": "10.1006/bbrc.1998.8604", "volume": "246", "author": "T Oikawa", "year": "1998", "unstructured": "Oikawa T, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998;246:243\u2013248.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "7_CR64", "doi-asserted-by": "publisher", "first-page": "96", "DOI": "10.1007/s000180050273", "volume": "55", "author": "DA Freedman", "year": "1999", "unstructured": "Freedman DA, et al. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96\u2013107.", "journal-title": "Cell Mol Life Sci"}, {"key": "7_CR65", "doi-asserted-by": "publisher", "first-page": "325", "DOI": "10.1016/S0092-8674(00)80416-X", "volume": "91", "author": "SY Shieh", "year": "1997", "unstructured": "Shieh SY, et al. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997;91:325\u2013334.", "journal-title": "Cell"}, {"key": "7_CR66", "doi-asserted-by": "publisher", "first-page": "3471", "DOI": "10.1101/gad.11.24.3471", "volume": "11", "author": "JD Siliciano", "year": "1997", "unstructured": "Siliciano JD, et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997;11:3471\u20133481.", "journal-title": "Genes Dev"}, {"key": "7_CR67", "doi-asserted-by": "publisher", "first-page": "1297", "DOI": "10.1128/MCB.21.4.1297-1310.2001", "volume": "21", "author": "C Koumenis", "year": "2001", "unstructured": "Koumenis C, et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 2001;21:1297\u20131310.", "journal-title": "Mol Cell Biol"}, {"key": "7_CR68", "doi-asserted-by": "publisher", "first-page": "1805", "DOI": "10.1093/emboj/18.7.1805", "volume": "18", "author": "T Unger", "year": "1999", "unstructured": "Unger T, et al. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 1999;18:1805\u20131814.", "journal-title": "EMBO J"}, {"key": "7_CR69", "doi-asserted-by": "publisher", "first-page": "10117", "DOI": "10.1021/bi970759w", "volume": "36", "author": "K Sakaguchi", "year": "1997", "unstructured": "Sakaguchi K, et al. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 1997;36:10117\u201310124.", "journal-title": "Biochemistry"}, {"key": "7_CR70", "doi-asserted-by": "publisher", "first-page": "1049", "DOI": "10.1126/science.2144364", "volume": "249", "author": "L Raycroft", "year": "1990", "unstructured": "Raycroft L, et al. Transcriptional activation by wild-type but not transforming mutants of the p53 antioncogene. Science 1990;249:1049\u20131051.", "journal-title": "Science"}, {"key": "7_CR71", "doi-asserted-by": "publisher", "first-page": "280", "DOI": "10.1006/excr.1998.4319", "volume": "246", "author": "AL Gartel", "year": "1999", "unstructured": "Gartel AL, et al. Transcriptional regulation of the p21 (WAF1/CIP1) gene. Exp Cell Res 1999;246:280\u2013289.", "journal-title": "Exp Cell Res"}, {"key": "7_CR72", "first-page": "1711", "volume": "60", "author": "G Xiao", "year": "2000", "unstructured": "Xiao G, et al. A DNA damage signal is required for p53 to activate gadd45. Cancer Res 2000;60:1711\u20131719.", "journal-title": "Cancer Res"}, {"key": "7_CR73", "doi-asserted-by": "publisher", "first-page": "684", "DOI": "10.1042/BST0290684", "volume": "29", "author": "M Schuler", "year": "2001", "unstructured": "Schuler M, et al. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001;29:684\u2013688.", "journal-title": "Biochem Soc Trans"}, {"key": "7_CR74", "doi-asserted-by": "publisher", "first-page": "2033", "DOI": "10.1084/jem.188.11.2033", "volume": "188", "author": "M Muller", "year": "1998", "unstructured": "Muller M, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188:2033\u20132045.", "journal-title": "J Exp Med"}, {"key": "7_CR75", "first-page": "3131", "volume": "54", "author": "T Miyashita", "year": "1994", "unstructured": "Miyashita T, et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131\u20133135.", "journal-title": "Cancer Res"}, {"key": "7_CR76", "doi-asserted-by": "publisher", "first-page": "6768", "DOI": "10.1128/MCB.21.20.6768-6781.2001", "volume": "21", "author": "E Sadot", "year": "2001", "unstructured": "Sadot E, et al. Down-regulation of beta-catenin by activated p53. Mol Cell Biol 2001;21:6768\u20136781.", "journal-title": "Mol Cell Biol"}, {"key": "7_CR77", "doi-asserted-by": "publisher", "first-page": "290", "DOI": "10.1126/science.282.5387.290", "volume": "282", "author": "M Bennett", "year": "1998", "unstructured": "Bennett M, et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998;282:290\u2013293.", "journal-title": "Science"}, {"key": "7_CR78", "doi-asserted-by": "publisher", "first-page": "16202", "DOI": "10.1074/jbc.275.21.16202", "volume": "275", "author": "ND Marchenko", "year": "2000", "unstructured": "Marchenko ND, et al. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 2000;275:16202\u201316212.", "journal-title": "J Biol Chem"}, {"key": "7_CR79", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.1016/S0014-5793(00)02368-1", "volume": "488", "author": "C Sansome", "year": "2001", "unstructured": "Sansome C, et al. Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett 2001;488:110\u2013115.", "journal-title": "FEBS Lett"}, {"key": "7_CR80", "first-page": "2649", "volume": "56", "author": "CG Maki", "year": "1996", "unstructured": "Maki CG, et al. In vivo ubiquitination and proteasome-mediated degradation of p53 (1). Cancer Res 1996;56:2649\u20132654.", "journal-title": "Cancer Res"}, {"key": "7_CR81", "doi-asserted-by": "publisher", "first-page": "327", "DOI": "10.1002/ijc.1040", "volume": "96", "author": "JF Kurland", "year": "2001", "unstructured": "Kurland JF, et al. Protease inhibitors restore radiation-induced apoptosis to bcl-2-expressing lymphoma cells. Int J Cancer 2001;96:327\u2013333.", "journal-title": "Int J Cancer"}, {"key": "7_CR82", "doi-asserted-by": "publisher", "first-page": "210", "DOI": "10.1038/sj.cdd.4400801", "volume": "8", "author": "AP MacLaren", "year": "2001", "unstructured": "MacLaren AP, et al. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001;8:210\u2013218.", "journal-title": "Cell Death Differ"}, {"key": "7_CR83", "doi-asserted-by": "publisher", "first-page": "564", "DOI": "10.1006/bbrc.1996.1546", "volume": "227", "author": "MV Blagosklonny", "year": "1996", "unstructured": "Blagosklonny MV, et al. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 1996;227:564\u2013569.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "7_CR84", "first-page": "239", "volume": "11", "author": "F Chen", "year": "2000", "unstructured": "Chen F, et al. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 2000;11:239\u2013246.", "journal-title": "Cell Growth Differ"}, {"key": "7_CR85", "doi-asserted-by": "publisher", "first-page": "181", "DOI": "10.1016/S0014-5793(98)01709-8", "volume": "443", "author": "H Kitagawa", "year": "1999", "unstructured": "Kitagawa H, et al. Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett 1999;443:181\u2013186.", "journal-title": "FEBS Lett"}, {"key": "7_CR86", "doi-asserted-by": "publisher", "first-page": "117", "DOI": "10.1159/000016308", "volume": "9", "author": "B Wagenknecht", "year": "1999", "unstructured": "Wagenknecht B, et al. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell Physiol Biochem 1999;9:117\u2013125.", "journal-title": "Cell Physiol Biochem"}, {"key": "7_CR87", "doi-asserted-by": "publisher", "first-page": "221", "DOI": "10.1034/j.1600-0609.2000.065004221.x", "volume": "65", "author": "C Naujokat", "year": "2000", "unstructured": "Naujokat C, et al. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cipl in human immature leukemic cells. Eur J Haematol 2000;65:221\u2013236.", "journal-title": "Eur J Haematol"}, {"key": "7_CR88", "doi-asserted-by": "publisher", "first-page": "2889", "DOI": "10.1038/sj.onc.1202221", "volume": "17", "author": "JL Herrmann", "year": "1998", "unstructured": "Herrmann JL, et al. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 1998;17:2889\u20132899.", "journal-title": "Oncogene"}, {"key": "7_CR89", "first-page": "1627", "volume": "2", "author": "CA Pettaway", "year": "1996", "unstructured": "Pettaway CA, et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627\u20131636.", "journal-title": "Clin Cancer Res"}, {"key": "7_CR90", "doi-asserted-by": "publisher", "first-page": "5113", "DOI": "10.1073/pnas.94.10.5113", "volume": "94", "author": "SL Schendel", "year": "1997", "unstructured": "Schendel SL, et al. Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 1997;94:5113\u20135118.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "7_CR91", "doi-asserted-by": "publisher", "first-page": "3225", "DOI": "10.1038/sj.onc.1202591", "volume": "17", "author": "JC Reed", "year": "1998", "unstructured": "Reed JC. Bcl-2 family proteins. Oncogene 1998;17:3225\u20133236.", "journal-title": "Oncogene"}, {"key": "7_CR92", "doi-asserted-by": "publisher", "first-page": "358", "DOI": "10.1038/ng0897-358", "volume": "16", "author": "CM Knudson", "year": "1997", "unstructured": "Knudson CM, et al. Bcl-2 and Bax function independently to regulate cell death. Nat Genet 1997;16:358\u2013363.", "journal-title": "Nat Genet"}, {"key": "7_CR93", "doi-asserted-by": "publisher", "first-page": "1815", "DOI": "10.1084/jem.189.11.1815", "volume": "189", "author": "S Dimmeler", "year": "1999", "unstructured": "Dimmeler S, et al. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J Exp Med 1999;189:1815\u20131822.", "journal-title": "J Exp Med"}, {"key": "7_CR94", "doi-asserted-by": "publisher", "first-page": "3850", "DOI": "10.1073/pnas.070047997", "volume": "97", "author": "B Li", "year": "2000", "unstructured": "Li B, et al. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000;97:3850\u20133855.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "7_CR95", "doi-asserted-by": "publisher", "first-page": "21648", "DOI": "10.1074/jbc.M001083200", "volume": "275", "author": "K Breitschopf", "year": "2000", "unstructured": "Breitschopf K, et al. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 2000;275:21648\u201321652.", "journal-title": "J Biol Chem"}, {"key": "7_CR96", "doi-asserted-by": "publisher", "first-page": "127", "DOI": "10.1042/0264-6021:3400127", "volume": "340", "author": "XM Zhang", "year": "1999", "unstructured": "Zhang XM, et al. Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Biochem J 1999;340:127\u2013133.", "journal-title": "Biochem J"}, {"key": "7_CR97", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1006/jsre.2001.6194", "volume": "100", "author": "RJ Bold", "year": "2001", "unstructured": "Bold RJ, et al. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11\u201317.", "journal-title": "J Surg Res"}, {"key": "7_CR98", "first-page": "3881", "volume": "57", "author": "VA Soldatenkov", "year": "1997", "unstructured": "Soldatenkov VA, et al. Apoptosis of Ewing\u2019s sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Cancer Res 1997;57:3881\u20133885.", "journal-title": "Cancer Res"}, {"key": "7_CR99", "doi-asserted-by": "publisher", "first-page": "126", "DOI": "10.1046/j.1365-2141.2001.02683.x", "volume": "113", "author": "D Soligo", "year": "2001", "unstructured": "Soligo D, et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001;113:126\u2013135.", "journal-title": "Br J Haematol"}, {"key": "7_CR100", "doi-asserted-by": "publisher", "first-page": "74", "DOI": "10.1006/bbrc.1996.0986", "volume": "224", "author": "E Fujita", "year": "1996", "unstructured": "Fujita E, et al. Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors. Biochem Biophys Res Commun 1996;224:74\u201379.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "7_CR101", "doi-asserted-by": "publisher", "first-page": "6121", "DOI": "10.1074/jbc.273.11.6121", "volume": "273", "author": "L Monney", "year": "1998", "unstructured": "Monney L, et al. Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by Bcl-2. J Biol Chem 1998;273:6121\u20136131.", "journal-title": "J Biol Chem"}, {"key": "7_CR102", "doi-asserted-by": "publisher", "first-page": "315", "DOI": "10.1034/j.1600-0609.2000.90110.x", "volume": "64", "author": "Y Yamada", "year": "2000", "unstructured": "Yamada Y, et al. Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fasresistant adult T-cell leukemia cell lines. Eur J Haematol 2000;64:315\u2013322.", "journal-title": "Eur J Haematol"}, {"key": "7_CR103", "doi-asserted-by": "publisher", "first-page": "2288", "DOI": "10.1046/j.1471-4159.2000.0752288.x", "volume": "75", "author": "B Wagenknecht", "year": "2000", "unstructured": "Wagenknecht B, et al. Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem 2000;75:2288\u20132297.", "journal-title": "J Neurochem"}, {"key": "7_CR104", "doi-asserted-by": "publisher", "first-page": "53", "DOI": "10.1016/S0014-5793(01)02770-3", "volume": "504", "author": "E Tani", "year": "2001", "unstructured": "Tani E, et al. Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells. FEBS Lett 2001;504:53\u201358.", "journal-title": "FEBS Lett"}, {"key": "7_CR105", "doi-asserted-by": "publisher", "first-page": "2619", "DOI": "10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J", "volume": "88", "author": "TH Wang", "year": "2000", "unstructured": "Wang TH, et al. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619\u20132628.", "journal-title": "Cancer"}, {"key": "7_CR106", "doi-asserted-by": "publisher", "first-page": "682", "DOI": "10.1126/science.7624798", "volume": "269", "author": "M Pagano", "year": "1995", "unstructured": "Pagano M, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclindependent kinase inhibitor p27. Science 1995;269:682\u2013685.", "journal-title": "Science"}, {"key": "7_CR107", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/S0304-3835(01)00847-3", "volume": "179", "author": "IB Roninson", "year": "2002", "unstructured": "Roninson IB. Oncogenic functions of tumour suppressor p21 (Wafl/Cipl/Sdil): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002;179:1\u201314.", "journal-title": "Cancer Lett"}, {"key": "7_CR108", "first-page": "916", "volume": "6", "author": "Y Kudo", "year": "2000", "unstructured": "Kudo Y, et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000;6:916\u2013923.", "journal-title": "Clin Cancer Res"}, {"key": "7_CR109", "first-page": "1243", "volume": "1", "author": "ST Nawrocki", "year": "2002", "unstructured": "Nawrocki ST, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243\u20131253.", "journal-title": "Mol Cancer Ther"}, {"key": "7_CR110", "first-page": "835", "volume": "2", "author": "S William", "year": "2003", "unstructured": "William S, Pettaway C, Song R, Papandreou C, Logothetis C, and McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003;2:835\u2013843.", "journal-title": "Mol Cancer Ther"}, {"key": "7_CR111", "first-page": "279", "volume": "3", "author": "AM Kamat", "year": "2004", "unstructured": "Kamat AM, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004;3:279\u2013290.", "journal-title": "Mol Cancer Ther"}, {"key": "7_CR112", "first-page": "4570", "volume": "9", "author": "JC Pahler", "year": "2003", "unstructured": "Pahler JC, et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res. 2003;9:4570\u20134577.", "journal-title": "Clin Cancer Res"}, {"key": "7_CR113", "first-page": "7338", "volume": "63", "author": "SA Williams", "year": "2003", "unstructured": "Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 2003;63:7338\u20137344.", "journal-title": "Cancer Res"}, {"key": "7_CR114", "first-page": "59", "volume": "3", "author": "ST Nawrocki", "year": "2004", "unstructured": "Nawrocki ST, et al. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3:59\u201370.", "journal-title": "Mol Cancer Ther"}, {"key": "7_CR115", "doi-asserted-by": "publisher", "first-page": "1211", "DOI": "10.1101/gad.13.10.1211", "volume": "13", "author": "RJ Kaufman", "year": "1999", "unstructured": "Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999;13:1211\u20131233.", "journal-title": "Genes Dev"}, {"key": "7_CR116", "doi-asserted-by": "crossref", "first-page": "1389", "DOI": "10.1172/JCI0216886", "volume": "110", "author": "RJ Kaufman", "year": "2002", "unstructured": "Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002;110:1389\u20131398.", "journal-title": "J Clin Invest"}, {"key": "7_CR117", "doi-asserted-by": "publisher", "first-page": "191", "DOI": "10.1016/0092-8674(91)90611-2", "volume": "66", "author": "LE Hightower", "year": "1991", "unstructured": "Hightower LE. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 1991;66:191\u2013197.", "journal-title": "Cell"}, {"key": "7_CR118", "doi-asserted-by": "publisher", "first-page": "9946", "DOI": "10.1073/pnas.1334037100", "volume": "100", "author": "AH Lee", "year": "2003", "unstructured": "Lee AH, et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003;100:9946\u20139951.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "7_CR119", "doi-asserted-by": "publisher", "first-page": "1530", "DOI": "10.1182/blood-2002-08-2543", "volume": "101", "author": "T Hideshima", "year": "2003", "unstructured": "Hideshima T, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530\u20131534.", "journal-title": "Blood"}, {"key": "7_CR120", "doi-asserted-by": "publisher", "first-page": "181", "DOI": "10.1038/nrm1052", "volume": "4", "author": "L Ellgaard", "year": "2003", "unstructured": "Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Bio 2003;4:181\u2013191.", "journal-title": "Nat Rev Mol Cell Bio"}, {"key": "7_CR121", "doi-asserted-by": "publisher", "first-page": "17593", "DOI": "10.1074/jbc.C300076200", "volume": "278", "author": "D Chauhan", "year": "2003", "unstructured": "Chauhan D, et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 2003;278;17593\u201317596.", "journal-title": "J Biol Chem"}], "container-title": ["Proteasome Inhibitors in Cancer Therapy"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-59259-794-9_7", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 10, 11]], "date-time": "2018-10-11T20:22:59Z", "timestamp": 1539289379000}, "score": 25.962275, "issued": {"date-parts": [[2004]]}, "ISBN": ["9781617374524", "9781592597949"], "references-count": 121, "URL": "http://dx.doi.org/10.1007/978-1-59259-794-9_7", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T23:16:47Z", "timestamp": 1575155807492}, "reference-count": 0, "publisher": "Clarivate Analytics (US)", "issue": "11", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drugs Fut"], "published-print": {"date-parts": [[2002]]}, "DOI": "10.1358/dof.2002.027.11.697067", "type": "journal-article", "created": {"date-parts": [[2005, 6, 17]], "date-time": "2005-06-17T13:04:37Z", "timestamp": 1119013477000}, "page": "1079", "source": "Crossref", "is-referenced-by-count": 13, "title": ["Bortezomib, a proteasome inhibitor, in cancer therapy: From concept to clinic"], "prefix": "10.1358", "volume": "27", "author": [{"given": "J.", "family": "Albanell", "sequence": "first", "affiliation": []}, {"given": "J.", "family": "Adams", "sequence": "additional", "affiliation": []}], "member": "71", "container-title": ["Drugs of the Future"], "language": "en", "deposited": {"date-parts": [[2011, 6, 23]], "date-time": "2011-06-23T14:20:56Z", "timestamp": 1308838856000}, "score": 25.78368, "issued": {"date-parts": [[2002]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2002]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1358/dof.2002.027.11.697067", "ISSN": ["0377-8282"], "issn-type": [{"value": "0377-8282", "type": "print"}], "subject": ["Pharmacology (medical)", "Pharmacology"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T11:25:41Z", "timestamp": 1574162741116}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2003, 5, 1]], "date-time": "2003-05-01T00:00:00Z", "timestamp": 1051747200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Treatment Reviews"], "published-print": {"date-parts": [[2003, 5]]}, "DOI": "10.1016/s0305-7372(03)00079-3", "type": "journal-article", "created": {"date-parts": [[2003, 5, 12]], "date-time": "2003-05-12T22:41:46Z", "timestamp": 1052779306000}, "page": "21-31", "source": "Crossref", "is-referenced-by-count": 75, "title": ["Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib"], "prefix": "10.1016", "volume": "29", "author": [{"given": "J", "family": "CUSACK", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Cancer Treatment Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0305-7372(03)00079-3?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0305-7372(03)00079-3?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 21]], "date-time": "2019-03-21T20:25:11Z", "timestamp": 1553199911000}, "score": 25.443491, "issued": {"date-parts": [[2003, 5]]}, "references-count": 0, "alternative-id": ["S0305-7372(03)00079-3"], "URL": "http://dx.doi.org/10.1016/s0305-7372(03)00079-3", "ISSN": ["0305-7372"], "issn-type": [{"value": "0305-7372", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T13:07:05Z", "timestamp": 1575292025287}, "publisher-location": "Totowa, NJ", "reference-count": 95, "publisher": "Humana Press", "isbn-type": [{"value": "9781934115299", "type": "print"}, {"value": "9781597454742", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2008]]}, "DOI": "10.1007/978-1-59745-474-2_5", "type": "book-chapter", "created": {"date-parts": [[2008, 7, 31]], "date-time": "2008-07-31T00:29:08Z", "timestamp": 1217464148000}, "page": "51-60", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Proteasome Inhibition: Potential for Sensitization of Immune Effector Mechanisms in Cancer"], "prefix": "10.1007", "author": [{"given": "Milad", "family": "Motarjemi", "sequence": "first", "affiliation": []}, {"given": "William H. D.", "family": "Hallett", "sequence": "additional", "affiliation": []}, {"given": "Minghui", "family": "Li", "sequence": "additional", "affiliation": []}, {"given": "William J.", "family": "Murphy", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "5_CR1_5", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1634/theoncologist.7-1-9", "volume": "7", "author": "J. Adams", "year": "2002", "unstructured": "Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002, 7:9\u201316.", "journal-title": "Oncologist"}, {"key": "5_CR2_5", "doi-asserted-by": "publisher", "first-page": "613", "DOI": "10.1016/S0093-7754(01)90034-X", "volume": "28", "author": "J. Adams", "year": "2001", "unstructured": "Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001, 28:613\u2013619.", "journal-title": "Semin Oncol"}, {"key": "5_CR3_5", "doi-asserted-by": "publisher", "first-page": "628", "DOI": "10.1097/00001622-200211000-00007", "volume": "14", "author": "J. Adams", "year": "2002", "unstructured": "Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002, 14:628\u2013634.", "journal-title": "Curr Opin Oncol"}, {"key": "5_CR4_5", "doi-asserted-by": "publisher", "first-page": "13", "DOI": "10.1016/0092-8674(94)90396-4", "volume": "79", "author": "A. Ciechanover", "year": "1994", "unstructured": "Ciechanover A. The ubiquitin-proteasome proteo-lytic pathway. Cell 1994, 79:13\u201321.", "journal-title": "Cell"}, {"key": "5_CR5_5", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, Palombella VJ, Sausville EA, et al. Protea-some inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59:2615\u20132622.", "journal-title": "Cancer Res"}, {"key": "5_CR6_5", "doi-asserted-by": "publisher", "first-page": "313", "DOI": "10.1007/s12094-006-0176-8", "volume": "8", "author": "C Montagut", "year": "2006", "unstructured": "Montagut C, Rovira A, Albanell J. The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 2006, 8:313\u2013317.", "journal-title": "Clin Transl Oncol"}, {"key": "5_CR7_5", "first-page": "255", "volume": "3", "author": "J Wang", "year": "2006", "unstructured": "Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 2006, 3:255\u2013261.", "journal-title": "Cell Mol Immunol"}, {"key": "5_CR8_5", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.1016/S1367-5931(02)00343-5", "volume": "6", "author": "J. Adams", "year": "2002", "unstructured": "Adams J. Preclinical and clinical evaluation of pro-teasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002, 6:493\u2013500.", "journal-title": "Curr Opin Chem Biol"}, {"key": "5_CR9_5", "doi-asserted-by": "publisher", "first-page": "109", "DOI": "10.1023/A:1006321828515", "volume": "18", "author": "J Adams", "year": "2000", "unstructured": "Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000, 18:109\u2013121.", "journal-title": "Invest New Drugs"}, {"key": "5_CR10_5", "doi-asserted-by": "publisher", "first-page": "425", "DOI": "10.1146/annurev.biochem.67.1.425", "volume": "67", "author": "A Hershko", "year": "1998", "unstructured": "Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998, 67:425\u2013479.", "journal-title": "Annu Rev Biochem"}, {"key": "5_CR11_5", "doi-asserted-by": "publisher", "first-page": "15671", "DOI": "10.1073/pnas.95.26.15671", "volume": "95", "author": "VJ Palombella", "year": "1998", "unstructured": "Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998, 95:15671\u201315676.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "5_CR12_5", "doi-asserted-by": "publisher", "first-page": "773", "DOI": "10.1016/S0092-8674(94)90482-0", "volume": "78", "author": "VJ Palombella", "year": "1994", "unstructured": "Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773\u2013785.", "journal-title": "Cell"}, {"key": "5_CR13_5", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1016/S0968-0004(97)01122-5", "volume": "22", "author": "A. Varshavsky", "year": "1997", "unstructured": "Varshavsky A. The ubiquitin system. Trends Biochem Sci 1997, 22:383\u2013387.", "journal-title": "Trends Biochem Sci"}, {"key": "5_CR14_5", "doi-asserted-by": "publisher", "first-page": "33", "DOI": "10.1053/sonc.2002.34878", "volume": "29", "author": "BD. Cheson", "year": "2002", "unstructured": "Cheson BD. Hematologic malignancies: new developments and future treatments. Semin Oncol 2002, 29:33\u201345.", "journal-title": "Semin Oncol"}, {"key": "5_CR15_5", "unstructured": "Anonymous. FDA approves Velcade for multiple myeloma treatment. FDA News 2003."}, {"key": "5_CR16_5", "doi-asserted-by": "publisher", "first-page": "2609", "DOI": "10.1056/NEJMoa030288", "volume": "348", "author": "PG Richardson", "year": "2003", "unstructured": "Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609\u20132617.", "journal-title": "N Engl J Med"}, {"key": "5_CR17_5", "doi-asserted-by": "publisher", "first-page": "433", "DOI": "10.1038/sj.leu.2402417", "volume": "16", "author": "JB Almond", "year": "2002", "unstructured": "Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002, 16:433\u2013443.", "journal-title": "Leukemia"}, {"key": "5_CR18_5", "doi-asserted-by": "publisher", "first-page": "179", "DOI": "10.1038/35056572", "volume": "2", "author": "PM. Kloetzel", "year": "2001", "unstructured": "Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001, 2:179\u2013187.", "journal-title": "Nat Rev Mol Cell Biol"}, {"key": "5_CR19_5", "doi-asserted-by": "publisher", "first-page": "801", "DOI": "10.1146/annurev.bi.65.070196.004101", "volume": "65", "author": "O Coux", "year": "1996", "unstructured": "Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996, 65:801\u2013847.", "journal-title": "Annu Rev Biochem"}, {"key": "5_CR20_5", "doi-asserted-by": "publisher", "first-page": "13437", "DOI": "10.1074/jbc.272.20.13437", "volume": "272", "author": "A Craiu", "year": "1997", "unstructured": "Craiu A, Gaczynska M, Akopian T, et al. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997, 272:13437\u201313445.", "journal-title": "J Biol Chem"}, {"key": "5_CR21_5", "doi-asserted-by": "publisher", "first-page": "10289", "DOI": "10.1021/bi00497a001", "volume": "29", "author": "M. Orlowski", "year": "1990", "unstructured": "Orlowski M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry 1990, 29:10289\u201310297.", "journal-title": "Biochemistry"}, {"key": "5_CR22_5", "doi-asserted-by": "publisher", "first-page": "311", "DOI": "10.1074/jbc.M206279200", "volume": "278", "author": "R Shringarpure", "year": "2003", "unstructured": "Shringarpure R, Grune T, Mehlhase J, et al. Ubiquitin conjugation is not required for the degradation of 0oxidized proteins by proteasome. J Biol Chem 2003, 278:311\u2013318.", "journal-title": "J Biol Chem"}, {"key": "5_CR23_5", "doi-asserted-by": "publisher", "first-page": "761", "DOI": "10.1016/S0092-8674(94)90462-6", "volume": "78", "author": "KL Rock", "year": "1994", "unstructured": "Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761\u2013771.", "journal-title": "Cell"}, {"key": "5_CR24_5", "first-page": "4859", "volume": "160", "author": "LC Anton", "year": "1998", "unstructured": "Anton LC, Snyder HL, Bennink JR, et al. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J Immunol 1998, 160:4859\u20134868.", "journal-title": "J Immunol"}, {"key": "5_CR25_5", "first-page": "112", "volume": "161", "author": "CJ Luckey", "year": "1998", "unstructured": "Luckey CJ, King GM, Marto JA, et al. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J Immunol 1998, 161:112\u2013121.", "journal-title": "J Immunol"}, {"key": "5_CR26_5", "first-page": "554", "volume": "159", "author": "A Vinitsky", "year": "1997", "unstructured": "Vinitsky A, Anton LC, Snyder HL, et al. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing? J Immunol 1997, 159:554\u2013564.", "journal-title": "J Immunol"}, {"key": "5_CR27_5", "first-page": "3227", "volume": "158", "author": "AJ Yellen-Shaw", "year": "1997", "unstructured": "Yellen-Shaw AJ, Wherry EJ, Dubois GC, et al. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J Immunol 1997, 158:3227\u20133234.", "journal-title": "J Immunol"}, {"key": "5_CR28_5", "doi-asserted-by": "crossref", "first-page": "2249", "DOI": "10.4049/jimmunol.176.4.2249", "volume": "176", "author": "EJ Wherry", "year": "2006", "unstructured": "Wherry EJ, Golovina TN, Morrison SE, et al. Re-evaluating the generation of a \u201cproteasome-inde-pendent\u201d MHC class I-restricted CD8 T cell epitope. J Immunol 2006, 176:2249\u20132261.", "journal-title": "J Immunol"}, {"key": "5_CR29_5", "doi-asserted-by": "publisher", "first-page": "6800", "DOI": "10.1038/sj.onc.1209938", "volume": "25", "author": "J Dutta", "year": "2006", "unstructured": "Dutta J, Fan Y, Gupta N, et al. Current insights into the regulation of programmed cell death by NF-kap-paB. Oncogene 2006, 25:6800\u20136816.", "journal-title": "Oncogene"}, {"key": "5_CR30_5", "first-page": "1367", "volume": "13", "author": "TD Gilmore", "year": "1996", "unstructured": "Gilmore TD, Koedood M, Piffat KA, et al. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene 1996, 13:1367\u20131378.", "journal-title": "Oncogene"}, {"key": "5_CR31_5", "doi-asserted-by": "publisher", "first-page": "16639", "DOI": "10.1074/jbc.M200360200", "volume": "277", "author": "T Hideshima", "year": "2002", "unstructured": "Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639\u201316647.", "journal-title": "J Biol Chem"}, {"key": "5_CR32_5", "doi-asserted-by": "publisher", "first-page": "6867", "DOI": "10.1038/sj.onc.1203219", "volume": "18", "author": "M. Karin", "year": "1999", "unstructured": "Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999, 18:6867\u20136874.", "journal-title": "Oncogene"}, {"key": "5_CR33_5", "doi-asserted-by": "publisher", "first-page": "621", "DOI": "10.1146/annurev.immunol.18.1.621", "volume": "18", "author": "M Karin", "year": "2000", "unstructured": "Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621\u2013663.", "journal-title": "Annu Rev Immunol"}, {"key": "5_CR34_5", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1006/smim.2000.0210", "volume": "12", "author": "M Karin", "year": "2000", "unstructured": "Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000, 12:85\u201398.", "journal-title": "Semin Immunol"}, {"key": "5_CR35_5", "doi-asserted-by": "publisher", "first-page": "4079", "DOI": "10.1182/blood.V99.11.4079", "volume": "99", "author": "N Mitsiades", "year": "2002", "unstructured": "Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002, 99:4079\u20134086.", "journal-title": "Blood"}, {"key": "5_CR36_5", "doi-asserted-by": "publisher", "first-page": "196", "DOI": "10.1097/00007890-200107270-00005", "volume": "72", "author": "H Luo", "year": "2001", "unstructured": "Luo H, Wu Y, Qi S, et al. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001, 72:196\u2013202.", "journal-title": "Transplantation"}, {"key": "5_CR37_5", "doi-asserted-by": "publisher", "first-page": "8120", "DOI": "10.1073/pnas.0401563101", "volume": "101", "author": "K Sun", "year": "2004", "unstructured": "Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the protea-some inhibitor bortezomib. Proc Natl Acad Sci USA 2004, 101:8120\u20138125.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "5_CR38_5", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.1006/jaut.2000.0370", "volume": "14", "author": "CL Vanderlugt", "year": "2000", "unstructured": "Vanderlugt CL, Rahbe SM, Elliott PJ, et al. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 2000, 14:205\u2013211.", "journal-title": "J Autoimmun"}, {"key": "5_CR39_5", "doi-asserted-by": "publisher", "first-page": "949", "DOI": "10.1038/sj.bmt.1703574", "volume": "29", "author": "T Wu", "year": "2002", "unstructured": "Wu T, Sozen H, Luo B, et al. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy. Bone Marrow Transplant 2002, 29:949\u2013956.", "journal-title": "Bone Marrow Transplant"}, {"key": "5_CR40_5", "doi-asserted-by": "crossref", "first-page": "671", "DOI": "10.1172/JCI0212736", "volume": "109", "author": "TM Zollner", "year": "2002", "unstructured": "Zollner TM, Podda M, Pien C, et al. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 2002, 109:671\u2013679.", "journal-title": "J Clin Invest"}, {"key": "5_CR41_5", "doi-asserted-by": "publisher", "first-page": "3293", "DOI": "10.1182/blood-2004-11-4526", "volume": "106", "author": "K Sun", "year": "2005", "unstructured": "Sun K, Wilkins DE, Anver MR, et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005, 106:3293\u20133299.", "journal-title": "Blood"}, {"key": "5_CR42_5", "doi-asserted-by": "publisher", "first-page": "827", "DOI": "10.1182/blood-2005-05-1820", "volume": "107", "author": "S Vodanovic-Jankovic", "year": "2006", "unstructured": "Vodanovic-Jankovic S, Hari P, Jacobs P, et al. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006, 107:827\u2013834.", "journal-title": "Blood"}, {"key": "5_CR43_5", "doi-asserted-by": "publisher", "first-page": "7414", "DOI": "10.1038/sj.onc.1206945", "volume": "22", "author": "SH Kaufmann", "year": "2003", "unstructured": "Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003, 22:7414\u20137430.", "journal-title": "Oncogene"}, {"issue": "Suppl 3", "key": "5_CR44_5", "doi-asserted-by": "publisher", "first-page": "S127", "DOI": "10.1186/ar567", "volume": "4", "author": "F Sallusto", "year": "2002", "unstructured": "Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res 2002, 4(Suppl 3):S127\u2013132.", "journal-title": "Arthritis Res"}, {"key": "5_CR45_5", "doi-asserted-by": "publisher", "first-page": "1859", "DOI": "10.1084/jem.20052136", "volume": "203", "author": "A Kukreja", "year": "2006", "unstructured": "Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006, 203:1859\u20131865.", "journal-title": "J Exp Med"}, {"key": "5_CR46_5", "doi-asserted-by": "publisher", "first-page": "487", "DOI": "10.1038/88678", "volume": "2", "author": "A Lanzavecchia", "year": "2001", "unstructured": "LanzavecchiaA, Sallusto F. Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol 2001, 2:487\u2013492.", "journal-title": "Nat Immunol"}, {"key": "5_CR47_5", "doi-asserted-by": "publisher", "first-page": "263", "DOI": "10.1016/S0092-8674(01)00455-X", "volume": "106", "author": "A Lanzavecchia", "year": "2001", "unstructured": "Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263\u2013266.", "journal-title": "Cell"}, {"key": "5_CR48_5", "doi-asserted-by": "crossref", "first-page": "2373", "DOI": "10.4049/jimmunol.177.4.2373", "volume": "177", "author": "L Chen", "year": "2006", "unstructured": "Chen L, Arora M, Yarlagadda M, et al. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide. J Immunol 2006, 177:2373\u20132383.", "journal-title": "J Immunol"}, {"key": "5_CR49_5", "doi-asserted-by": "crossref", "first-page": "3548", "DOI": "10.4049/jimmunol.176.6.3548", "volume": "176", "author": "X Chen", "year": "2006", "unstructured": "Chen X, Reed-Loisel LM, Karlsson L, et al. H2-O expression in primary dendritic cells. J Immunol 2006, 176:3548\u20133556.", "journal-title": "J Immunol"}, {"issue": "11", "key": "5_CR50_5", "doi-asserted-by": "publisher", "first-page": "4839", "DOI": "10.1182/blood-2006-10-054221", "volume": "109", "author": "R Spisek", "year": "2007", "unstructured": "Spisek R, Charalambous A, Mazumder A, et al. Bortezomib enhances dendritic cell (DC) mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007, 109(11):4839\u20134845.", "journal-title": "Blood"}, {"key": "5_CR51_5", "first-page": "1.", "volume": "3", "author": "J Dai", "year": "2003", "unstructured": "Dai J, Liu B, Caudill MM, et al. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immunol 2003, 3:1.", "journal-title": "Cancer Immunol"}, {"key": "5_CR52_5", "doi-asserted-by": "publisher", "first-page": "15824", "DOI": "10.1073/pnas.2635458100", "volume": "100", "author": "B Liu", "year": "2003", "unstructured": "Liu B, Dai J, Zheng H, et al. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci U S A 2003, 100:15824\u201315829.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "5_CR53_5", "first-page": "2505", "volume": "8", "author": "C Aghajanian", "year": "2002", "unstructured": "Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002, 8:2505\u20132511.", "journal-title": "Clin Cancer Res"}, {"key": "5_CR54_5", "doi-asserted-by": "publisher", "first-page": "1794", "DOI": "10.1002/cncr.21414", "volume": "104", "author": "H Ludwig", "year": "2005", "unstructured": "Ludwig H, Khayat D, Giaccone G, et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005, 104:1794\u20131807.", "journal-title": "Cancer"}, {"key": "5_CR55_5", "unstructured": "Weber CN, Cerniglia CJ, Maity A, et al. Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biol Ther 2007, 6.", "DOI": "10.4161/cbt.6.2.3556", "doi-asserted-by": "crossref"}, {"key": "5_CR56_5", "doi-asserted-by": "publisher", "first-page": "975", "DOI": "10.1089/hum.2006.17.975", "volume": "17", "author": "S Anai", "year": "2006", "unstructured": "Anai S, Goodison S, Shiverick K, et al. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Hum Gene Ther 2006, 17:975\u2013984.", "journal-title": "Hum Gene Ther"}, {"key": "5_CR57_5", "first-page": "375", "volume": "30", "author": "KT Ng", "year": "2007", "unstructured": "Ng KT, Man K, Ho JW, et al. Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. Int J Oncol 2007, 30:375\u2013380.", "journal-title": "Int J Oncol"}, {"key": "5_CR58_5", "doi-asserted-by": "publisher", "first-page": "55", "DOI": "10.1016/j.cytogfr.2004.12.001", "volume": "16", "author": "H Wajant", "year": "2005", "unstructured": "Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 2005, 16:55\u201376.", "journal-title": "Cytokine Growth Factor Rev"}, {"key": "5_CR59_5", "doi-asserted-by": "publisher", "first-page": "76", "DOI": "10.1007/s00262-005-0676-3", "volume": "55", "author": "TJ Sayers", "year": "2006", "unstructured": "Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing lig-and (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006, 55:76\u201384.", "journal-title": "Cancer Immunol Immunother"}, {"key": "5_CR60_5", "doi-asserted-by": "publisher", "first-page": "157", "DOI": "10.1038/5517", "volume": "5", "author": "H Walczak", "year": "1999", "unstructured": "Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157\u2013163.", "journal-title": "Nat Med"}, {"key": "5_CR61_5", "doi-asserted-by": "publisher", "first-page": "228", "DOI": "10.1038/sj.cgt.7700792", "volume": "12", "author": "L Zhang", "year": "2005", "unstructured": "Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005, 12:228\u2013237.", "journal-title": "Cancer Gene Ther"}, {"key": "5_CR62_5", "doi-asserted-by": "publisher", "first-page": "2251", "DOI": "10.1158/1535-7163.MCT-06-0075", "volume": "5", "author": "S Khanbolooki", "year": "2006", "unstructured": "Khanbolooki S, Nawrocki ST, Arumugam T, et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006, 5:2251\u20132260.", "journal-title": "Mol Cancer Ther"}, {"key": "5_CR63_5", "doi-asserted-by": "publisher", "first-page": "1022", "DOI": "10.1158/1535-7163.MCT-06-0545", "volume": "6", "author": "AM Kamat", "year": "2007", "unstructured": "Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeu-tic agents and cytokines through down-regulation of nuclear factor-{kappa}B and nuclear factor-{kappa}B-regulated gene products in IFN-{alpha}-sensitive and IFN-{alpha}-resistant human bladder cancer cells. Mol Cancer Ther 2007, 6:1022\u20131030.", "journal-title": "Mol Cancer Ther"}, {"key": "5_CR64_5", "doi-asserted-by": "publisher", "first-page": "160", "DOI": "10.1196/annals.1339.042", "volume": "1059", "author": "AD Brooks", "year": "2005", "unstructured": "Brooks AD, Ramirez T, Toh U, et al. The protea-some inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apop-tosis. Ann N Y Acad Sci 2005, 1059:160\u2013167.", "journal-title": "Ann N Y Acad Sci"}, {"key": "5_CR65_5", "doi-asserted-by": "publisher", "first-page": "303", "DOI": "10.1182/blood-2002-09-2975", "volume": "102", "author": "TJ Sayers", "year": "2003", "unstructured": "Sayers TJ, Brooks AD, Koh CY, et al. The protea-some inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003, 102:303\u2013310.", "journal-title": "Blood"}, {"key": "5_CR66_5", "doi-asserted-by": "publisher", "first-page": "211", "DOI": "10.1007/s10495-006-0528-4", "volume": "12", "author": "P Clarke", "year": "2007", "unstructured": "Clarke P, Tyler KL. Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis. Apoptosis 2007, 12:211\u2013223.", "journal-title": "Apoptosis"}, {"key": "5_CR67_5", "doi-asserted-by": "publisher", "first-page": "257", "DOI": "10.1016/j.critrevonc.2005.10.001", "volume": "58", "author": "J Brody", "year": "2006", "unstructured": "Brody J, Advani R. Treatment of mantle cell lym-phoma: current approach and future directions. Crit Rev Oncol/Hematol 2006, 58:257\u2013265.", "journal-title": "Crit Rev Oncol/Hematol"}, {"key": "5_CR68_5", "first-page": "495", "volume": "47", "author": "M. Ogura", "year": "2006", "unstructured": "Ogura M. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lym-phoma]. [Rinsho ketsueki] Japanese J Clin Hematol 2006, 47:495\u2013512.", "journal-title": "[Rinsho ketsueki] Japanese J Clin Hematol"}, {"key": "5_CR69_5", "doi-asserted-by": "crossref", "first-page": "1923", "DOI": "10.4049/jimmunol.178.3.1923", "volume": "178", "author": "G Roue", "year": "2007", "unstructured": "Roue G, Perez-Galan P, Lopez-Guerra M, et al. Selective inhibition of I{kappa}B kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007, 178:1923\u20131930.", "journal-title": "J Immunol"}, {"key": "5_CR70_5", "first-page": "4537", "volume": "9", "author": "J An", "year": "2003", "unstructured": "An J, Sun YP, Adams J, et al. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 2003, 9:4537\u20134545.", "journal-title": "Clin Cancer Res"}, {"key": "5_CR71_5", "doi-asserted-by": "crossref", "first-page": "88", "DOI": "10.4049/jimmunol.171.1.88", "volume": "171", "author": "LV Pham", "year": "2003", "unstructured": "Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003, 171:88\u201395.", "journal-title": "J Immunol"}, {"key": "5_CR72_5", "doi-asserted-by": "publisher", "first-page": "2205", "DOI": "10.1074/jbc.M410660200", "volume": "280", "author": "RF Kelley", "year": "2005", "unstructured": "Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/ tumor necrosis factor-related apoptosis-inducing lig-and reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005, 280:2205\u20132212.", "journal-title": "J Biol Chem"}, {"key": "5_CR73_5", "doi-asserted-by": "publisher", "first-page": "133", "DOI": "10.1007/BF02893359", "volume": "12", "author": "K Nagy", "year": "2006", "unstructured": "Nagy K, Szekely-Szuts K, Izeradjene K, et al. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathol Oncol Res 2006, 12:133\u2013142.", "journal-title": "Pathol Oncol Res"}, {"key": "5_CR74_5", "doi-asserted-by": "publisher", "first-page": "147", "DOI": "10.1016/S0092-8674(00)80085-9", "volume": "86", "author": "X Liu", "year": "1996", "unstructured": "Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996, 86:147\u2013157.", "journal-title": "Cell"}, {"key": "5_CR75_5", "doi-asserted-by": "publisher", "first-page": "43", "DOI": "10.1016/S0092-8674(00)00009-X", "volume": "102", "author": "AM Verhagen", "year": "2000", "unstructured": "Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43\u201353.", "journal-title": "Cell"}, {"key": "5_CR76_5", "doi-asserted-by": "publisher", "first-page": "33", "DOI": "10.1016/S0092-8674(00)00008-8", "volume": "102", "author": "C Du", "year": "2000", "unstructured": "Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent cas-pase activation by eliminating IAP inhibition. Cell 2000, 102:33\u201342.", "journal-title": "Cell"}, {"key": "5_CR77_5", "doi-asserted-by": "publisher", "first-page": "729", "DOI": "10.1038/sj.cdd.4401232", "volume": "10", "author": "I Petak", "year": "2003", "unstructured": "Petak I, Vernes R, Szucs KS, et al. A caspase-8-inde-pendent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells. Cell Death Diff 2003, 10:729\u2013739.", "journal-title": "Cell Death Diff"}, {"key": "5_CR78_5", "doi-asserted-by": "publisher", "first-page": "4953", "DOI": "10.1038/sj.onc.1206656", "volume": "22", "author": "TR Johnson", "year": "2003", "unstructured": "Johnson TR, Stone K, Nikrad M, et al. The protea-some inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overex-pressing cells. Oncogene 2003, 22:4953\u20134963.", "journal-title": "Oncogene"}, {"key": "5_CR79_5", "first-page": "443", "volume": "4", "author": "M Nikrad", "year": "2005", "unstructured": "Nikrad M, Johnson T, Puthalalath H, et al. The protea-some inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005, 4:443\u2013449.", "journal-title": "Mol Cancer Ther"}, {"key": "5_CR80_5", "doi-asserted-by": "publisher", "first-page": "781", "DOI": "10.1158/1535-7163.MCT-04-0330", "volume": "4", "author": "H Zhu", "year": "2005", "unstructured": "Zhu H, Guo W, Zhang L, et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 2005, 4:781\u2013786.", "journal-title": "Cancer Biol Ther"}, {"key": "5_CR81_5", "doi-asserted-by": "publisher", "first-page": "4993", "DOI": "10.1038/sj.onc.1208683", "volume": "24", "author": "H Zhu", "year": "2005", "unstructured": "Zhu H, Zhang L, Dong F, et al. Bik/NBK accumulation correlates with apoptosis-induction by bort-ezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005, 24:4993\u20134999.", "journal-title": "Oncogene"}, {"key": "5_CR82_5", "doi-asserted-by": "publisher", "first-page": "491", "DOI": "10.1016/S0092-8674(00)81590-1", "volume": "94", "author": "H Li", "year": "1998", "unstructured": "Li H, Zhu H, Xu CJ, et al. Cleavage of BID by cas-pase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491\u2013501.", "journal-title": "Cell"}, {"key": "5_CR83_5", "doi-asserted-by": "publisher", "first-page": "6627", "DOI": "10.1093/emboj/20.23.6627", "volume": "20", "author": "C Adrain", "year": "2001", "unstructured": "Adrain C, Creagh EM, Martin SJ. Apoptosis-associ-ated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J 2001, 20:6627\u20136636.", "journal-title": "EMBO J"}, {"key": "5_CR84_5", "doi-asserted-by": "publisher", "first-page": "1513", "DOI": "10.1084/jem.134.6.1513", "volume": "134", "author": "G Cudkowicz", "year": "1971", "unstructured": "Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med 1971, 134:1513\u20131528.", "journal-title": "J Exp Med"}, {"key": "5_CR85_5", "doi-asserted-by": "publisher", "first-page": "367", "DOI": "10.1016/j.semcancer.2006.07.003", "volume": "16", "author": "WH Hallett", "year": "2006", "unstructured": "Hallett WH, Murphy WJ. Positive and negative regulation of Natural Killer cells: therapeutic implications. Sem Cancer Biol 2006, 16:367\u2013382.", "journal-title": "Sem Cancer Biol"}, {"key": "5_CR86_5", "first-page": "670", "volume": "80", "author": "WJ Murphy", "year": "1992", "unstructured": "Murphy WJ, Keller JR, Harrison CL, et al. Interleukin-2-activated natural killer cells can support hemat-opoiesis in vitro and promote marrow engraftment in vivo. Blood 1992, 80:670\u2013677.", "journal-title": "Blood"}, {"key": "5_CR87_5", "first-page": "119", "volume": "68", "author": "S Chintharlapalli", "year": "2005", "unstructured": "Chintharlapalli S, Papineni S, Konopleva M, et al. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol Pharmacol 2005, 68:119\u2013128.", "journal-title": "Mol Pharmacol"}, {"key": "5_CR88_5", "doi-asserted-by": "publisher", "first-page": "1158", "DOI": "10.1124/mol.105.018572", "volume": "69", "author": "RD Couch", "year": "2006", "unstructured": "Couch RD, Ganem NJ, Zhou M, et al. 2-cyano-3,12-dioxooleana-1,9(11)-diene-28-oic acid disrupts microtubule polymerization: a possible mechanism contributing to apoptosis. Mol Pharmacol 2006, 69:1158\u20131165.", "journal-title": "Mol Pharmacol"}, {"key": "5_CR89_5", "doi-asserted-by": "publisher", "first-page": "1350", "DOI": "10.1038/sj.leu.2403828", "volume": "19", "author": "M Konopleva", "year": "2005", "unstructured": "Konopleva M, Contractor R, Kurinna SM, et al. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute mye-loid leukemia cells. Leukemia 2005, 19:1350\u20131354.", "journal-title": "Leukemia"}, {"key": "5_CR90_5", "doi-asserted-by": "publisher", "first-page": "317", "DOI": "10.1158/1535-7163.MCT-05-0350", "volume": "5", "author": "M Konopleva", "year": "2006", "unstructured": "Konopleva M, Zhang W, Shi YX, et al. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overex-pressing breast cancer cells. Mol Cancer Ther 2006, 5:317\u2013328.", "journal-title": "Mol Cancer Ther"}, {"key": "5_CR91_5", "first-page": "5926", "volume": "63", "author": "H Lapillonne", "year": "2003", "unstructured": "Lapillonne H, Konopleva M, Tsao T, et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003, 63:5926\u20135939.", "journal-title": "Cancer Res"}, {"key": "5_CR92_5", "doi-asserted-by": "publisher", "first-page": "2965", "DOI": "10.1182/blood-2002-04-1174", "volume": "100", "author": "IM Pedersen", "year": "2002", "unstructured": "Pedersen IM, Kitada S, Schimmer A, et al. The trit-erpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 2002, 100:2965\u20132972.", "journal-title": "Blood"}, {"key": "5_CR93_5", "doi-asserted-by": "publisher", "first-page": "1182", "DOI": "10.1124/mol.105.018051", "volume": "69", "author": "I Samudio", "year": "2006", "unstructured": "Samudio I, Konopleva M, Pelicano H, et al. A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate: direct permeabili-zation of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol Pharmacol 2006, 69:1182\u20131193.", "journal-title": "Mol Pharmacol"}, {"key": "5_CR94_5", "doi-asserted-by": "publisher", "first-page": "1828", "DOI": "10.1158/1078-0432.CCR-05-2044", "volume": "12", "author": "S Shishodia", "year": "2006", "unstructured": "Shishodia S, Sethi G, Konopleva M, et al. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 2006, 12:1828\u20131838.", "journal-title": "Clin Cancer Res"}, {"key": "5_CR95_5", "doi-asserted-by": "publisher", "first-page": "3158", "DOI": "10.1182/blood-2003-08-2873", "volume": "103", "author": "D Chauhan", "year": "2004", "unstructured": "Chauhan D, Li G, Podar K, et al. The borte-zomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2004, 103:3158\u20133166.", "journal-title": "Blood"}], "container-title": ["Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-59745-474-2_5", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 2]], "date-time": "2019-03-02T20:11:31Z", "timestamp": 1551557491000}, "score": 25.286715, "issued": {"date-parts": [[2008]]}, "ISBN": ["9781934115299", "9781597454742"], "references-count": 95, "URL": "http://dx.doi.org/10.1007/978-1-59745-474-2_5", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:36:41Z", "timestamp": 1574134601399}, "reference-count": 58, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2002, 8, 1]], "date-time": "2002-08-01T00:00:00Z", "timestamp": 1028160000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Current Opinion in Chemical Biology"], "published-print": {"date-parts": [[2002, 8]]}, "DOI": "10.1016/s1367-5931(02)00343-5", "type": "journal-article", "created": {"date-parts": [[2002, 9, 17]], "date-time": "2002-09-17T16:34:42Z", "timestamp": 1032280482000}, "page": "493-500", "source": "Crossref", "is-referenced-by-count": 88, "title": ["Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer"], "prefix": "10.1016", "volume": "6", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Current Opinion in Chemical Biology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1367593102003435?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1367593102003435?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 9]], "date-time": "2019-04-09T17:23:02Z", "timestamp": 1554830582000}, "score": 25.000788, "issued": {"date-parts": [[2002, 8]]}, "references-count": 58, "journal-issue": {"published-print": {"date-parts": [[2002, 8]]}, "issue": "4"}, "alternative-id": ["S1367593102003435"], "URL": "http://dx.doi.org/10.1016/s1367-5931(02)00343-5", "ISSN": ["1367-5931"], "issn-type": [{"value": "1367-5931", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T20:12:44Z", "timestamp": 1574107964268}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2001, 4, 1]], "date-time": "2001-04-01T00:00:00Z", "timestamp": 986083200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2001, 4]]}, "DOI": "10.1016/s0959-8049(01)81024-8", "type": "journal-article", "created": {"date-parts": [[2003, 12, 10]], "date-time": "2003-12-10T12:24:32Z", "timestamp": 1071059072000}, "page": "S144", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AIPCa) treated with the proteasome inhibitor PS-341"], "prefix": "10.1016", "volume": "37", "author": [{"given": "C.", "family": "Papandreou", "sequence": "first", "affiliation": []}, {"given": "D.", "family": "Daliani", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Millikan", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Tu", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Pagliaro", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Adams", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Elliot", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Dieringer", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Logothetis", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804901810248?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804901810248?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 16]], "date-time": "2019-02-16T09:52:32Z", "timestamp": 1550310752000}, "score": 24.782816, "issued": {"date-parts": [[2001, 4]]}, "references-count": 0, "alternative-id": ["S0959804901810248"], "URL": "http://dx.doi.org/10.1016/s0959-8049(01)81024-8", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T00:47:22Z", "timestamp": 1574124442371}, "reference-count": 139, "publisher": "Springer Science and Business Media LLC", "issue": "5", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2004, 5, 1]], "date-time": "2004-05-01T00:00:00Z", "timestamp": 1083369600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Cancer"], "published-print": {"date-parts": [[2004, 5]]}, "DOI": "10.1038/nrc1361", "type": "journal-article", "created": {"date-parts": [[2004, 4, 30]], "date-time": "2004-04-30T14:39:38Z", "timestamp": 1083335978000}, "page": "349-360", "source": "Crossref", "is-referenced-by-count": 719, "title": ["The proteasome: a suitable antineoplastic target"], "prefix": "10.1038", "volume": "4", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "BFnrc1361_CR1", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1016/S0092-8674(00)81683-9", "volume": "100", "author": "D Hanahan", "year": "2000", "unstructured": "Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).", "journal-title": "Cell"}, {"key": "BFnrc1361_CR2", "doi-asserted-by": "crossref", "first-page": "13", "DOI": "10.1016/0092-8674(94)90396-4", "volume": "79", "author": "A Ciechanover", "year": "1994", "unstructured": "Ciechanover, A. The ubiquitin\u2013proteasome proteolytic pathway. Cell 79, 13\u201321 (1994).", "journal-title": "Cell"}, {"key": "BFnrc1361_CR3", "first-page": "8303", "volume": "262", "author": "R Hough", "year": "1987", "unstructured": "Hough, R., Pratt, G. & Rechsteiner, M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J. Biol. Chem. 262, 8303\u20138313 (1987).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR4", "first-page": "2451", "volume": "262", "author": "L Waxman", "year": "1987", "unstructured": "Waxman, L., Fagan, J. M. & Goldberg, A. L. Demonstration of two distinct high molecular weight proteases in rabbit reticulocytes, one of which degrades ubiquitin conjugates. J. Biol. Chem. 262, 2451\u20132457 (1987).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR5", "unstructured": "Bortezomib (Velcade) for multiple myeloma. Med. Lett. Drugs Ther. 45, 57\u201358 (2003)."}, {"key": "BFnrc1361_CR6", "doi-asserted-by": "crossref", "first-page": "155", "DOI": "10.1042/bj3460155", "volume": "346", "author": "P Brooks", "year": "2000", "unstructured": "Brooks, P. et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem. J. 346, 155\u2013161 (2000). This paper demonstrates the complexity of proteasomal populations and localizations in mammalian cells.", "journal-title": "Biochem. J."}, {"key": "BFnrc1361_CR7", "doi-asserted-by": "crossref", "first-page": "932", "DOI": "10.1006/jmbi.1993.1646", "volume": "234", "author": "JM Peters", "year": "1993", "unstructured": "Peters, J. M., Cejka, Z., Harris, J. R., Kleinschmidt, J. A. & Baumeister, W. Structural features of the 26 S proteasome complex. J. Mol. Biol. 234, 932\u2013937 (1993).", "journal-title": "J. Mol. Biol."}, {"key": "BFnrc1361_CR8", "doi-asserted-by": "crossref", "first-page": "637", "DOI": "10.1309/44HW-5YCJ-FLLP-3R56", "volume": "116", "author": "PJ Elliott", "year": "2001", "unstructured": "Elliott, P. J. & Ross, J. S. The proteasome: a new target for novel drug therapies. Am. J. Clin. Pathol. 116, 637\u2013646 (2001).", "journal-title": "Am. J. Clin. Pathol."}, {"key": "BFnrc1361_CR9", "doi-asserted-by": "crossref", "first-page": "367", "DOI": "10.1016/S0092-8674(00)80929-0", "volume": "92", "author": "W Baumeister", "year": "1998", "unstructured": "Baumeister, W., Walz, J., Zuhl, F. & Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367\u2013380 (1998).", "journal-title": "Cell"}, {"key": "BFnrc1361_CR10", "doi-asserted-by": "crossref", "first-page": "7151", "DOI": "10.1093/emboj/17.24.7151", "volume": "17", "author": "A Ciechanover", "year": "1998", "unstructured": "Ciechanover, A. The ubiquitin\u2013proteasome pathway: on protein death and cell life. EMBO J. 17, 7151\u20137160 (1998).", "journal-title": "EMBO J."}, {"key": "BFnrc1361_CR11", "doi-asserted-by": "crossref", "first-page": "22123", "DOI": "10.1074/jbc.274.32.22123", "volume": "274", "author": "GN DeMartino", "year": "1999", "unstructured": "DeMartino, G. N. & Slaughter, C. A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274, 22123\u201322126 (1999).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR12", "doi-asserted-by": "crossref", "first-page": "395", "DOI": "10.1016/S1097-2765(00)80341-X", "volume": "4", "author": "AF Kisselev", "year": "1999", "unstructured": "Kisselev, A. F., Akopian, T. N., Castillo, V. & Goldberg, A. L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol. Cell 4, 395\u2013402 (1999).", "journal-title": "Mol. Cell"}, {"key": "BFnrc1361_CR13", "doi-asserted-by": "crossref", "first-page": "147", "DOI": "10.1016/S0161-5890(02)00098-6", "volume": "39", "author": "AL Goldberg", "year": "2002", "unstructured": "Goldberg, A. L., Cascio, P., Saric, T. & Rock, K. L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39, 147\u2013164 (2002).", "journal-title": "Mol. Immunol."}, {"key": "BFnrc1361_CR14", "doi-asserted-by": "crossref", "first-page": "35869", "DOI": "10.1074/jbc.M303725200", "volume": "278", "author": "AF Kisselev", "year": "2003", "unstructured": "Kisselev, A. F. et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J. Biol. Chem. 278, 35869\u201335877 (2003).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR15", "doi-asserted-by": "crossref", "first-page": "615", "DOI": "10.1016/S0092-8674(00)81603-7", "volume": "94", "author": "MH Glickman", "year": "1998", "unstructured": "Glickman, M. H. et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 94, 615\u2013623 (1998).", "journal-title": "Cell"}, {"key": "BFnrc1361_CR16", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1016/S1097-2765(02)00775-X", "volume": "11", "author": "N Benaroudj", "year": "2003", "unstructured": "Benaroudj, N., Zwickl, P., Seemuller, E., Baumeister, W. & Goldberg, A. L. ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol. Cell 11, 69\u201378 (2003).", "journal-title": "Mol. Cell"}, {"key": "BFnrc1361_CR17", "doi-asserted-by": "crossref", "first-page": "3263", "DOI": "10.1073/pnas.0538058100", "volume": "100", "author": "RF Kalejta", "year": "2003", "unstructured": "Kalejta, R. F. & Shenk, T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl Acad. Sci. USA 100, 3263\u20133268 (2003).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1361_CR18", "doi-asserted-by": "crossref", "first-page": "311", "DOI": "10.1016/S0300-9084(01)01244-5", "volume": "83", "author": "N Benaroudj", "year": "2001", "unstructured": "Benaroudj, N., Tarcsa, E., Cascio, P. & Goldberg, A. L. The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes. Biochimie 83, 311\u2013318 (2001).", "journal-title": "Biochimie"}, {"key": "BFnrc1361_CR19", "doi-asserted-by": "crossref", "first-page": "18237", "DOI": "10.1074/jbc.271.30.18237", "volume": "271", "author": "K Ahn", "year": "1996", "unstructured": "Ahn, K. et al. In vivo characterization of the proteasome regulator PA28. J. Biol. Chem. 271, 18237\u201318242 (1996).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR20", "first-page": "10515", "volume": "267", "author": "CP Ma", "year": "1992", "unstructured": "Ma, C. P., Slaughter, C. A. & DeMartino, G. N. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J. Biol. Chem. 267, 10515\u201310523 (1992).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR21", "first-page": "31466", "volume": "269", "author": "JD Mott", "year": "1994", "unstructured": "Mott, J. D. et al. PA28, an activator of the 20 S proteasome, is composed of two nonidentical but homologous subunits. J. Biol. Chem. 269, 31466\u201331471 (1994).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR22", "doi-asserted-by": "crossref", "first-page": "209", "DOI": "10.1111/j.1365-2249.1990.tb05180.x", "volume": "79", "author": "T Nikaido", "year": "1990", "unstructured": "Nikaido, T. et al. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 79, 209\u2013214 (1990).", "journal-title": "Clin. Exp. Immunol."}, {"key": "BFnrc1361_CR23", "doi-asserted-by": "crossref", "first-page": "25483", "DOI": "10.1074/jbc.272.41.25483", "volume": "272", "author": "C Realini", "year": "1997", "unstructured": "Realini, C. et al. Characterization of recombinant REG\u03b1, REG\u03b2, and REG\u03b3 proteasome activators. J. Biol. Chem. 272, 25483\u201325492 (1997).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR24", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1042/bj3450001", "volume": "345", "author": "M Rechsteiner", "year": "2000", "unstructured": "Rechsteiner, M., Realini, C. & Ustrell, V. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem. J. 345, 1\u201315 (2000).", "journal-title": "Biochem. J."}, {"key": "BFnrc1361_CR25", "doi-asserted-by": "crossref", "first-page": "166", "DOI": "10.1038/381166a0", "volume": "381", "author": "M Groettrup", "year": "1996", "unstructured": "Groettrup, M. et al. A role for the proteasome regulator PA28\u03b1 in antigen presentation. Nature 381, 166\u2013168 (1996).", "journal-title": "Nature"}, {"key": "BFnrc1361_CR26", "doi-asserted-by": "crossref", "first-page": "5898", "DOI": "10.1093/emboj/20.21.5898", "volume": "20", "author": "S Murata", "year": "2001", "unstructured": "Murata, S. et al. Immunoproteasome assembly and antigen presentation in mice lacking both PA28\u03b1 and PA28\u03b2. EMBO J. 20, 5898\u20135907 (2001).", "journal-title": "EMBO J."}, {"key": "BFnrc1361_CR27", "doi-asserted-by": "crossref", "first-page": "264", "DOI": "10.1038/365264a0", "volume": "365", "author": "M Gaczynska", "year": "1993", "unstructured": "Gaczynska, M., Rock, K. L. & Goldberg, A. L. \u03b3-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365, 264\u2013267 (1993).", "journal-title": "Nature"}, {"key": "BFnrc1361_CR28", "first-page": "291", "volume": "353", "author": "S Bose", "year": "2001", "unstructured": "Bose, S., Brooks, P., Mason, G. G. & Rivett, A. J. \u03b3-interferon decreases the level of 26 S proteasomes and changes the pattern of phosphorylation. Biochem. J. 353, 291\u2013297 (2001).", "journal-title": "Biochem. J."}, {"key": "BFnrc1361_CR29", "first-page": "73", "volume": "268", "author": "CP Hill", "year": "2002", "unstructured": "Hill, C. P., Masters, E. I. & Whitby, F. G. The 11S regulators of 20S proteasome activity. Curr. Top. Microbiol. Immunol. 268, 73\u201389 (2002).", "journal-title": "Curr. Top. Microbiol. Immunol."}, {"key": "BFnrc1361_CR30", "doi-asserted-by": "crossref", "first-page": "115", "DOI": "10.1038/35040607", "volume": "408", "author": "FG Whitby", "year": "2000", "unstructured": "Whitby, F. G. et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408, 115\u2013120 (2000).", "journal-title": "Nature"}, {"key": "BFnrc1361_CR31", "doi-asserted-by": "crossref", "first-page": "109", "DOI": "10.1016/0014-5793(94)00569-9", "volume": "348", "author": "C Realini", "year": "1994", "unstructured": "Realini, C., Rogers, S. W. & Rechsteiner, M. KEKE motifs. Proposed roles in protein-protein association and presentation of peptides by MHC class I receptors. FEBS Lett. 348, 109\u2013113 (1994).", "journal-title": "FEBS Lett."}, {"key": "BFnrc1361_CR32", "doi-asserted-by": "crossref", "first-page": "401", "DOI": "10.1042/bj3160401", "volume": "316", "author": "A Palmer", "year": "1996", "unstructured": "Palmer, A. et al. Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol. Biochem. J. 316, 401\u2013407 (1996).", "journal-title": "Biochem. J."}, {"key": "BFnrc1361_CR33", "doi-asserted-by": "crossref", "first-page": "99", "DOI": "10.1073/pnas.90.1.99", "volume": "90", "author": "A Amsterdam", "year": "1993", "unstructured": "Amsterdam, A., Pitzer, F. & Baumeister, W. Changes in intracellular localization of proteasomes in immortalized ovarian granulosa cells during mitosis associated with a role in cell cycle control. Proc. Natl Acad. Sci. USA 90, 99\u2013103 (1993).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1361_CR34", "first-page": "163", "volume": "64", "author": "A Palmer", "year": "1994", "unstructured": "Palmer, A., Mason, G. G., Paramio, J. M., Knecht, E. & Rivett, A. J. Changes in proteasome localization during the cell cycle. Eur. J. Cell Biol. 64, 163\u2013175 (1994).", "journal-title": "Eur. J. Cell Biol."}, {"key": "BFnrc1361_CR35", "doi-asserted-by": "crossref", "first-page": "313", "DOI": "10.1002/glia.10075", "volume": "38", "author": "M Lafarga", "year": "2002", "unstructured": "Lafarga, M., Fernandez, R., Mayo, I., Berciano, M. T. & Castano, J. G. Proteasome dynamics during cell cycle in rat Schwann cells. Glia 38, 313\u2013328 (2002).", "journal-title": "Glia"}, {"key": "BFnrc1361_CR36", "doi-asserted-by": "crossref", "first-page": "6087", "DOI": "10.1093/emboj/16.20.6087", "volume": "16", "author": "EA Reits", "year": "1997", "unstructured": "Reits, E. A., Benham, A. M., Plougastel, B., Neefjes, J. & Trowsdale, J. Dynamics of proteasome distribution in living cells. EMBO J. 16, 6087\u20136094 (1997). This paper demonstrates the free and rapid diffusion of the vast majority (> 90%) of the proteasome within, but not between, the cytoplasmic and nuclear compartments of the cell, and how the cytoplasmically generated proteasome enters the nucleus.", "journal-title": "EMBO J."}, {"key": "BFnrc1361_CR37", "doi-asserted-by": "crossref", "first-page": "579", "DOI": "10.1016/S1357-2725(02)00380-1", "volume": "35", "author": "C Wojcik", "year": "2003", "unstructured": "Wojcik, C. & DeMartino, G. N. Intracellular localization of proteasomes. Int. J. Biochem. Cell Biol. 35, 579\u2013589 (2003).", "journal-title": "Int. J. Biochem. Cell Biol."}, {"key": "BFnrc1361_CR38", "first-page": "175", "volume": "268", "author": "C Gordon", "year": "2002", "unstructured": "Gordon, C. The intracellular localization of the proteasome. Curr. Top. Microbiol. Immunol. 268, 175\u2013184 (2002).", "journal-title": "Curr. Top. Microbiol. Immunol."}, {"key": "BFnrc1361_CR39", "doi-asserted-by": "crossref", "first-page": "499", "DOI": "10.1016/S1097-2765(01)00347-1", "volume": "8", "author": "CM Pickart", "year": "2001", "unstructured": "Pickart, C. M. Ubiquitin enters the new millennium. Mol. Cell 8, 499\u2013504 (2001).", "journal-title": "Mol. Cell"}, {"key": "BFnrc1361_CR40", "doi-asserted-by": "crossref", "first-page": "527", "DOI": "10.1016/S0092-8674(01)00485-8", "volume": "106", "author": "L Hicke", "year": "2001", "unstructured": "Hicke, L. A new ticket for entry into budding vesicles-ubiquitin. Cell 106, 527\u2013530 (2001).", "journal-title": "Cell"}, {"key": "BFnrc1361_CR41", "doi-asserted-by": "crossref", "first-page": "895", "DOI": "10.1038/nature02263", "volume": "426", "author": "AL Goldberg", "year": "2003", "unstructured": "Goldberg, A. L. Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895\u2013899 (2003).", "journal-title": "Nature"}, {"key": "BFnrc1361_CR42", "doi-asserted-by": "crossref", "first-page": "790", "DOI": "10.1096/fj.02-0654rev", "volume": "17", "author": "Y Yang", "year": "2003", "unstructured": "Yang, Y. & Yu, X. Regulation of apoptosis: the ubiquitous way. FASEB J. 17, 790\u2013799 (2003).", "journal-title": "FASEB J."}, {"key": "BFnrc1361_CR43", "doi-asserted-by": "crossref", "first-page": "1652", "DOI": "10.1126/science.274.5293.1652", "volume": "274", "author": "RW King", "year": "1996", "unstructured": "King, R. W., Deshaies, R. J., Peters, J. M. & Kirschner, M. W. How proteolysis drives the cell cycle. Science 274, 1652\u20131659 (1996).", "journal-title": "Science"}, {"key": "BFnrc1361_CR44", "doi-asserted-by": "crossref", "first-page": "221", "DOI": "10.1016/S0092-8674(03)01080-8", "volume": "116", "author": "AW Murray", "year": "2004", "unstructured": "Murray, A. W. Recycling the cell cycle: cyclins revisited. Cell 116, 221\u2013234 (2004).", "journal-title": "Cell"}, {"key": "BFnrc1361_CR45", "doi-asserted-by": "crossref", "first-page": "132", "DOI": "10.1038/349132a0", "volume": "349", "author": "M Glotzer", "year": "1991", "unstructured": "Glotzer, M., Murray, A. W. & Kirschner, M. W. Cyclin is degraded by the ubiquitin pathway. Nature 349, 132\u2013138 (1991).", "journal-title": "Nature"}, {"key": "BFnrc1361_CR46", "doi-asserted-by": "crossref", "first-page": "957", "DOI": "10.1101/gad.11.8.957", "volume": "11", "author": "JA Diehl", "year": "1997", "unstructured": "Diehl, J. A., Zindy, F. & Sherr, C. J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11, 957\u2013972 (1997).", "journal-title": "Genes Dev."}, {"key": "BFnrc1361_CR47", "doi-asserted-by": "crossref", "first-page": "1979", "DOI": "10.1101/gad.10.16.1979", "volume": "10", "author": "BE Clurman", "year": "1996", "unstructured": "Clurman, B. E., Sheaff, R. J., Thress, K., Groudine, M. & Roberts, J. M. Turnover of cyclin E by the ubiquitin\u2013proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 10, 1979\u20131990 (1996).", "journal-title": "Genes Dev."}, {"key": "BFnrc1361_CR48", "doi-asserted-by": "crossref", "first-page": "682", "DOI": "10.1126/science.7624798", "volume": "269", "author": "M Pagano", "year": "1995", "unstructured": "Pagano, M. et al. Role of the ubiquitin\u2013proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682\u2013685 (1995).", "journal-title": "Science"}, {"key": "BFnrc1361_CR49", "doi-asserted-by": "crossref", "first-page": "13886", "DOI": "10.1074/jbc.274.20.13886", "volume": "274", "author": "M Shirane", "year": "1999", "unstructured": "Shirane, M. et al. Down-regulation of p27Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 274, 13886\u201313893 (1999).", "journal-title": "J. Biol. Chem."}, {"issue": "Suppl 3", "key": "BFnrc1361_CR50", "first-page": "363", "volume": "11", "author": "SW Tam", "year": "1997", "unstructured": "Tam, S. W., Theodoras, A. M. & Pagano, M. Kip1 degradation via the ubiquitin\u2013proteasome pathway. Leukemia 11(Suppl 3), 363\u2013366 (1997).", "journal-title": "Leukemia"}, {"key": "BFnrc1361_CR51", "doi-asserted-by": "crossref", "first-page": "1425", "DOI": "10.1126/science.288.5470.1425", "volume": "288", "author": "N Mailand", "year": "2000", "unstructured": "Mailand, N. et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425\u20131429 (2000).", "journal-title": "Science"}, {"key": "BFnrc1361_CR52", "doi-asserted-by": "crossref", "first-page": "2447", "DOI": "10.1038/sj.onc.1203564", "volume": "19", "author": "R Bernardi", "year": "2000", "unstructured": "Bernardi, R., Liebermann, D. A. & Hoffman, B. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 19, 2447\u20132454 (2000).", "journal-title": "Oncogene"}, {"key": "BFnrc1361_CR53", "doi-asserted-by": "crossref", "first-page": "32731", "DOI": "10.1074/jbc.272.52.32731", "volume": "272", "author": "V Baldin", "year": "1997", "unstructured": "Baldin, V., Cans, C., Knibiehler, M. & Ducommun, B. Phosphorylation of human CDC25B phosphatase by CDK1\u2013cyclin A triggers its proteasome-dependent degradation. J. Biol. Chem. 272, 32731\u201332734 (1997).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR54", "doi-asserted-by": "crossref", "first-page": "1990", "DOI": "10.1073/pnas.032428899", "volume": "99", "author": "F Chen", "year": "2002", "unstructured": "Chen, F. et al. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc. Natl Acad. Sci. USA 99, 1990\u20131995 (2002).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1361_CR55", "doi-asserted-by": "crossref", "first-page": "102", "DOI": "10.1038/nrc991", "volume": "3", "author": "P Ch\u00e8ne", "year": "2003", "unstructured": "Ch\u00e8ne, P. Inhibiting the p53\u2013MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer 3, 102\u2013109 (2003).", "journal-title": "Nature Rev. Cancer"}, {"key": "BFnrc1361_CR56", "doi-asserted-by": "crossref", "first-page": "121", "DOI": "10.1111/j.1749-6632.2000.tb06705.x", "volume": "910", "author": "T Soussi", "year": "2000", "unstructured": "Soussi, T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann. NY Acad. Sci. 910, 121\u2013137 (2000).", "journal-title": "Ann. NY Acad. Sci."}, {"key": "BFnrc1361_CR57", "doi-asserted-by": "crossref", "first-page": "15", "DOI": "10.1016/S0378-1119(99)00487-4", "volume": "242", "author": "J Momand", "year": "2000", "unstructured": "Momand, J., Wu, H. H. & Dasgupta, G. MDM2\u2014master regulator of the p53 tumor suppressor protein. Gene 242, 15\u201329 (2000).", "journal-title": "Gene"}, {"key": "BFnrc1361_CR58", "doi-asserted-by": "crossref", "first-page": "94", "DOI": "10.1016/S0959-437X(99)00038-6", "volume": "10", "author": "CJ Sherr", "year": "2000", "unstructured": "Sherr, C. J. & Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10, 94\u201399 (2000).", "journal-title": "Curr. Opin. Genet. Dev."}, {"key": "BFnrc1361_CR59", "first-page": "2649", "volume": "56", "author": "CG Maki", "year": "1996", "unstructured": "Maki, C. G., Huibregtse, J. M. & Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56, 2649\u20132654 (1996).", "journal-title": "Cancer Res."}, {"key": "BFnrc1361_CR60", "doi-asserted-by": "crossref", "first-page": "299", "DOI": "10.1038/387299a0", "volume": "387", "author": "MH Kubbutat", "year": "1997", "unstructured": "Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299\u2013303 (1997).", "journal-title": "Nature"}, {"key": "BFnrc1361_CR61", "doi-asserted-by": "crossref", "first-page": "296", "DOI": "10.1038/387296a0", "volume": "387", "author": "Y Haupt", "year": "1997", "unstructured": "Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296\u2013299 (1997).", "journal-title": "Nature"}, {"key": "BFnrc1361_CR62", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1016/S0014-5793(97)01480-4", "volume": "420", "author": "R Honda", "year": "1997", "unstructured": "Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25\u201327 (1997).", "journal-title": "FEBS Lett."}, {"key": "BFnrc1361_CR63", "doi-asserted-by": "crossref", "first-page": "8945", "DOI": "10.1074/jbc.275.12.8945", "volume": "275", "author": "S Fang", "year": "2000", "unstructured": "Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945\u20138951 (2000).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR64", "doi-asserted-by": "crossref", "first-page": "301", "DOI": "10.1038/nrc780", "volume": "2", "author": "M Karin", "year": "2002", "unstructured": "Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-\u03baB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer 2, 301\u2013310 (2002).", "journal-title": "Nature Rev. Cancer"}, {"key": "BFnrc1361_CR65", "doi-asserted-by": "crossref", "first-page": "773", "DOI": "10.1016/S0092-8674(94)90482-0", "volume": "78", "author": "VJ Palombella", "year": "1994", "unstructured": "Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-\u03baB1 precursor protein and the activation of NF-\u03baB. Cell 78, 773\u2013785 (1994).", "journal-title": "Cell"}, {"key": "BFnrc1361_CR66", "doi-asserted-by": "crossref", "first-page": "292", "DOI": "10.1006/bbrc.1995.2465", "volume": "215", "author": "CC Li", "year": "1995", "unstructured": "Li, C. C., Dai, R. M. & Longo, D. L. Inactivation of NF-\u03baB inhibitor I\u03baB\u03b1: ubiquitin-dependent proteolysis and its degradation product. Biochem. Biophys. Res. Commun. 215, 292\u2013301 (1995).", "journal-title": "Biochem. Biophys. Res. Commun."}, {"key": "BFnrc1361_CR67", "doi-asserted-by": "crossref", "first-page": "S49", "DOI": "10.1016/S1471-4914(02)02315-8", "volume": "8", "author": "J Adams", "year": "2002", "unstructured": "Adams, J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med. 8, S49\u2013S54 (2002).", "journal-title": "Trends Mol. Med."}, {"key": "BFnrc1361_CR68", "doi-asserted-by": "crossref", "first-page": "1680", "DOI": "10.1126/science.281.5383.1680", "volume": "281", "author": "CY Wang", "year": "1998", "unstructured": "Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V. & Baldwin, A. S. Jr. NF-\u03baB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680\u20131683 (1998). An early study demonstrating that proteasome inhibition induces apoptosis in proliferating (but not quiescent and differentiated) leukaemic cells in a manner that is associated with the activation of CPP32 and increased KIP1 levels.", "journal-title": "Science"}, {"key": "BFnrc1361_CR69", "doi-asserted-by": "crossref", "first-page": "267", "DOI": "10.1016/S1074-7613(00)80609-3", "volume": "9", "author": "EE Varfolomeev", "year": "1998", "unstructured": "Varfolomeev, E. E. et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 9, 267\u2013276 (1998).", "journal-title": "Immunity."}, {"key": "BFnrc1361_CR70", "doi-asserted-by": "crossref", "first-page": "855", "DOI": "10.1073/pnas.94.3.855", "volume": "94", "author": "HC Drexler", "year": "1997", "unstructured": "Drexler, H. C. Activation of the cell death program by inhibition of proteasome function. Proc. Natl Acad. Sci. USA 94, 855\u2013860 (1997).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1361_CR71", "doi-asserted-by": "crossref", "first-page": "752", "DOI": "10.1046/j.1365-2141.1999.01388.x", "volume": "105", "author": "P Masdehors", "year": "1999", "unstructured": "Masdehors, P. et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol. 105, 752\u2013757 (1999).", "journal-title": "Br. J. Haematol."}, {"key": "BFnrc1361_CR72", "doi-asserted-by": "crossref", "first-page": "65", "DOI": "10.1096/fasebj.14.1.65", "volume": "14", "author": "HC Drexler", "year": "2000", "unstructured": "Drexler, H. C., Risau, W. & Konerding, M. A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 14, 65\u201377 (2000).", "journal-title": "FASEB J."}, {"key": "BFnrc1361_CR73", "first-page": "916", "volume": "6", "author": "Y Kudo", "year": "2000", "unstructured": "Kudo, Y. et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. 6, 916\u2013923 (2000).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrc1361_CR74", "doi-asserted-by": "crossref", "first-page": "218", "DOI": "10.1016/S0301-472X(02)01076-7", "volume": "31", "author": "C Bogner", "year": "2003", "unstructured": "Bogner, C. et al. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and-independent pathways. Exp. Hematol. 31, 218\u2013225 (2003).", "journal-title": "Exp. Hematol."}, {"key": "BFnrc1361_CR75", "first-page": "3071", "volume": "61", "author": "T Hideshima", "year": "2001", "unstructured": "Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071\u20133076 (2001).", "journal-title": "Cancer Res."}, {"key": "BFnrc1361_CR76", "doi-asserted-by": "crossref", "first-page": "16220", "DOI": "10.1073/pnas.252462599", "volume": "99", "author": "ML Guzman", "year": "2002", "unstructured": "Guzman, M. L. et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl Acad. Sci. USA 99, 16220\u201316225 (2002). This study shows the ability of proteasome inhibition to combine well with anthracycline therapy to target leukaemic cells  in vitro  and  in vivo , through NF-\u03baB- and p53-related mechanisms.", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1361_CR77", "doi-asserted-by": "crossref", "first-page": "3589", "DOI": "10.1182/blood.V97.11.3589", "volume": "97", "author": "DL Stirewalt", "year": "2001", "unstructured": "Stirewalt, D. L. et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97, 3589\u20133595 (2001).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR78", "doi-asserted-by": "crossref", "first-page": "49", "DOI": "10.3816/CLM.2002.n.011", "volume": "3", "author": "D Schenkein", "year": "2002", "unstructured": "Schenkein, D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin. Lymphoma 3, 49\u201355 (2002).", "journal-title": "Clin. Lymphoma"}, {"key": "BFnrc1361_CR79", "first-page": "269", "volume": "96", "author": "P Masdehors", "year": "2000", "unstructured": "Masdehors, P. et al. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 96, 269\u2013274 (2000).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR80", "doi-asserted-by": "crossref", "first-page": "399", "DOI": "10.1038/sj.leu.2401705", "volume": "14", "author": "U Kordes", "year": "2000", "unstructured": "Kordes, U., Krappmann, D., Heissmeyer, V., Ludwig, W. D. & Scheidereit, C. Transcription factor NF-\u03baB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14, 399\u2013402 (2000).", "journal-title": "Leukemia"}, {"key": "BFnrc1361_CR81", "first-page": "3044", "volume": "93", "author": "R Feinman", "year": "1999", "unstructured": "Feinman, R. et al. Role of NF-\u03baB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93, 3044\u20133052 (1999).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR82", "doi-asserted-by": "crossref", "first-page": "279", "DOI": "10.1046/j.1365-2141.2001.03102.x", "volume": "115", "author": "H Ni", "year": "2001", "unstructured": "Ni, H. et al. Analysis of expression of nuclear factor \u03baB (NF-\u03baB) in multiple myeloma: downregulation of NF-\u03baB induces apoptosis. Br. J. Haematol. 115, 279\u2013286 (2001).", "journal-title": "Br. J. Haematol."}, {"key": "BFnrc1361_CR83", "first-page": "4624", "volume": "91", "author": "I Jeremias", "year": "1998", "unstructured": "Jeremias, I. et al. Inhibition of nuclear factor \u03baB activation attenuates apoptosis resistance in lymphoid cells. Blood 91, 4624\u20134631 (1998). This paper demonstrates that inhibition of NF-\u03baB activity, either through proteasome inhibition or by mutant I\u03baB\u03b1, increases the sensitivity of cells to apoptosis, including cells resistant to apoptosis, following treatment with various agents.", "journal-title": "Blood"}, {"key": "BFnrc1361_CR84", "doi-asserted-by": "crossref", "first-page": "90", "DOI": "10.1038/sj.onc.1206056", "volume": "22", "author": "M Bentires-Alj", "year": "2003", "unstructured": "Bentires-Alj, M. et al. NF-\u03baB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22, 90\u201397 (2003).", "journal-title": "Oncogene"}, {"key": "BFnrc1361_CR85", "doi-asserted-by": "crossref", "first-page": "109", "DOI": "10.1023/A:1006321828515", "volume": "18", "author": "J Adams", "year": "2000", "unstructured": "Adams, J., Palombella, V. J. & Elliott, P. J. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs 18, 109\u2013121 (2000).", "journal-title": "Invest. New Drugs"}, {"key": "BFnrc1361_CR86", "doi-asserted-by": "crossref", "first-page": "433", "DOI": "10.1038/sj.leu.2402417", "volume": "16", "author": "JB Almond", "year": "2002", "unstructured": "Almond, J. B. & Cohen, G. M. The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433\u2013443 (2002).", "journal-title": "Leukemia"}, {"key": "BFnrc1361_CR87", "doi-asserted-by": "crossref", "first-page": "16455", "DOI": "10.1074/jbc.271.28.16455", "volume": "271", "author": "ME Figueiredo-Pereira", "year": "1996", "unstructured": "Figueiredo-Pereira, M. E., Chen, W. E., Li, J. & Johdo, O. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J. Biol. Chem. 271, 16455\u201316459 (1996).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR88", "doi-asserted-by": "crossref", "first-page": "1391", "DOI": "10.1016/S0006-2952(97)00655-2", "volume": "55", "author": "RT Lum", "year": "1998", "unstructured": "Lum, R. T. et al. A new structural class of proteasome inhibitors that prevent NF-\u03baB activation. Biochem. Pharmacol. 55, 1391\u20131397 (1998).", "journal-title": "Biochem. Pharmacol."}, {"key": "BFnrc1361_CR89", "doi-asserted-by": "crossref", "first-page": "209", "DOI": "10.1016/S0960-894X(98)00015-8", "volume": "8", "author": "RT Lum", "year": "1998", "unstructured": "Lum, R. T. et al. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides. Bioorg. Med. Chem. Lett. 8, 209\u2013214 (1998).", "journal-title": "Bioorg. Med. Chem. Lett."}, {"key": "BFnrc1361_CR90", "first-page": "471", "volume": "50", "author": "S Wilk", "year": "1991", "unstructured": "Wilk, S., Pereira, M. & Yu, B. Probing the specificity of the bovine pituitary multicatalytic proteinase complex by inhibitors, activators, and by chemical modification. Biomed. Biochim. Acta 50, 471\u2013478 (1991).", "journal-title": "Biomed. Biochim. Acta"}, {"key": "BFnrc1361_CR91", "doi-asserted-by": "crossref", "first-page": "1563", "DOI": "10.1021/bi00057a022", "volume": "32", "author": "M Orlowski", "year": "1993", "unstructured": "Orlowski, M., Cardozo, C. & Michaud, C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 32, 1563\u20131572 (1993).", "journal-title": "Biochemistry"}, {"key": "BFnrc1361_CR92", "first-page": "2798", "volume": "59", "author": "L Meng", "year": "1999", "unstructured": "Meng, L., Kwok, B. H., Sin, N. & Crews, C. M. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 59, 2798\u20132801 (1999).", "journal-title": "Cancer Res."}, {"key": "BFnrc1361_CR93", "doi-asserted-by": "crossref", "first-page": "3335", "DOI": "10.1016/S0960-894X(99)00612-5", "volume": "9", "author": "KB Kim", "year": "1999", "unstructured": "Kim, K. B., Myung, J., Sin, N. & Crews, C. M. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg. Med. Chem. Lett. 9, 3335\u20133340 (1999).", "journal-title": "Bioorg. Med. Chem. Lett."}, {"key": "BFnrc1361_CR94", "doi-asserted-by": "crossref", "first-page": "6629", "DOI": "10.1073/pnas.94.13.6629", "volume": "94", "author": "M Bogyo", "year": "1997", "unstructured": "Bogyo, M. et al. Covalent modification of the active site threonine of proteasomal \u03b2 subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc. Natl Acad. Sci. USA 94, 6629\u20136634 (1997).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1361_CR95", "doi-asserted-by": "crossref", "first-page": "235", "DOI": "10.1007/s00109-003-0422-2", "volume": "81", "author": "PJ Elliott", "year": "2003", "unstructured": "Elliott, P. J., Zollner, T. M. & Bochncke, W. -H. Proteasome inhibition: a new anti-inflammatory strategy. J. Mol. Med. 81, 235\u2013245 (2003).", "journal-title": "J. Mol. Med."}, {"key": "BFnrc1361_CR96", "doi-asserted-by": "crossref", "first-page": "1062", "DOI": "10.1038/sj.cdd.4400436", "volume": "5", "author": "B An", "year": "1998", "unstructured": "An, B., Goldfarb, R. H., Siman, R. & Dou, Q. P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5, 1062\u20131075 (1998).", "journal-title": "Cell Death Differ."}, {"key": "BFnrc1361_CR97", "doi-asserted-by": "crossref", "first-page": "333", "DOI": "10.1016/S0960-894X(98)00029-8", "volume": "8", "author": "J Adams", "year": "1998", "unstructured": "Adams, J. et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333\u2013338 (1998).", "journal-title": "Bioorg. Med. Chem. Lett."}, {"key": "BFnrc1361_CR98", "doi-asserted-by": "crossref", "first-page": "269", "DOI": "10.1046/j.1365-2125.2002.01638.x", "volume": "54", "author": "IM Shah", "year": "2002", "unstructured": "Shah, I. M., Lees, K. R., Pien, C. P. & Elliott, P. J. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 54, 269\u2013276 (2002).", "journal-title": "Br. J. Clin. Pharmacol."}, {"key": "BFnrc1361_CR99", "doi-asserted-by": "crossref", "first-page": "13120", "DOI": "10.1073/pnas.95.22.13120", "volume": "95", "author": "P Andre", "year": "1998", "unstructured": "Andre, P. et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl Acad. Sci. USA 95, 13120\u201313124 (1998).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1361_CR100", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615\u20132622 (1999). A key paper describing the selection, characteristics, and early  in vitro  and  in vivo  studies of PS-341, later named bortezomib.", "journal-title": "Cancer Res."}, {"key": "BFnrc1361_CR101", "doi-asserted-by": "crossref", "first-page": "10815", "DOI": "10.1073/pnas.93.20.10815", "volume": "93", "author": "C Dietrich", "year": "1996", "unstructured": "Dietrich, C., Bartsch, T., Schanz, F., Oesch, F. & Wieser, R. J. p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl Acad. Sci. USA 93, 10815\u201310819 (1996).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1361_CR102", "doi-asserted-by": "crossref", "first-page": "12893", "DOI": "10.1074/jbc.272.20.12893", "volume": "272", "author": "UG Lopes", "year": "1997", "unstructured": "Lopes, U. G., Erhardt, P., Yao, R. & Cooper, G. M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem. 272, 12893\u201312896 (1997).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR103", "first-page": "841", "volume": "1", "author": "YH Ling", "year": "2002", "unstructured": "Ling, Y. H. et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther. 1, 841\u2013849 (2002).", "journal-title": "Mol. Cancer Ther."}, {"key": "BFnrc1361_CR104", "first-page": "781", "volume": "289", "author": "QP Dou", "year": "1999", "unstructured": "Dou, Q. P., McGuire, T. F., Peng, Y. & An, B. Proteasome inhibition leads to significant reduction of Bcr\u2013Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J. Pharmacol. Exp. Ther. 289, 781\u2013790 (1999).", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "BFnrc1361_CR105", "doi-asserted-by": "crossref", "first-page": "14017", "DOI": "10.1074/jbc.272.22.14017", "volume": "272", "author": "CL Yu", "year": "1997", "unstructured": "Yu, C. L. & Burakoff, S. J. Involvement of proteasomes in regulating Jak\u2013STAT pathways upon interleukin-2 stimulation. J. Biol. Chem. 272, 14017\u201314020 (1997).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR106", "first-page": "3182", "volume": "91", "author": "BA Callus", "year": "1998", "unstructured": "Callus, B. A. & Mathey-Prevot, B. Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors. Blood 91, 3182\u20133192 (1998).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR107", "doi-asserted-by": "crossref", "first-page": "4635", "DOI": "10.1523/JNEUROSCI.23-11-04635.2003", "volume": "23", "author": "LA Pasquini", "year": "2003", "unstructured": "Pasquini, L. A., Paez, P. M., Moreno, M. A., Pasquini, J. M. & Soto, E. F. Inhibition of the proteasome by lactacystin enhances oligodendroglial cell differentiation. J. Neurosci. 23, 4635\u20134644 (2003).", "journal-title": "J. Neurosci."}, {"key": "BFnrc1361_CR108", "doi-asserted-by": "crossref", "first-page": "110", "DOI": "10.1002/jcb.1150", "volume": "82", "author": "SA Shah", "year": "2001", "unstructured": "Shah, S. A. et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 82, 110\u2013122 (2001).", "journal-title": "J. Cell Biochem."}, {"key": "BFnrc1361_CR109", "doi-asserted-by": "crossref", "first-page": "183", "DOI": "10.1016/S0360-3016(01)01446-8", "volume": "50", "author": "SM Russo", "year": "2001", "unstructured": "Russo, S. M. et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-\u03baB. Int. J. Radiat. Oncol. Biol. Phys. 50, 183\u2013193 (2001). This paper demonstrates the ability of bortezomib to enhance the sensitivity of neoplastic cells to radiation therapy  in vitro  and  in vivo  in a manner that is associated with the inhibition of radiation-induced NF-\u03baB activation.", "journal-title": "Int. J. Radiat. Oncol. Biol. Phys."}, {"key": "BFnrc1361_CR110", "first-page": "3535", "volume": "61", "author": "JC Cusack Jr.", "year": "2001", "unstructured": "Cusack, J. C. Jr. et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61, 3535\u20133540 (2001). A demonstration of the ability of bortezomib to act in combination with conventional chemotherapy in solid tumour cells  in vitro  and  in vivo . This paper also demonstrates the ability of bortezomib to inhibit the NF-\u03baB activation induced by SN-38.", "journal-title": "Cancer Res."}, {"key": "BFnrc1361_CR111", "first-page": "1136", "volume": "9", "author": "MH Ma", "year": "2003", "unstructured": "Ma, M. H. et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9, 1136\u20131144 (2003).", "journal-title": "Clin. Cancer Res."}, {"issue": "Suppl 1", "key": "BFnrc1361_CR112", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1016/S0305-7372(03)00082-3", "volume": "29", "author": "HJ Lenz", "year": "2003", "unstructured": "Lenz, H. J. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat. Rev. 29(Suppl 1), 41\u201348 (2003).", "journal-title": "Cancer Treat. Rev."}, {"key": "BFnrc1361_CR113", "first-page": "6174", "volume": "63", "author": "D Chauhan", "year": "2003", "unstructured": "Chauhan, D. et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 63, 6174\u20136177 (2003).", "journal-title": "Cancer Res."}, {"key": "BFnrc1361_CR114", "first-page": "4220", "volume": "92", "author": "J Chandra", "year": "1998", "unstructured": "Chandra, J. et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92, 4220\u20134229 (1998).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR115", "first-page": "853", "volume": "88", "author": "S Gatto", "year": "2003", "unstructured": "Gatto, S. et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88, 853\u2013863 (2003).", "journal-title": "Haematologica"}, {"key": "BFnrc1361_CR116", "doi-asserted-by": "crossref", "first-page": "16639", "DOI": "10.1074/jbc.M200360200", "volume": "277", "author": "T Hideshima", "year": "2002", "unstructured": "Hideshima, T. et al. NF-kB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277, 16639\u201316647 (2002).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrc1361_CR117", "doi-asserted-by": "crossref", "first-page": "14374", "DOI": "10.1073/pnas.202445099", "volume": "99", "author": "N Mitsiades", "year": "2002", "unstructured": "Mitsiades, N. et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99, 14374\u201314379 (2002).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrc1361_CR118", "doi-asserted-by": "crossref", "first-page": "1530", "DOI": "10.1182/blood-2002-08-2543", "volume": "101", "author": "T Hideshima", "year": "2003", "unstructured": "Hideshima, T. et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101, 1530\u20131534 (2003).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR119", "first-page": "4996", "volume": "62", "author": "R LeBlanc", "year": "2002", "unstructured": "LeBlanc, R. et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996\u20135000 (2002).", "journal-title": "Cancer Res."}, {"key": "BFnrc1361_CR120", "first-page": "1419", "volume": "7", "author": "JB Sunwoo", "year": "2001", "unstructured": "Sunwoo, J. B. et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-\u03baB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7, 1419\u20131428 (2001).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrc1361_CR121", "first-page": "2638", "volume": "5", "author": "BA Teicher", "year": "1999", "unstructured": "Teicher, B. A., Ara, G., Herbst, R., Palombella, V. J. & Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5, 2638\u20132645 (1999).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrc1361_CR122", "doi-asserted-by": "crossref", "first-page": "412", "DOI": "10.1038/7410", "volume": "5", "author": "CY Wang", "year": "1999", "unstructured": "Wang, C. Y., Cusack, J. C. J., Liu, R. & Baldwin, A. S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-\u03baB. Nature Med. 5, 412\u2013417 (1999).", "journal-title": "Nature Med."}, {"key": "BFnrc1361_CR123", "doi-asserted-by": "crossref", "first-page": "2377", "DOI": "10.1182/blood-2002-06-1768", "volume": "101", "author": "N Mitsiades", "year": "2003", "unstructured": "Mitsiades, N. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377\u20132380 (2003). This paper demonstrates the synergistic activity of bortezomib used in combination with DNA-damaging agents in multiple myeloma cells, as well as the ability of bortezomib to remove cell-adhesion-mediated drug resistance. Bortezomib is also shown to downregulate multiple DNA-repair proteins.", "journal-title": "Blood"}, {"key": "BFnrc1361_CR124", "doi-asserted-by": "crossref", "first-page": "11", "DOI": "10.1006/jsre.2001.6194", "volume": "100", "author": "RJ Bold", "year": "2001", "unstructured": "Bold, R. J., Virudachalam, S. & McConkey, D. J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100, 11\u201317 (2001).", "journal-title": "J. Surg. Res."}, {"key": "BFnrc1361_CR125", "first-page": "2505", "volume": "8", "author": "C Aghajanian", "year": "2002", "unstructured": "Aghajanian, C. et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8, 2505\u20132511 (2002).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrc1361_CR126", "doi-asserted-by": "crossref", "first-page": "4420", "DOI": "10.1200/JCO.2002.01.133", "volume": "20", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski, R. Z. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420\u20134427 (2002). One of two key Phase I clinical trials of bortezomib. This was a dose-ranging study in patients with advanced haematological malignancies, including multiple myeloma. The study demonstrated patient responses and acceptable toxicities and, in conjunction with reference 125, helped define the dose for the Phase II trials.", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrc1361_CR127", "doi-asserted-by": "crossref", "first-page": "2609", "DOI": "10.1056/NEJMoa030288", "volume": "348", "author": "PG Richardson", "year": "2003", "unstructured": "Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609\u20132617 (2003). The key Phase II trial that led to the approval of the first proteasome inhibitor for the treatment of patients with multiple myeloma.", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrc1361_CR128", "doi-asserted-by": "crossref", "first-page": "493", "DOI": "10.1016/1074-7613(95)90030-6", "volume": "2", "author": "MA Read", "year": "1995", "unstructured": "Read, M. A. et al. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2, 493\u2013506 (1995).", "journal-title": "Immunity"}, {"key": "BFnrc1361_CR129", "doi-asserted-by": "crossref", "first-page": "1175", "DOI": "10.1038/sj.leu.2402924", "volume": "17", "author": "Y Nefedova", "year": "2003", "unstructured": "Nefedova, Y., Landowski, T. H. & Dalton, W. S. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17, 1175\u20131182 (2003).", "journal-title": "Leukemia"}, {"key": "BFnrc1361_CR130", "first-page": "1658", "volume": "93", "author": "JS Damiano", "year": "1999", "unstructured": "Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658\u20131667 (1999).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR131", "first-page": "597", "volume": "26", "author": "I Grigorieva", "year": "1998", "unstructured": "Grigorieva, I., Thomas, X. & Epstein, J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp. Hematol. 26, 597\u2013603 (1998).", "journal-title": "Exp. Hematol."}, {"key": "BFnrc1361_CR132", "first-page": "3064", "volume": "93", "author": "A Vacca", "year": "1999", "unstructured": "Vacca, A. et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93, 3064\u20133073 (1999).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR133", "doi-asserted-by": "crossref", "first-page": "243", "DOI": "10.1006/bbrc.1998.8604", "volume": "246", "author": "T Oikawa", "year": "1998", "unstructured": "Oikawa, T. et al. The proteasome is involved in angiogenesis. Biochem. Biophys. Res. Commun. 246, 243\u2013248 (1998).", "journal-title": "Biochem. Biophys. Res. Commun."}, {"key": "BFnrc1361_CR134", "doi-asserted-by": "crossref", "first-page": "1138", "DOI": "10.1002/jcb.10587", "volume": "89", "author": "J Mezquita", "year": "2003", "unstructured": "Mezquita, J., Mezquita, B., Pau, M. & Mezquita, C. Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262. J. Cell Biochem. 89, 1138\u20131147 (2003).", "journal-title": "J. Cell Biochem."}, {"key": "BFnrc1361_CR135", "doi-asserted-by": "crossref", "first-page": "1115", "DOI": "10.1046/j.1365-2141.1998.00930.x", "volume": "102", "author": "J Blad\u00e9", "year": "1998", "unstructured": "Blad\u00e9, J. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 102, 1115\u20131123 (1998).", "journal-title": "Br. J. Haematol."}, {"key": "BFnrc1361_CR136", "first-page": "710", "volume": "22", "author": "JR Berenson", "year": "2003", "unstructured": "Berenson, J. R. et al. Experience with long\u2013term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM). Proc. Am. Soc. Clin. Oncol. 22, 710 (2003).", "journal-title": "Proc. Am. Soc. Clin. Oncol."}, {"key": "BFnrc1361_CR137", "doi-asserted-by": "crossref", "first-page": "449a", "DOI": "10.1182/blood-2002-12-3882", "volume": "102", "author": "RZ Orlowski", "year": "2003", "unstructured": "Orlowski, R. Z. et al. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood 102, 449a (2003).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR138", "first-page": "235a", "volume": "102", "author": "HH Yang", "year": "2004", "unstructured": "Yang, H. H. et al. A phase I/II trial of VELCADE\u2122 and melphalan combination therapy (Vc+M) for patients with relapsed or refractory multiple myeloma (MM). Blood 102, 235a (2004).", "journal-title": "Blood"}, {"key": "BFnrc1361_CR139", "first-page": "149a", "volume": "102", "author": "PG Richardson", "year": "2003", "unstructured": "Richardson, P. G. et al. Peripheral neuropathy following bortezomib (VELCADE\u2122, formerly PS\u2013341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility. Blood 102, 149a (2003).", "journal-title": "Blood"}], "container-title": ["Nature Reviews Cancer"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrc1361.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrc1361", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrc1361.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 17]], "date-time": "2019-03-17T17:34:44Z", "timestamp": 1552844084000}, "score": 24.645824, "issued": {"date-parts": [[2004, 5]]}, "references-count": 139, "journal-issue": {"published-print": {"date-parts": [[2004, 5]]}, "issue": "5"}, "alternative-id": ["BFnrc1361"], "URL": "http://dx.doi.org/10.1038/nrc1361", "relation": {"cites": []}, "ISSN": ["1474-175X", "1474-1768"], "issn-type": [{"value": "1474-175X", "type": "print"}, {"value": "1474-1768", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T13:43:32Z", "timestamp": 1576849412856}, "reference-count": 52, "publisher": "Elsevier BV", "issue": "5", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2004, 5, 1]], "date-time": "2004-05-01T00:00:00Z", "timestamp": 1083369600000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "https://www.elsevier.com/open-access/userlicense/1.0/", "start": {"date-parts": [[2013, 8, 17]], "date-time": "2013-08-17T00:00:00Z", "timestamp": 1376697600000}, "delay-in-days": 3395, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Cell"], "published-print": {"date-parts": [[2004, 5]]}, "DOI": "10.1016/s1535-6108(04)00120-5", "type": "journal-article", "created": {"date-parts": [[2004, 5, 24]], "date-time": "2004-05-24T11:03:40Z", "timestamp": 1085396620000}, "page": "417-421", "source": "Crossref", "is-referenced-by-count": 463, "title": ["The development of proteasome inhibitors as anticancer drugs"], "prefix": "10.1016", "volume": "5", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Cancer Cell"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1535610804001205?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1535610804001205?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 8]], "date-time": "2019-02-08T06:27:02Z", "timestamp": 1549607222000}, "score": 24.645824, "issued": {"date-parts": [[2004, 5]]}, "references-count": 52, "journal-issue": {"published-print": {"date-parts": [[2004, 5]]}, "issue": "5"}, "alternative-id": ["S1535610804001205"], "URL": "http://dx.doi.org/10.1016/s1535-6108(04)00120-5", "ISSN": ["1535-6108"], "issn-type": [{"value": "1535-6108", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T23:10:38Z", "timestamp": 1574377838788}, "reference-count": 13, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2008, 7, 1]], "date-time": "2008-07-01T00:00:00Z", "timestamp": 1214870400000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "https://www.elsevier.com/open-access/userlicense/1.0/", "start": {"date-parts": [[2013, 8, 22]], "date-time": "2013-08-22T00:00:00Z", "timestamp": 1377129600000}, "delay-in-days": 1878, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Cell"], "published-print": {"date-parts": [[2008, 7]]}, "DOI": "10.1016/j.ccr.2008.06.011", "type": "journal-article", "created": {"date-parts": [[2008, 7, 8]], "date-time": "2008-07-08T10:45:53Z", "timestamp": 1215513953000}, "page": "1-2", "source": "Crossref", "is-referenced-by-count": 4, "title": ["A Novel Role for a Familiar Protein in Apoptosis Induced by Proteasome Inhibition"], "prefix": "10.1016", "volume": "14", "author": [{"given": "David J.", "family": "McConkey", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Cancer Cell"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1535610808001980?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1535610808001980?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 27]], "date-time": "2018-12-27T10:23:20Z", "timestamp": 1545906200000}, "score": 24.601004, "issued": {"date-parts": [[2008, 7]]}, "references-count": 13, "journal-issue": {"published-print": {"date-parts": [[2008, 7]]}, "issue": "1"}, "alternative-id": ["S1535610808001980"], "URL": "http://dx.doi.org/10.1016/j.ccr.2008.06.011", "ISSN": ["1535-6108"], "issn-type": [{"value": "1535-6108", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T15:45:13Z", "timestamp": 1576770313607}, "reference-count": 52, "publisher": "Informa UK Limited", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Investigation"], "published-print": {"date-parts": [[2004, 1]]}, "DOI": "10.1081/cnv-120030218", "type": "journal-article", "created": {"date-parts": [[2004, 4, 26]], "date-time": "2004-04-26T19:40:34Z", "timestamp": 1083008434000}, "page": "304-311", "source": "Crossref", "is-referenced-by-count": 384, "title": ["Development of the Proteasome Inhibitor Velcade\u2122 (Bortezomib)"], "prefix": "10.1081", "volume": "22", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": []}, {"given": "Michael", "family": "Kauffman", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2009, 8, 24]]}, "reference": [{"key": "CIT0001", "author": "Adams J.", "volume": "59", "first-page": "2615", "year": "1999", "journal-title": "Cancer Res."}, {"key": "CIT0002", "DOI": "10.1006/jsre.2001.6194", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "author": "Cusack J. C.", "volume": "61", "first-page": "3535", "year": "2001", "journal-title": "Cancer Res."}, {"key": "CIT0004", "author": "Hideshima T.", "volume": "61", "first-page": "3071306", "year": "2001", "journal-title": "Cancer Res."}, {"key": "CIT0005", "DOI": "10.1002/jcb.1150", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "author": "Logothetis C. J.", "volume": "20", "first-page": "186a", "year": "2001", "journal-title": "Proc. Am. Soc. Clin. Oncol."}, {"key": "CIT0007", "DOI": "10.1038/386463a0", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1126/science.7725097", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1101/SQB.1995.060.01.056", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1073/pnas.95.21.12504", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1634/theoncologist.7-1-9", "doi-asserted-by": "publisher"}, {"key": "CIT0012", "author": "Adams J.", "volume": "8", "first-page": "33333", "year": "1998", "journal-title": "Bioorg. Med. Chem. Lett."}, {"key": "CIT0013", "DOI": "10.1073/pnas.93.20.10815", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1038/sj.leu.2401812", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "DOI": "10.1002/(SICI)1097-4644(20000315)76:4<596::AID-JCB8>3.0.CO;2-N", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "DOI": "10.1016/0092-8674(94)90379-4", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "DOI": "10.1126/science.274.5293.1652", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1126/science.7624798", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1074/jbc.272.39.24159", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "author": "Ogiso Y.", "volume": "60", "first-page": "2429", "year": "2000", "journal-title": "Cancer Res."}, {"key": "CIT0021", "DOI": "10.1023/A:1006321828515", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1073/pnas.94.3.855", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "DOI": "10.1046/j.1365-2141.1999.01388.x", "doi-asserted-by": "publisher"}, {"key": "CIT0024", "DOI": "10.1038/sj.cdd.4400436", "doi-asserted-by": "publisher"}, {"key": "CIT0025", "DOI": "10.1038/sj.leu.2401705", "doi-asserted-by": "publisher"}, {"key": "CIT0026", "DOI": "10.1016/S0140-6736(00)00019-2", "doi-asserted-by": "publisher"}, {"key": "CIT0027", "DOI": "10.1038/sj.onc.1203768", "doi-asserted-by": "publisher"}, {"key": "CIT0028", "author": "Jeremias I.", "volume": "91", "first-page": "4624", "year": "1998", "journal-title": "Blood"}, {"key": "CIT0029", "DOI": "10.1172/JCI11991", "doi-asserted-by": "publisher"}, {"key": "CIT0030", "DOI": "10.1073/pnas.92.24.11259", "doi-asserted-by": "publisher"}, {"key": "CIT0031", "DOI": "10.1101/gad.13.3.284", "doi-asserted-by": "publisher"}, {"key": "CIT0032", "DOI": "10.1101/gad.13.3.270", "doi-asserted-by": "publisher"}, {"key": "CIT0033", "DOI": "10.1073/pnas.92.23.10599", "doi-asserted-by": "publisher"}, {"key": "CIT0034", "DOI": "10.1074/jbc.271.1.376", "doi-asserted-by": "publisher"}, {"key": "CIT0035", "DOI": "10.1101/gad.9.13.1586", "doi-asserted-by": "publisher"}, {"key": "CIT0036", "author": "Lin Y. C.", "volume": "92", "first-page": "526", "year": "1995", "journal-title": "Proc. Natl. Acad. Sci. U. S. A."}, {"key": "CIT0037", "DOI": "10.1074/jbc.271.13.7844", "doi-asserted-by": "publisher"}, {"key": "CIT0038", "DOI": "10.1128/MCB.20.8.2687-2695.2000", "doi-asserted-by": "publisher"}, {"key": "CIT0039", "DOI": "10.1126/science.281.5383.1680", "doi-asserted-by": "publisher"}, {"key": "CIT0040", "author": "Wang C. Y.", "volume": "19", "first-page": "5923", "year": "1999", "journal-title": "Mol. Cell. Biol.", "DOI": "10.1128/MCB.19.9.5923", "doi-asserted-by": "crossref"}, {"key": "CIT0041", "DOI": "10.1101/gad.13.4.382", "doi-asserted-by": "publisher"}, {"key": "CIT0042", "DOI": "10.1016/S0360-3016(01)01446-8", "doi-asserted-by": "publisher"}, {"key": "CIT0043", "author": "LeBlanc R.", "volume": "98", "issue": "11", "year": "2001", "journal-title": "Blood"}, {"key": "CIT0044", "author": "Pham L.", "volume": "98", "issue": "11", "year": "2001", "journal-title": "Blood"}, {"key": "CIT0045", "author": "Ma M. H.", "volume": "98", "issue": "11", "year": "2001", "journal-title": "Blood"}, {"key": "CIT0046", "author": "Feinman R.", "volume": "98", "issue": "11", "year": "2001", "journal-title": "Blood"}, {"key": "CIT0047", "author": "Steiner P.", "volume": "98", "issue": "11", "year": "2001", "journal-title": "Blood"}, {"key": "CIT0048", "author": "Nix D.", "volume": "20", "first-page": "86a", "year": "2001", "journal-title": "Proc. Am. Soc. Clin. Oncol."}, {"key": "CIT0049", "author": "Lightcap E. S.", "volume": "46", "first-page": "673", "year": "2000", "journal-title": "Clin. Chem."}, {"key": "CIT0050", "DOI": "10.1016/S0093-7754(01)90034-X", "doi-asserted-by": "publisher"}, {"key": "CIT0051", "author": "Papandreou C.", "volume": "20", "first-page": "86a", "year": "2001", "journal-title": "Proc. Am. Soc. Oncol."}, {"key": "CIT0052", "author": "Richardson P.", "volume": "98", "issue": "11", "year": "2001", "journal-title": "Blood"}], "container-title": ["Cancer Investigation"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1081/CNV-120030218", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 16]], "date-time": "2017-06-16T06:25:22Z", "timestamp": 1497594322000}, "score": 23.781113, "issued": {"date-parts": [[2004, 1]]}, "references-count": 52, "journal-issue": {"published-online": {"date-parts": [[2009, 8, 24]]}, "published-print": {"date-parts": [[2004, 1]]}, "issue": "2"}, "alternative-id": ["10.1081/CNV-120030218"], "URL": "http://dx.doi.org/10.1081/cnv-120030218", "relation": {"cites": []}, "ISSN": ["0735-7907", "1532-4192"], "issn-type": [{"value": "0735-7907", "type": "print"}, {"value": "1532-4192", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T00:11:43Z", "timestamp": 1576800703622}, "reference-count": 0, "publisher": "IOS Press", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["BD"], "published-print": {"date-parts": [[2002, 6, 1]]}, "DOI": "10.3233/bd-2002-15107", "type": "journal-article", "created": {"date-parts": [[2016, 6, 22]], "date-time": "2016-06-22T18:48:12Z", "timestamp": 1466621292000}, "page": "61-70", "source": "Crossref", "is-referenced-by-count": 11, "title": ["The Proteasome as a Novel Target for the Treatment of Breast Cancer1"], "prefix": "10.3233", "volume": "15", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": [{"name": "Millennium Pharmaceuticals, Inc, Cambridge, MA, USA"}]}], "member": "7437", "container-title": ["Breast Disease"], "link": [{"URL": "https://content.iospress.com/download?id=10.3233/BD-2002-15107", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T01:19:31Z", "timestamp": 1575076771000}, "score": 23.290436, "editor": [{"given": "Stan", "family": "Lipkowitz", "sequence": "additional", "affiliation": [{"name": "NIH, Bethesda, MD, USA"}]}], "issued": {"date-parts": [[2002, 6, 1]]}, "references-count": 0, "journal-issue": {"issue": "1"}, "URL": "http://dx.doi.org/10.3233/bd-2002-15107", "ISSN": ["1558-1551", "0888-6008"], "issn-type": [{"value": "0888-6008", "type": "print"}, {"value": "1558-1551", "type": "electronic"}], "subject": ["Cancer Research", "Oncology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T15:57:50Z", "timestamp": 1574524670582}, "publisher-location": "Totowa, NJ", "reference-count": 94, "publisher": "Humana Press", "isbn-type": [{"value": "9781617374524", "type": "print"}, {"value": "9781592597949", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2004]]}, "DOI": "10.1007/978-1-59259-794-9_19", "type": "book-chapter", "created": {"date-parts": [[2012, 12, 28]], "date-time": "2012-12-28T15:58:01Z", "timestamp": 1356710281000}, "page": "233-269", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Preclinical Development of Bortezomib (VELCADE\u2122)"], "prefix": "10.1007", "author": [{"given": "Julian", "family": "Adams", "sequence": "first", "affiliation": []}, {"given": "Peter J.", "family": "Elliott", "sequence": "additional", "affiliation": []}, {"given": "Page", "family": "Bouchard", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "19_CR1", "first-page": "3071", "volume": "61", "author": "T Hideshima", "year": "2001", "unstructured": "Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. CancerRes 2001;61:3071\u20133076.", "journal-title": "CancerRes"}, {"key": "19_CR2", "doi-asserted-by": "publisher", "first-page": "626", "DOI": "10.1016/S0093-7754(01)90036-3", "volume": "28", "author": "JR Berenson", "year": "2001", "unstructured": "Berenson JR, Ma HM, Vescio R. The role of nuclear factor-KB in the biology and treatment of multiple myeloma. Semin Oncol 2001;28:626\u2013633.", "journal-title": "Semin Oncol"}, {"key": "19_CR3", "doi-asserted-by": "publisher", "first-page": "752", "DOI": "10.1046/j.1365-2141.1999.01388.x", "volume": "105", "author": "P Masdehors", "year": "1999", "unstructured": "Masdehors P, Omura S, Merle-Beral H, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999;105:752\u2013757.", "journal-title": "Br J Haematol"}, {"key": "19_CR4", "doi-asserted-by": "publisher", "first-page": "1103", "DOI": "10.1038/bjc.1998.183", "volume": "77", "author": "J Delic", "year": "1998", "unstructured": "Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alphainitiated apoptosis. Br J Cancer 1998;77:1103\u20131107.", "journal-title": "Br J Cancer"}, {"key": "19_CR5", "first-page": "4342", "volume": "58", "author": "RZ Orlowski", "year": "1998", "unstructured": "Orlowski RZ, Eswara JR, Lafond-Walker A, Greyer MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor. Cancer Res 1998;58:4342\u20134348.", "journal-title": "Cancer Res"}, {"key": "19_CR6", "doi-asserted-by": "publisher", "first-page": "210", "DOI": "10.1038/sj.cdd.4400801", "volume": "8", "author": "AP MacLaren", "year": "2001", "unstructured": "MacLaren AP, Chapman RS, Wyllie AH, Watson CJ. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001;8:210\u2013218.", "journal-title": "Cell Death Differ"}, {"key": "19_CR7", "doi-asserted-by": "crossref", "first-page": "65", "DOI": "10.1096/fasebj.14.1.65", "volume": "14", "author": "HC Drexler", "year": "2000", "unstructured": "Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;14:65\u201377.", "journal-title": "FASEB J"}, {"key": "19_CR8", "doi-asserted-by": "publisher", "first-page": "739", "DOI": "10.1016/S1074-5521(01)00056-4", "volume": "8", "author": "AF Kisselev", "year": "2001", "unstructured": "Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739\u2013758.", "journal-title": "Chem Biol"}, {"key": "19_CR9", "first-page": "3719", "volume": "6", "author": "A Frankel", "year": "2000", "unstructured": "Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719\u20133728.", "journal-title": "Clin Cancer Res"}, {"key": "19_CR10", "doi-asserted-by": "publisher", "first-page": "1388", "DOI": "10.1038/sj.leu.2402201", "volume": "15", "author": "JB Almond", "year": "2001", "unstructured": "Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain K, Cohen GM. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia 2001;15:1388\u20131397.", "journal-title": "Leukemia"}, {"key": "19_CR11", "doi-asserted-by": "publisher", "first-page": "7071", "DOI": "10.1073/pnas.87.18.7071", "volume": "87", "author": "A Kumatori", "year": "1990", "unstructured": "Kumatori A, Tanaka K, Inamura N, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990;87:7071\u20137075.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "19_CR12", "author": "A Palermo", "first-page": "7", "year": "2001", "unstructured": "Palermo A, Mulligan G, D\u2019Cruz C, et al. Coordinate regulation of proteasome genes in cancer. In: Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001:7.", "volume-title": "Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"}, {"key": "19_CR13", "first-page": "4996", "volume": "62", "author": "R LeBlanc", "year": "2002", "unstructured": "LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996\u20135000.", "journal-title": "Cancer Res"}, {"key": "19_CR14", "doi-asserted-by": "crossref", "first-page": "3835", "DOI": "10.1002/j.1460-2075.1996.tb00757.x", "volume": "15", "author": "LM Grimm", "year": "1996", "unstructured": "Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA. Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996;15:3835\u20133844.", "journal-title": "EMBO J"}, {"key": "19_CR15", "doi-asserted-by": "crossref", "first-page": "3845", "DOI": "10.1002/j.1460-2075.1996.tb00758.x", "volume": "15", "author": "R Sadoul", "year": "1996", "unstructured": "Sadoul R, Fernandez PA, Quiquerez AL et al. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J 1996;15:3845\u20133852.", "journal-title": "EMBO J"}, {"key": "19_CR16", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1186/1471-2261-2-3", "volume": "2", "author": "J Theuer", "year": "2002", "unstructured": "Theuer J, Dechend R, Muller DN et al. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord 2002;2:3.", "journal-title": "BMC Cardiovasc Disord"}, {"key": "19_CR17", "doi-asserted-by": "publisher", "first-page": "2687", "DOI": "10.1128/MCB.20.8.2687-2695.2000", "volume": "20", "author": "C Chen", "year": "2000", "unstructured": "Chen C, Edelstein LC, Gelinas C. The Rel/NF-\u03baB family directly activates expression of the apoptosis inhibitor Bc1-xL. Mol Cell Biol 2000;20:2687\u20132695.", "journal-title": "Mol Cell Biol"}, {"key": "19_CR18", "doi-asserted-by": "publisher", "first-page": "1680", "DOI": "10.1126/science.281.5383.1680", "volume": "281", "author": "CY Wang", "year": "1998", "unstructured": "Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-\u03baB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680\u20131683.", "journal-title": "Science"}, {"key": "19_CR19", "first-page": "435", "volume": "7", "author": "CC Bancroft", "year": "2001", "unstructured": "Bancroft CC, Chen Z, Dong G, et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001;7:435\u2013442.", "journal-title": "Clin Cancer Res"}, {"key": "19_CR20", "first-page": "1104", "volume": "87", "author": "D Chauhan", "year": "1996", "unstructured": "Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-\u03baB. Blood 1996;87:1104\u20131112.", "journal-title": "Blood"}, {"key": "19_CR21", "doi-asserted-by": "publisher", "first-page": "221", "DOI": "10.1034/j.1600-0609.2000.065004221.x", "volume": "65", "author": "C Naujokat", "year": "2000", "unstructured": "Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S, Possinger K. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000;65:221\u2013236.", "journal-title": "Eur J Haematol"}, {"key": "19_CR22", "doi-asserted-by": "publisher", "first-page": "2288", "DOI": "10.1046/j.1471-4159.2000.0752288.x", "volume": "75", "author": "B Wagenknecht", "year": "2000", "unstructured": "Wagenknecht B, Hermisson M, Groscurth P, Liston P, Krammer PH, Weller M. Proteasome inhibitorinduced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem 2000;75:2288\u20132297.", "journal-title": "J Neurochem"}, {"key": "19_CR23", "doi-asserted-by": "publisher", "first-page": "481", "DOI": "10.1002/ijc.1373", "volume": "93", "author": "XM Fan", "year": "2001", "unstructured": "Fan XM, Wong BC, Wang WP, et al. Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer 2001;93:481\u2013488.", "journal-title": "Int J Cancer"}, {"key": "19_CR24", "doi-asserted-by": "publisher", "first-page": "333", "DOI": "10.1016/S0960-894X(98)00029-8", "volume": "8", "author": "J Adams", "year": "1998", "unstructured": "Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333\u2013338.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "19_CR25", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615\u20132622.", "journal-title": "Cancer Res"}, {"key": "19_CR26", "first-page": "2638", "volume": "5", "author": "BA Teicher", "year": "1999", "unstructured": "Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638\u20132645.", "journal-title": "Clin Cancer Res"}, {"key": "19_CR27", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.1002/jcb.1150", "volume": "82", "author": "SA Shah", "year": "2001", "unstructured": "Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110\u2013122.", "journal-title": "J Cell Biochem"}, {"key": "19_CR28", "first-page": "1419", "volume": "7", "author": "JB Sunwoo", "year": "2001", "unstructured": "Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-KB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419\u20131428.", "journal-title": "Clin Cancer Res"}, {"key": "19_CR29", "first-page": "2429", "volume": "60", "author": "Y Ogiso", "year": "2000", "unstructured": "Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000;60:2429\u20132434.", "journal-title": "Cancer Res"}, {"key": "19_CR30", "first-page": "465a", "volume": "98", "author": "L Pham", "year": "2001", "unstructured": "Pham L, Tamayo A, Lo P, Yoshimura L, Ford RJ. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood 2001;98:465a.", "journal-title": "Blood"}, {"key": "19_CR31", "first-page": "640a", "volume": "98", "author": "R Feinman", "year": "2001", "unstructured": "Feinman R, Gangurde P, Miller S et al. Proteasome inhibitor PS-341 inhibits constitutive NF-\u03baB activation and bypasses the anti-apoptotic bc -2 signal in human multiple myeloma cells. Blood 2001;98:640a.", "journal-title": "Blood"}, {"key": "19_CR32", "doi-asserted-by": "publisher", "first-page": "2889", "DOI": "10.1038/sj.onc.1202221", "volume": "17", "author": "JL Herrmann", "year": "1998", "unstructured": "Herrmann JL, Briones F, Jr, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 1998;17:2889\u20132899.", "journal-title": "Oncogene"}, {"key": "19_CR33", "doi-asserted-by": "publisher", "first-page": "1276", "DOI": "10.1038/sj.leu.2401812", "volume": "14", "author": "WG An", "year": "2000", "unstructured": "An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000;14:1276\u20131283.", "journal-title": "Leukemia"}, {"key": "19_CR34", "first-page": "825", "volume": "8", "author": "H Oyaizu", "year": "2001", "unstructured": "Oyaizu H, Adachi Y, Okumura T et al. Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol Rep 2001;8:825\u2013829.", "journal-title": "Oncol Rep"}, {"key": "19_CR35", "doi-asserted-by": "publisher", "first-page": "126", "DOI": "10.1046/j.1365-2141.2001.02683.x", "volume": "113", "author": "D Soligo", "year": "2001", "unstructured": "Soligo D, Servida F, Delia D et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001;113:126\u2013135.", "journal-title": "Br J Haematol"}, {"key": "19_CR36", "unstructured": "Li QQ, Yunmbam MK, Zhong X et al. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Cell Mol Biol (Noisyle-grand) 2001;47 Online Pub:OL61\u2013OL72."}, {"key": "19_CR37", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1006/jsre.2001.6194", "volume": "100", "author": "RJ Bold", "year": "2001", "unstructured": "Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11\u201317.", "journal-title": "J Surg Res"}, {"key": "19_CR38", "first-page": "3535", "volume": "61", "author": "JC Cusack Jr", "year": "2001", "unstructured": "Cusack JC Jr, Liu R, Houston M et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535\u20133540.", "journal-title": "Cancer Res"}, {"key": "19_CR39", "author": "S Williams", "first-page": "7", "year": "2001", "unstructured": "Williams S, Logothetis CJ, Papandreou C, McConkey DJ. Preclinical evaluation of PS-341-based combination chemotherapy in prostate cancer. In: Proceedings of the American Association for Cancer Research, 2001:7.", "volume-title": "Proceedings of the American Association for Cancer Research"}, {"key": "19_CR40", "first-page": "101a", "volume": "98", "author": "SR Gatto", "year": "2001", "unstructured": "Gatto SR, Scappini B, Verstovsek S et al. In vitro effects of PS-341 alone and in combination with STI571 in BCR-ABL positive cell lines both sensitive and resistant to STI571. Blood 2001;98:101a.", "journal-title": "Blood"}, {"key": "19_CR41", "first-page": "158", "volume": "43", "author": "M Pink", "year": "2002", "unstructured": "Pink M, Pien CS, Worland P, Adams J, Kauffman MG. PS-341 enhances chemotherapeutic effect in human xenograft models. In: Proceedings of the American Association for Cancer Research, 2002;43:158.", "journal-title": "Proceedings of the American Association for Cancer Research"}, {"key": "19_CR42", "doi-asserted-by": "publisher", "first-page": "795", "DOI": "10.1182/blood.V98.3.795", "volume": "98", "author": "CS Mitsiades", "year": "2001", "unstructured": "Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795\u2013804.", "journal-title": "Blood"}, {"key": "19_CR43", "author": "TJ Sayers", "first-page": "7", "year": "2001", "unstructured": "Sayers TJ, Brooks A, Sekd N, Murphy WJ, Elliott P. The proteasome inhibitor PS-341 sensitizes tumor cells to TRAIL-mediated apoptosis. In: Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001;7.", "volume-title": "Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"}, {"key": "19_CR44", "author": "EG Mimnaugh", "first-page": "7", "year": "2001", "unstructured": "Mimnaugh EG, Neckers L. Biologic rationale for the combination of an Hsp90 antagonist with a proteasome inhibitor. In: Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001:7.", "volume-title": "Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"}, {"key": "19_CR45", "doi-asserted-by": "publisher", "first-page": "1025", "DOI": "10.1016/S0360-3016(00)00516-2", "volume": "47", "author": "F Pajonk", "year": "2000", "unstructured": "Pajonk F, Pajonk K, McBride WH. Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 2000;47:1025\u20131032.", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"key": "19_CR46", "author": "B Ng", "first-page": "7", "year": "2001", "unstructured": "Ng B, Kramer E, Devitt ML et al. Proteasome inhibitor, PS-341, enhances in vitro radiosensitivity of human breast cancer cells treated with radiotherapy or radioimmunotherapy. In: Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001:7.", "volume-title": "Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"}, {"key": "19_CR47", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1016/S0360-3016(01)01446-8", "volume": "50", "author": "SM Russo", "year": "2001", "unstructured": "Russo SM, Tepper JE, Baldwin AS et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-\u03baB. Int J Radiat Oncol Biol Phys 2001;50:183\u2013193.", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"key": "19_CR48", "doi-asserted-by": "publisher", "first-page": "481", "DOI": "10.1097/00000421-200110000-00013", "volume": "24", "author": "M Pervan", "year": "2001", "unstructured": "Pervan M, Pajonk F, Sun JR, Withers HR, McBride WH. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 2001;24:481\u2013485.", "journal-title": "Am J Clin Oncol"}, {"key": "19_CR49", "doi-asserted-by": "publisher", "first-page": "327", "DOI": "10.1002/ijc.1040", "volume": "96", "author": "JF Kurland", "year": "2001", "unstructured": "Kurland JF, Meyn RE. Protease inhibitors restore radiation-induced apoptosis to Bcl-2- expressing lymphoma cells. Int J Cancer 2001;96:327\u2013333.", "journal-title": "Int J Cancer"}, {"key": "19_CR50", "first-page": "4220", "volume": "92", "author": "J Chandra", "year": "1998", "unstructured": "Chandra J, Niemer I, Gilbreath J et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998;92:4220\u20134229.", "journal-title": "Blood"}, {"key": "19_CR51", "author": "DJ McConkey", "first-page": "7", "year": "2001", "unstructured": "McConkey DJ, Pahler JC, Szanto S, Faderl S, Keating M. Efficacy and mechanisms of proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia. In: Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001:7.", "volume-title": "Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"}, {"key": "19_CR52", "first-page": "437a", "volume": "98", "author": "MH Ma", "year": "2001", "unstructured": "Ma MH, Parker KM, Manyak S et al. Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-kappaB pathway. Blood 2001;98:437a.", "journal-title": "Blood"}, {"key": "19_CR53", "first-page": "169b", "volume": "20", "author": "SA Williams", "year": "2001", "unstructured": "Williams SA, Papandreou C, McConkey D. Preclinical effects of proteasome inhibitor PS-341 in combination chemotherapy for prostate cancer. In: Proceedings of the American Society of Clinical Oncology-37th Annual Meeting, 2001,20:169b.", "journal-title": "Proceedings of the American Society of Clinical Oncology-37th Annual Meeting"}, {"key": "19_CR54", "first-page": "157", "volume": "7", "author": "PH Gumerlock", "year": "2001", "unstructured": "Gumerlock PH, Moisan LP, Lau AH, Mack PC, Lara PN, Gandara DR. Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increases response in non-small cell lung carcinoma (NSCLC). Clin Cancer Res 2001;7:157.", "journal-title": "Clin Cancer Res"}, {"key": "19_CR55", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1016/S0093-7754(01)90148-4", "volume": "28", "author": "KJ Pienta", "year": "2001", "unstructured": "Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001;28:3\u20137.", "journal-title": "Semin Oncol"}, {"key": "19_CR56", "doi-asserted-by": "publisher", "first-page": "823", "DOI": "10.1006/bbrc.1999.1291", "volume": "262", "author": "P Chadebech", "year": "1999", "unstructured": "Chadebech P, Brichese L, Baldin V, Vidal S, Valette A. Phosphorylation and proteasome-dependent degradation of Bc1\u20132 in mitotic-arrested cells after microtubule damage. Biochem Biophys Res Commun 1999;262:823\u2013827.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "19_CR57", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1634/theoncologist.7-1-9", "volume": "7", "author": "J Adams", "year": "2002", "unstructured": "Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9\u201316.", "journal-title": "Oncologist"}, {"key": "19_CR58", "first-page": "98", "volume": "310a", "author": "P Steiner", "year": "2001", "unstructured": "Steiner P, Neumeier H, Lightcap ES, et al. Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. Blood 2001;98:310a.", "journal-title": "Blood"}, {"key": "19_CR59", "doi-asserted-by": "publisher", "first-page": "412", "DOI": "10.1038/10577", "volume": "5", "author": "CY Wang", "year": "1999", "unstructured": "Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced antitumor therapy through increased apoptosis by inhibition of NF-\u03baB. Nat Med 1999;5:412\u2013417.", "journal-title": "Nat Med"}, {"key": "19_CR60", "doi-asserted-by": "crossref", "first-page": "5923", "DOI": "10.1128/MCB.19.9.5923", "volume": "19", "author": "CY Wang", "year": "1999", "unstructured": "Wang CY, Guttridge DC, Mayo MW, Baldwin AS, Jr. NF-\u03baB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923\u20135929.", "journal-title": "Mol Cell Biol"}, {"key": "19_CR61", "doi-asserted-by": "publisher", "first-page": "271", "DOI": "10.1054/drup.1999.0094", "volume": "2", "author": "JC Cusack", "year": "1999", "unstructured": "Cusack JC, Liu R, Baldwin AS. NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B. Drug Resist Updat 1999;2:271\u2013273.", "journal-title": "Drug Resist Updat"}, {"key": "19_CR62", "doi-asserted-by": "publisher", "first-page": "557", "DOI": "10.1097/00001622-200011000-00008", "volume": "12", "author": "KH Shain", "year": "2000", "unstructured": "Shain KH, Landowski TH, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol 2000;12:557\u2013563.", "journal-title": "Curr Opin Oncol"}, {"key": "19_CR63", "first-page": "1658", "volume": "93", "author": "JS Damiano", "year": "1999", "unstructured": "Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658\u20131667.", "journal-title": "Blood"}, {"key": "19_CR64", "first-page": "3712", "volume": "82", "author": "H Uchiyama", "year": "1993", "unstructured": "Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myelomaderived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712\u20133720.", "journal-title": "Blood"}, {"key": "19_CR65", "doi-asserted-by": "publisher", "first-page": "4519", "DOI": "10.1038/sj.onc.1204623", "volume": "20", "author": "T Hideshima", "year": "2001", "unstructured": "Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519\u20134527.", "journal-title": "Oncogene"}, {"key": "19_CR66", "doi-asserted-by": "publisher", "first-page": "607", "DOI": "10.1016/S0093-7754(01)90033-8", "volume": "28", "author": "T Hideshima", "year": "2001", "unstructured": "Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607\u2013612.", "journal-title": "Semin Oncol"}, {"key": "19_CR67", "first-page": "98", "volume": "377a", "author": "TH Landowski", "year": "2001", "unstructured": "Landowski TH, Dalton WS. Myeloma cell adhesion to fibronectin activates NF-\u03baB and induces the expression of genes contributing to cell adhesion-mediated drug resistance. Blood 2001;98:377a.", "journal-title": "Blood"}, {"key": "19_CR68", "doi-asserted-by": "publisher", "first-page": "243", "DOI": "10.1006/bbrc.1998.8604", "volume": "246", "author": "T Oikawa", "year": "1998", "unstructured": "Oikawa T, Sasaki T, Nakamura M et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998;246:243\u2013248.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "19_CR69", "author": "J Rottman", "year": "2003", "unstructured": "Rottman J, Csizmadia V, Ozkaynak E, Kadambi V, Ganley K, Cardoza K. Investigative cardiovascular study of the proteasome inhibitor PS-341 in the mouse. Presented at the 42nd Annual Meeting of the Society of Toxicology, March 9\u201313, 2003, Salt Lake City, UT.", "volume-title": "Investigative cardiovascular study of the proteasome inhibitor PS-341 in the mouse"}, {"key": "19_CR70", "first-page": "673", "volume": "46", "author": "ES Lightcap", "year": "2000", "unstructured": "Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673\u2013683.", "journal-title": "Clin Chem"}, {"key": "19_CR71", "author": "V Csizmadia", "year": "2003", "unstructured": "Csizmadia V, Rottman J, Bouchard P, Raczynski A, Juedes M, White P. The proteasome inhibitor PS-341 induces COX-2 in murine and human endothelial cells. Presented at the 42nd Annual Meeting of the Society of Toxicology, March 9\u201313, 2003, Salt Lake City, UT.", "volume-title": "The proteasome inhibitor PS-341 induces COX-2 in murine and human endothelial cells"}, {"key": "19_CR72", "first-page": "4340", "volume": "87", "author": "RC Bargou", "year": "1996", "unstructured": "Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-\u03baB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87:4340\u20134347.", "journal-title": "Blood"}, {"key": "19_CR73", "doi-asserted-by": "publisher", "first-page": "1861", "DOI": "10.1084/jem.194.12.1861", "volume": "194", "author": "RE Davis", "year": "2001", "unstructured": "Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor KB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861\u20131874.", "journal-title": "J Exp Med"}, {"key": "19_CR74", "doi-asserted-by": "publisher", "first-page": "523", "DOI": "10.1089/10799900152434402", "volume": "21", "author": "PC Rath", "year": "2001", "unstructured": "Rath PC, Aggarwal BB. Antiproliferative effects of IFN-\u03b1 correlate with the downregulation of nuclear factor-KB in human Burkitt lymphoma Daudi cells. J Interferon Cytokine Res 2001;21:523\u2013528.", "journal-title": "J Interferon Cytokine Res"}, {"key": "19_CR75", "doi-asserted-by": "crossref", "first-page": "7", "DOI": "10.1002/jlb.55.1.7", "volume": "55", "author": "JD Wolchok", "year": "1994", "unstructured": "Wolchok JD, Goodman AR, Vilcek J. Activation of NF-\u03baB may be necessary but is not sufficient for induction of H-2 antigens by TNF in J558L murine myeloma cells. J Leukoc Biol 1994;55:7\u201312.", "journal-title": "J Leukoc Biol"}, {"key": "19_CR76", "doi-asserted-by": "publisher", "first-page": "345", "DOI": "10.1111/j.1600-0609.1999.tb01138.x", "volume": "63", "author": "M Borset", "year": "1999", "unstructured": "Borset M, Hjorth-Hansen H, Johnsen AC, et al. Apoptosis, proliferation and NF-\u03baB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor. Eur J Haematol 1999;63:345\u2013353.", "journal-title": "Eur J Haematol"}, {"key": "19_CR77", "first-page": "3044", "volume": "93", "author": "R Feinman", "year": "1999", "unstructured": "Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-\u03baB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bc -2. Blood 1999;93:3044\u20133052.", "journal-title": "Blood"}, {"key": "19_CR78", "first-page": "2360", "volume": "93", "author": "N Mori", "year": "1999", "unstructured": "Mori N, Fujimori M, Ikeda S, et al. Constitutive activation of NF-\u03baB in primary adult T-cell leukemia cells. Blood 1999;93:2360\u20132368.", "journal-title": "Blood"}, {"key": "19_CR79", "doi-asserted-by": "publisher", "first-page": "399", "DOI": "10.1038/sj.leu.2401705", "volume": "14", "author": "U Kordes", "year": "2000", "unstructured": "Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-\u03baB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000;14:399\u2013402.", "journal-title": "Leukemia"}, {"key": "19_CR80", "doi-asserted-by": "crossref", "first-page": "2200", "DOI": "10.4049/jimmunol.164.4.2200", "volume": "164", "author": "RR Furman", "year": "2000", "unstructured": "Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-\u03baB activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200\u20132206.", "journal-title": "J Immunol"}, {"key": "19_CR81", "doi-asserted-by": "publisher", "first-page": "395", "DOI": "10.3109/10428190009087031", "volume": "38", "author": "G Munzert", "year": "2000", "unstructured": "Munzert G, Kreitmeier S, Bergmann L. Normal structure of NFKB2, C-REL and BCL-3 gene loci in lymphoproliferative and myeloproliferative disorders. Leuk Lymphoma 2000;38:395\u2013400.", "journal-title": "Leuk Lymphoma"}, {"key": "19_CR82", "doi-asserted-by": "publisher", "first-page": "2301", "DOI": "10.1182/blood.V98.8.2301", "volume": "98", "author": "ML Guzman", "year": "2001", "unstructured": "Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-KB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98:2301\u20132307.", "journal-title": "Blood"}, {"key": "19_CR83", "doi-asserted-by": "publisher", "first-page": "471", "DOI": "10.1023/A:1011845725394", "volume": "18", "author": "PF Lindholm", "year": "2001", "unstructured": "Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdacsy-Balla A. The role of constitutive NF-\u03baB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis 2001;18:471\u2013479.", "journal-title": "Clin Exp Metastasis"}, {"key": "19_CR84", "first-page": "141", "volume": "115", "author": "AV Gasparian", "year": "2002", "unstructured": "Gasparian AV, Yao YJ, Kowalczyk D, et al. The role of IKK in constitutive activation of NF-\u03baB transcription factor in prostate carcinoma cells. J Cell Sci 2002;115:141\u2013151.", "journal-title": "J Cell Sci"}, {"key": "19_CR85", "doi-asserted-by": "crossref", "first-page": "3629", "DOI": "10.1128/MCB.17.7.3629", "volume": "17", "author": "H Nakshatri", "year": "1997", "unstructured": "Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-\u03baB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629\u20133639.", "journal-title": "Mol Cell Biol"}, {"key": "19_CR86", "doi-asserted-by": "publisher", "first-page": "2952", "DOI": "10.1172/JCI119848", "volume": "100", "author": "MA Sovak", "year": "1997", "unstructured": "Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-KB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952\u20132960.", "journal-title": "J Clin Invest"}, {"key": "19_CR87", "doi-asserted-by": "publisher", "first-page": "7389", "DOI": "10.1038/sj.onc.1203160", "volume": "18", "author": "ST Palayoor", "year": "1999", "unstructured": "Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IKB kinase \u03b1 and NF-\u03baB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999;18:7389\u20137394.", "journal-title": "Oncogene"}, {"key": "19_CR88", "doi-asserted-by": "publisher", "first-page": "145", "DOI": "10.1016/0006-2952(94)90448-0", "volume": "47", "author": "V Bours", "year": "1994", "unstructured": "Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-\u03baB transcription factor and cancer: high expression of NF-\u03baB- and IKB-related proteins in tumor cell lines. Biochem Pharmacol 1994;47:145\u2013149.", "journal-title": "Biochem Pharmacol"}, {"key": "19_CR89", "doi-asserted-by": "publisher", "first-page": "3887", "DOI": "10.1093/nar/23.19.3887", "volume": "23", "author": "U Reuning", "year": "1995", "unstructured": "Reuning U, Wilhelm O, Nishiguchi T, et al. Inhibition of NF-\u03baB-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Res 1995;23:3887\u20133893.", "journal-title": "Nucleic Acids Res"}, {"key": "19_CR90", "doi-asserted-by": "publisher", "first-page": "3815", "DOI": "10.1210/jc.85.10.3815", "volume": "85", "author": "C Grundker", "year": "2000", "unstructured": "Grundker C, Schulz K, Gunthert AR, Emons G. Luteinizing hormone-releasing hormone induces nuclear factor KB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 2000;85:3815\u20133820.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "19_CR91", "doi-asserted-by": "publisher", "first-page": "363", "DOI": "10.1067/msy.2001.116672", "volume": "130", "author": "DS Lind", "year": "2001", "unstructured": "Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-\u03ba B is upregulated in colorectal cancer. Surgery 2001;130:363\u2013369.", "journal-title": "Surgery"}, {"key": "19_CR92", "first-page": "119", "volume": "5", "author": "W Wang", "year": "1999", "unstructured": "Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-KB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119\u2013127.", "journal-title": "Clin Cancer Res"}, {"key": "19_CR93", "first-page": "910", "volume": "62", "author": "A Arlt", "year": "2002", "unstructured": "Arlt A, Vorndamm J, Muerkoster S, et al. Autocrine production of interleukin 1\u03b23 confers constitutive nuclear factor kB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002;62:910\u2013916.", "journal-title": "Cancer Res"}, {"key": "19_CR94", "first-page": "999", "volume": "11", "author": "T Mukhopadhyay", "year": "1995", "unstructured": "Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-\u03baB transcription factor complex in non-small cell lung carcinoma. Oncogene 1995;11:999\u20131003.", "journal-title": "Oncogene"}], "container-title": ["Proteasome Inhibitors in Cancer Therapy"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-59259-794-9_19", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 10]], "date-time": "2019-05-10T02:32:28Z", "timestamp": 1557455548000}, "score": 23.143637, "issued": {"date-parts": [[2004]]}, "ISBN": ["9781617374524", "9781592597949"], "references-count": 94, "URL": "http://dx.doi.org/10.1007/978-1-59259-794-9_19", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T20:43:50Z", "timestamp": 1575146630966}, "reference-count": 75, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2005, 10, 27]], "date-time": "2005-10-27T00:00:00Z", "timestamp": 1130371200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Immunol Immunother"], "published-print": {"date-parts": [[2006, 1]]}, "DOI": "10.1007/s00262-005-0676-3", "type": "journal-article", "created": {"date-parts": [[2005, 4, 27]], "date-time": "2005-04-27T14:05:44Z", "timestamp": 1114610744000}, "page": "76-84", "source": "Crossref", "is-referenced-by-count": 59, "title": ["Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy"], "prefix": "10.1007", "volume": "55", "author": [{"given": "Thomas J.", "family": "Sayers", "sequence": "first", "affiliation": []}, {"given": "William J.", "family": "Murphy", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2005, 10, 27]]}, "reference": [{"key": "676_CR1", "doi-asserted-by": "crossref", "first-page": "673", "DOI": "10.1016/1074-7613(95)90057-8", "volume": "3", "author": "SR Wiley", "year": "1995", "unstructured": "Wiley SR, Schooley K, Smolak PJ, Din WS, Huang C-P, Nicholl JK, Sutherland GR, Smith CA, Goodwin RG (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673", "journal-title": "Immunity"}, {"key": "676_CR2", "doi-asserted-by": "crossref", "first-page": "12687", "DOI": "10.1074/jbc.271.22.12687", "volume": "271", "author": "RM Pitti", "year": "1996", "unstructured": "Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687", "journal-title": "J Biol Chem"}, {"key": "676_CR3", "doi-asserted-by": "crossref", "first-page": "633", "DOI": "10.1021/bi992242l", "volume": "39", "author": "SG Hymowitz", "year": "2000", "unstructured": "Hymowitz SG, O\u2018Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF (2000) A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39:633", "journal-title": "Biochemistry"}, {"key": "676_CR4", "doi-asserted-by": "crossref", "first-page": "750", "DOI": "10.1016/S0960-9822(09)00456-4", "volume": "6", "author": "SA Marsters", "year": "1996", "unstructured": "Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A (1996) Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 6:750", "journal-title": "Curr Biol"}, {"key": "676_CR5", "doi-asserted-by": "crossref", "first-page": "157", "DOI": "10.1038/5517", "volume": "5", "author": "H Walczak", "year": "1999", "unstructured": "Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157", "journal-title": "Nat Med"}, {"key": "676_CR6", "doi-asserted-by": "crossref", "first-page": "155", "DOI": "10.1172/JCI6926", "volume": "104", "author": "A Ashkenazi", "year": "1999", "unstructured": "Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155", "journal-title": "J Clin Invest"}, {"key": "676_CR7", "doi-asserted-by": "crossref", "first-page": "135", "DOI": "10.1016/S1044-579X(02)00131-1", "volume": "13", "author": "N Ozoren", "year": "2003", "unstructured": "Ozoren N, el Deiry WS (2003) Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 13:135", "journal-title": "Semin Cancer Biol"}, {"key": "676_CR8", "doi-asserted-by": "crossref", "first-page": "559", "DOI": "10.1016/S0952-7915(98)80224-0", "volume": "10", "author": "TS Griffith", "year": "1998", "unstructured": "Griffith TS, Lynch DH (1998) TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10:559", "journal-title": "Curr Opin Immunol"}, {"key": "676_CR9", "first-page": "2747", "volume": "59", "author": "XD Zhang", "year": "1999", "unstructured": "Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59:2747", "journal-title": "Cancer Res"}, {"key": "676_CR10", "first-page": "553", "volume": "60", "author": "M Leverkus", "year": "2000", "unstructured": "Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, and Walczak H (2000) Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60:553", "journal-title": "Cancer Res"}, {"key": "676_CR11", "doi-asserted-by": "crossref", "first-page": "66", "DOI": "10.1038/sj.cdd.4401187", "volume": "10", "author": "HN LeBlanc", "year": "2003", "unstructured": "LeBlanc HN, Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10:66", "journal-title": "Cell Death Differ"}, {"key": "676_CR12", "doi-asserted-by": "crossref", "first-page": "5579", "DOI": "10.1002/j.1460-2075.1995.tb00245.x", "volume": "14", "author": "FC Kischkel", "year": "1995", "unstructured": "Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579", "journal-title": "EMBO J"}, {"key": "676_CR13", "doi-asserted-by": "crossref", "first-page": "443", "DOI": "10.1016/S0092-8674(00)80430-4", "volume": "91", "author": "GS Salvesen", "year": "1997", "unstructured": "Salvesen GS, Dixit VM (1997) Caspases: intracellular signaling by proteolysis. Cell 91:443", "journal-title": "Cell"}, {"key": "676_CR14", "doi-asserted-by": "crossref", "first-page": "517", "DOI": "10.1038/386517a0", "volume": "386", "author": "M Thome", "year": "1997", "unstructured": "Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517", "journal-title": "Nature"}, {"key": "676_CR15", "doi-asserted-by": "crossref", "first-page": "1675", "DOI": "10.1093/emboj/17.6.1675", "volume": "17", "author": "C Scaffidi", "year": "1998", "unstructured": "Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17:1675", "journal-title": "EMBO J"}, {"key": "676_CR16", "doi-asserted-by": "crossref", "first-page": "491", "DOI": "10.1016/S0092-8674(00)81590-1", "volume": "94", "author": "H Li", "year": "1998", "unstructured": "Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491", "journal-title": "Cell"}, {"key": "676_CR17", "doi-asserted-by": "crossref", "first-page": "551", "DOI": "10.1038/sj.neo.7900270", "volume": "4", "author": "N Ozoren", "year": "2002", "unstructured": "Ozoren N, el Deiry WS (2002) Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4:551", "journal-title": "Neoplasia"}, {"key": "676_CR18", "doi-asserted-by": "crossref", "first-page": "401", "DOI": "10.1038/nrm830", "volume": "3", "author": "GS Salvesen", "year": "2002", "unstructured": "Salvesen GS, Duckett CS (2002) IAP proteins: blocking the road to death\u2019s door. Nat Rev Mol Cell Biol 3:401", "journal-title": "Nat Rev Mol Cell Biol"}, {"key": "676_CR19", "doi-asserted-by": "crossref", "first-page": "808", "DOI": "10.1038/nm735", "volume": "8", "author": "S Fulda", "year": "2002", "unstructured": "Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/T-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808", "journal-title": "Nat Med"}, {"key": "676_CR20", "doi-asserted-by": "crossref", "first-page": "44236", "DOI": "10.1074/jbc.M207578200", "volume": "277", "author": "CR Arnt", "year": "2002", "unstructured": "Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH (2002) Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 277:44236", "journal-title": "J Biol Chem"}, {"key": "676_CR21", "doi-asserted-by": "crossref", "first-page": "1471", "DOI": "10.1126/science.1098231", "volume": "305", "author": "L Li", "year": "2004", "unstructured": "Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG (2004) A small molecule smac mimic potentiates TRAIL- and TNF\u03b1-mediated cell death. Science 305:1471", "journal-title": "Science"}, {"key": "676_CR22", "doi-asserted-by": "crossref", "first-page": "831", "DOI": "10.1016/S1074-7613(00)80401-X", "volume": "7", "author": "P Schneider", "year": "1997", "unstructured": "Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7:831", "journal-title": "Immunity"}, {"key": "676_CR23", "doi-asserted-by": "crossref", "first-page": "813", "DOI": "10.1016/S1074-7613(00)80399-4", "volume": "7", "author": "MA Degli-Esposti", "year": "1997", "unstructured": "Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, and Goodwin RG (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813", "journal-title": "Immunity"}, {"key": "676_CR24", "doi-asserted-by": "crossref", "first-page": "821", "DOI": "10.1016/S1074-7613(00)80400-8", "volume": "7", "author": "PM Chaudhary", "year": "1997", "unstructured": "Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD- dependent apoptosis and activate the NF-kappaB pathway. Immunity 7:821", "journal-title": "Immunity"}, {"key": "676_CR25", "doi-asserted-by": "crossref", "first-page": "554", "DOI": "10.1038/8432", "volume": "5", "author": "A Schneider", "year": "1999", "unstructured": "Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M (1999) NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 5:554", "journal-title": "Nat Med"}, {"key": "676_CR26", "doi-asserted-by": "crossref", "first-page": "892", "DOI": "10.1038/35009130", "volume": "404", "author": "KM Ryan", "year": "2000", "unstructured": "Ryan KM, Ernst MK, Rice NR, Vousden KH (2000) Role of NF-kappaB in p53-mediated programmed cell death. Nature 404:892", "journal-title": "Nature"}, {"key": "676_CR27", "doi-asserted-by": "crossref", "first-page": "337", "DOI": "10.1016/S1359-6101(03)00029-7", "volume": "14", "author": "A Almasan", "year": "2003", "unstructured": "Almasan A, Ashkenazi A (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14:337", "journal-title": "Cytokine Growth Factor Rev"}, {"key": "676_CR28", "doi-asserted-by": "crossref", "first-page": "777", "DOI": "10.1111/j.1349-7006.2004.tb02181.x", "volume": "95", "author": "H Yagita", "year": "2004", "unstructured": "Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K (2004) TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95:777", "journal-title": "Cancer Sci"}, {"key": "676_CR29", "doi-asserted-by": "crossref", "first-page": "795", "DOI": "10.1182/blood.V98.3.795", "volume": "98", "author": "CS Mitsiades", "year": "2001", "unstructured": "Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98:795", "journal-title": "Blood"}, {"key": "676_CR30", "first-page": "5800", "volume": "62", "author": "T Naka", "year": "2002", "unstructured": "Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA (2002) Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients\u2019 colon tumors grown in SCID mice. Cancer Res 62:5800", "journal-title": "Cancer Res"}, {"key": "676_CR31", "first-page": "31", "volume": "299", "author": "SK Kelley", "year": "2001", "unstructured": "Kelley SK, Harris LA, Xie D, DeForge L, Totpal K, Bussiere J, and Fox JA (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31", "journal-title": "J Pharmacol Exp Ther"}, {"key": "676_CR32", "doi-asserted-by": "crossref", "first-page": "954", "DOI": "10.1038/91000", "volume": "7", "author": "K Ichikawa", "year": "2001", "unstructured": "Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954", "journal-title": "Nat Med"}, {"key": "676_CR33", "first-page": "2597", "volume": "162", "author": "TS Griffith", "year": "1999", "unstructured": "Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, Goodwin RG, Kubin MZ (1999) Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 162:2597", "journal-title": "J Immunol"}, {"key": "676_CR34", "doi-asserted-by": "crossref", "first-page": "4891", "DOI": "10.4049/jimmunol.166.8.4891", "volume": "166", "author": "A Chuntharapai", "year": "2001", "unstructured": "Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A, Kim KJ (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166:4891", "journal-title": "J Immunol"}, {"key": "676_CR35", "first-page": "iii22", "volume": "15", "author": "Halpern", "year": "2004", "unstructured": "Halpern W, Lincoln C, Roach C, Sharifi A, Askaa J, Welcher R, Klein-Szanto A, Cohen R (2004) TRAIL-R2 expression in normal and tumor tissues. Ann Oncol 15 (Suppl 3):iii22", "journal-title": "Ann Oncol"}, {"issue": "Suppl", "key": "676_CR36", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1016/S1359-6349(04)80233-7", "volume": "2", "author": "W Halpern", "year": "2004", "unstructured": "Halpern W, Lincoln C, Sharifi A, Askaa J, Klein-Szanto A, Cohen R (2004) Variable distribution of TRAIL receptor 1 in primary human tumor and normal tissues. Eur J Cancer 2 (Suppl):69", "journal-title": "Eur J Cancer"}, {"key": "676_CR37", "doi-asserted-by": "crossref", "first-page": "1754", "DOI": "10.1073/pnas.030545097", "volume": "97", "author": "AM Chinnaiyan", "year": "2000", "unstructured": "Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97:1754", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "676_CR38", "first-page": "5754", "volume": "60", "author": "B Gong", "year": "2000", "unstructured": "Gong B, Almasan A (2000) Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res 60:5754", "journal-title": "Cancer Res"}, {"key": "676_CR39", "doi-asserted-by": "crossref", "first-page": "274", "DOI": "10.1038/nm0302-274", "volume": "8", "author": "H LeBlanc", "year": "2002", "unstructured": "LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A (2002) Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8:274", "journal-title": "Nat Med"}, {"key": "676_CR40", "doi-asserted-by": "crossref", "first-page": "15095", "DOI": "10.1073/pnas.2435285100", "volume": "100", "author": "S Wang", "year": "2003", "unstructured": "Wang S, el Deiry WS (2003) Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 100:15095", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "676_CR41", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615", "journal-title": "Cancer Res"}, {"key": "676_CR42", "doi-asserted-by": "crossref", "first-page": "613", "DOI": "10.1016/S0093-7754(01)90034-X", "volume": "28", "author": "J Adams", "year": "2001", "unstructured": "Adams J (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28:613", "journal-title": "Semin Oncol"}, {"key": "676_CR43", "doi-asserted-by": "crossref", "first-page": "637", "DOI": "10.1309/44HW-5YCJ-FLLP-3R56", "volume": "116", "author": "PJ Elliott", "year": "2001", "unstructured": "Elliott PJ, Ross JS (2001) The proteasome: a new target for novel drug therapies. Am J Clin Pathol 116:637", "journal-title": "Am J Clin Pathol"}, {"key": "676_CR44", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.1023/A:1006458407515", "volume": "64", "author": "MM Keane", "year": "2000", "unstructured": "Keane MM, Rubinstein Y, Cuello M, Ettenberg SA, Banerjee P, Nau MM, and Lipkowitz S (2000) Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 64:211", "journal-title": "Breast Cancer Res Treat"}, {"key": "676_CR45", "first-page": "4624", "volume": "91", "author": "I Jeremias", "year": "1998", "unstructured": "Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM (1998) Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 91:4624", "journal-title": "Blood"}, {"key": "676_CR46", "doi-asserted-by": "crossref", "first-page": "5337", "DOI": "10.4049/jimmunol.166.9.5337", "volume": "166", "author": "AV Franco", "year": "2001", "unstructured": "Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, Nguyen T, Hersey P (2001) The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)- induced apoptosis of melanoma cells. J Immunol 166:5337", "journal-title": "J Immunol"}, {"key": "676_CR47", "first-page": "4243", "volume": "20", "author": "JE Pawlowski", "year": "2000", "unstructured": "Pawlowski JE, Nesterov A, Scheinman RI, Johnson TR, Kraft AS (2000) NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL). Anticancer Res 20:4243", "journal-title": "Anticancer Res"}, {"key": "676_CR48", "doi-asserted-by": "crossref", "first-page": "22320", "DOI": "10.1074/jbc.M202458200", "volume": "277", "author": "Y Kim", "year": "2002", "unstructured": "Kim Y, Suh N, Sporn M, Reed JC (2002) An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 277:22320", "journal-title": "J Biol Chem"}, {"key": "676_CR49", "doi-asserted-by": "crossref", "first-page": "30603", "DOI": "10.1074/jbc.274.43.30603", "volume": "274", "author": "WH Hu", "year": "1999", "unstructured": "Hu WH, Johnson H, Shu HB (1999) Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274:30603", "journal-title": "J Biol Chem"}, {"key": "676_CR50", "doi-asserted-by": "crossref", "first-page": "303", "DOI": "10.1182/blood-2002-09-2975", "volume": "102", "author": "TJ Sayers", "year": "2003", "unstructured": "Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102:303", "journal-title": "Blood"}, {"key": "676_CR51", "doi-asserted-by": "crossref", "first-page": "4953", "DOI": "10.1038/sj.onc.1206656", "volume": "22", "author": "TR Johnson", "year": "2003", "unstructured": "Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS (2003) The proteasome inhibitor PS-341 overcomes TRAIL resistance in bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22:4953", "journal-title": "Oncogene"}, {"key": "676_CR52", "doi-asserted-by": "crossref", "first-page": "6666", "DOI": "10.1158/0008-5472.CAN-04-1734", "volume": "64", "author": "S Wang", "year": "2004", "unstructured": "Wang S, el Deiry WS (2004) Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 64:6666", "journal-title": "Cancer Res"}, {"key": "676_CR53", "doi-asserted-by": "crossref", "first-page": "297", "DOI": "10.1016/j.ccr.2004.08.012", "volume": "6", "author": "JL Luo", "year": "2004", "unstructured": "Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6:297", "journal-title": "Cancer Cell"}, {"key": "676_CR54", "doi-asserted-by": "crossref", "first-page": "3130", "DOI": "10.4049/jimmunol.166.5.3130", "volume": "166", "author": "V Marshansky", "year": "2001", "unstructured": "Marshansky V, Wang X, Bertrand R, Luo H, Duguid W, Chinnadurai G, Kanaan N, Vu MD, Wu J (2001) Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 166:3130", "journal-title": "J Immunol"}, {"key": "676_CR55", "doi-asserted-by": "crossref", "first-page": "127", "DOI": "10.1042/bj3400127", "volume": "340", "author": "XM Zhang", "year": "1999", "unstructured": "Zhang XM, Lin H, Chen C, Chen BD (1999) Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Biochem J 340:127", "journal-title": "Biochem J"}, {"key": "676_CR56", "doi-asserted-by": "crossref", "first-page": "777", "DOI": "10.1128/MCB.23.3.777-790.2003", "volume": "23", "author": "M Leverkus", "year": "2003", "unstructured": "Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E, Brocker EB, Goebeler M, Neumann M, Walczak H (2003) Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 23:777", "journal-title": "Mol Cell Biol"}, {"key": "676_CR57", "doi-asserted-by": "crossref", "first-page": "94", "DOI": "10.1038/83416", "volume": "7", "author": "Y Hayakawa", "year": "2001", "unstructured": "Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K, Takeda K (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94", "journal-title": "Nat Med"}, {"key": "676_CR58", "doi-asserted-by": "crossref", "first-page": "161", "DOI": "10.1084/jem.20011171", "volume": "195", "author": "K Takeda", "year": "2002", "unstructured": "Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, and Okumura K (2002) Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195:161", "journal-title": "J Exp Med"}, {"key": "676_CR59", "doi-asserted-by": "crossref", "first-page": "94", "DOI": "10.1038/83416", "volume": "7", "author": "K Takeda", "year": "2001", "unstructured": "Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94", "journal-title": "Nat Med"}, {"key": "676_CR60", "doi-asserted-by": "crossref", "first-page": "1356", "DOI": "10.4049/jimmunol.168.3.1356", "volume": "168", "author": "E Cretney", "year": "2002", "unstructured": "Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ (2002) Increased susceptibility to tumor initiation and metastasis in TNF- related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356", "journal-title": "J Immunol"}, {"key": "676_CR61", "first-page": "207", "volume": "63", "author": "N Seki", "year": "2003", "unstructured": "Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ (2003) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 63:207", "journal-title": "Cancer Res"}, {"key": "676_CR62", "doi-asserted-by": "crossref", "first-page": "661", "DOI": "10.1084/jem.193.6.661", "volume": "193", "author": "MJ Smyth", "year": "2001", "unstructured": "Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193:661", "journal-title": "J Exp Med"}, {"key": "676_CR63", "doi-asserted-by": "crossref", "first-page": "1720", "DOI": "10.1002/1521-4141(200106)31:6<1720::AID-IMMU1720>3.0.CO;2-U", "volume": "31", "author": "Y Hayakawa", "year": "2001", "unstructured": "Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, Saiki I, Okumura K (2001) Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 31:1720", "journal-title": "Eur J Immunol"}, {"key": "676_CR64", "doi-asserted-by": "crossref", "first-page": "1451", "DOI": "10.1084/jem.189.9.1451", "volume": "189", "author": "N Kayagaki", "year": "1999", "unstructured": "Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189:1451", "journal-title": "J Exp Med"}, {"key": "676_CR65", "doi-asserted-by": "crossref", "first-page": "1343", "DOI": "10.1084/jem.189.8.1343", "volume": "189", "author": "TS Griffith", "year": "1999", "unstructured": "Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, and Fanger NA (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189:1343", "journal-title": "J Exp Med"}, {"key": "676_CR66", "doi-asserted-by": "crossref", "first-page": "1155", "DOI": "10.1084/jem.190.8.1155", "volume": "190", "author": "NA Fanger", "year": "1999", "unstructured": "Fanger NA, Maliszewski CR, Schooley K, Griffith TS (1999) Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190:1155", "journal-title": "J Exp Med"}, {"key": "676_CR67", "doi-asserted-by": "crossref", "first-page": "1037", "DOI": "10.1158/0008-5472.CAN-03-1808", "volume": "64", "author": "Y Koga", "year": "2004", "unstructured": "Koga Y, Matsuzaki A, Suminoe A, Hattori H, Hara T (2004) Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res 64:1037", "journal-title": "Cancer Res"}, {"key": "676_CR68", "doi-asserted-by": "crossref", "first-page": "3386", "DOI": "10.1158/0008-5472.CAN-04-0374", "volume": "64", "author": "AT Ludwig", "year": "2004", "unstructured": "Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O\u2019Donnell MA, and Griffith TS (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette\u2013Guerin-induced antitumor activity. Cancer Res 64:3386", "journal-title": "Cancer Res"}, {"key": "676_CR69", "doi-asserted-by": "crossref", "first-page": "680", "DOI": "10.1038/89050", "volume": "7", "author": "L Altucci", "year": "2001", "unstructured": "Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, and Gronemeyer H (2001) Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 7:680", "journal-title": "Nat Med"}, {"key": "676_CR70", "doi-asserted-by": "crossref", "first-page": "1433", "DOI": "10.1038/nm1202-797", "volume": "8", "author": "C Schmaltz", "year": "2002", "unstructured": "Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon JJ, van den Brink MR (2002) T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 8:1433", "journal-title": "Nat Med"}, {"key": "676_CR71", "doi-asserted-by": "crossref", "first-page": "8120", "DOI": "10.1073/pnas.0401563101", "volume": "101", "author": "K Sun", "year": "2004", "unstructured": "Sun K, Welniak LA, Panoskaltsis-Mortari A, O\u2019Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ (2004) Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 101:8120", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "676_CR72", "first-page": "1717", "volume": "20", "author": "J Golab", "year": "2000", "unstructured": "Golab J, Stoklosa T, Czajka A, Dabrowska A, Jakobisiak M, Zagozdzon R, Wojcik C, Marczak M, Wilk S (2000) Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res 20:1717", "journal-title": "Anticancer Res"}, {"key": "676_CR73", "doi-asserted-by": "crossref", "first-page": "437", "DOI": "10.1084/jem.20031457", "volume": "199", "author": "K Takeda", "year": "2004", "unstructured": "Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437", "journal-title": "J Exp Med"}, {"key": "676_CR74", "doi-asserted-by": "crossref", "first-page": "489", "DOI": "10.1038/82732", "volume": "1", "author": "N Holler", "year": "2000", "unstructured": "Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 1:489", "journal-title": "Nat Immunol"}, {"key": "676_CR75", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1097/00002371-200501000-00001", "volume": "28", "author": "HJ Zeh III", "year": "2005", "unstructured": "Zeh HJ III, Lotze MT (2005) Addicated to death. Invasive cancer and immune response to unscheduled cell death. J Immunotherapy 28:1", "journal-title": "J Immunotherapy"}], "container-title": ["Cancer Immunology, Immunotherapy"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s00262-005-0676-3.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s00262-005-0676-3/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s00262-005-0676-3", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 24]], "date-time": "2019-05-24T16:33:01Z", "timestamp": 1558715581000}, "score": 22.936546, "issued": {"date-parts": [[2005, 10, 27]]}, "references-count": 75, "journal-issue": {"published-print": {"date-parts": [[2006, 1]]}, "issue": "1"}, "alternative-id": ["676"], "URL": "http://dx.doi.org/10.1007/s00262-005-0676-3", "relation": {"cites": []}, "ISSN": ["0340-7004", "1432-0851"], "issn-type": [{"value": "0340-7004", "type": "print"}, {"value": "1432-0851", "type": "electronic"}], "subject": ["Immunology", "Immunology and Allergy", "Cancer Research", "Oncology"]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}